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Preface 
The aim of this study is a neuroimmunological approach to West syndrome (WS) 
and Lennox-Gastaut syndrome (LGS), which are the most frequent malignant 
childhood epilepsies. 
After a general introduction (Chapter 1) the elements are introduced: the ma-
lignant childhood epilepsies, especially the cryptogenic types of WS and LGS 
(Chapter 2), and the human polyclonal immunoglobulin preparation (IVIg)(Chap-
ter 3). 
In Part 1 the clinical and electrophysiological effects of IVlg on epilepsies are 
investigated by reviewing the literature (Chapter 4) and by reporting an own study 
on IVlg in intractable cryptogenic WS and LGS (Chapter 5). 
In Part 2 the normal cerebrospinal fluid (CSF) is studied (Chapter 6), and the 
CSF in children with WS and LGS before as well as after IVlg treatment (Chapter 
7). Goals are: i) to study CSF composition for possible etiological factors in these 
cryptogenic types of epilepsy, and for consequences of the many seizures in these 
severe encephalopathies; ii) to assess adverse effects of IVlg administration, and to 
determine if IVlg administration significantly increases CSF IgG. If so, it is not im-
possible that IgG might reach the central nervous system (CNS). 
In Parts 3 and 4 possible interactions between IVlg and the CNS in epilepsy are 
further explored. In the case that the IgG molecules reach the CNS, what might 
be the interaction between the IgG molecules and the epileptic CNS? i) Are some 
epilepsies immune mediated (Part 3)? or ii) Does IVlg also have a neuromodula-
tive mechanism of action (Part 4)? 
Part 3 investigates some immunological aspects of childhood epilepsies: sero-
logical HLA typing for class I and II antigens (Chapter 8), light chain ratios and 
concentrations of serum immunoglobulins (Chapter 9), and a functional test of 
overall immune responsiveness (in vivo primary humoral immune response 
against the neoantigen haemocyanin) (Chapter 10). 
Part 4 explores a direct neuromodulating effect of IVlg in vivo, in an animal 
epilepsy model (Chapter 11). In addition, the possibility of a direct neuromodu-
lating effect of IVlg was investigated in vitro, on the GABAA receptor (Chapter 12), 
and on a human (muscle) cell with an excitable membrane (Chapter 13). 
A more extensive discussion of the questions and answers of this thesis can be 
found in Part 5 (Chapter 14). 
Part 6 (Chapter 15) contains open questions, consideration and speculations. 
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Abbreviations and glossary 
ACTH · Adrenocorticotropic hormone 
C D 4 + T-cells · Different Τ lymphocyte subpopulaüons can be identified by the molecules that 
are expressed on their cell surfaces These cell surface molecules, which can be identified quantità 
tively using monoclonal antibodies, have been given a numerical designation -"CD#" (cluster of dif 
ferentiaüon) CD4+ T-cells express the CD4 antigen on their surface and are also called Τ helper 
cells 
CD8+ T-cells · They express CD8 antigens on their surface and are called cytotoxic T-cells 
CNS · Central nervous system, ι e brain and spinal cord 
C R H · Comcotropin-releasing hormone 
Cryptogenic · The term "cryptogenic", from the Greek kryptos genos (hidden origin) relates to 
epilepsies in which a cause is supposed but cannot be identified 
CSF · Cerebrospinal fluid 
Cytokines · A genene term for soluble molecules which mediate interactions between cells 
DR antigens · HLA class II antigens found on B-cells and antigen presenting cells 
EEG · Electroencephalography 
Epitope · A single antigenic determinant Functionally it is the portion of an antigen which com­
bines with the antibody paratope 
Fab · Fragment of the antibody molecule containing the antigen-binding site, consisting of a light 
chain and part of the heavy chain 
Fc · The constant part of the heavy chains (crystalhsable fraction, Fc fragment), is the fragment 
of the antibody molecule that is responsible for binding to antibody receptors on cells and the Clq 
component of complement 
GABAA · Gamma amino butyric acid 
Gammaglobulins · Antibody molecules were originally defined as gammaglobulins by elec­
trophoresis of serum in agar and are generally referred to as immunoglobulins 
HLA · Human leucocyte antigens, they play an essential role in the recognition of and the re­
sponse to foreign antigens 
HLA class I · HLA class I antigens are transmembrane proteins that are expressed on virtually 
all nucleated cells They are recognized by CD8+ T-cells 
XIV 
H L A class II · HLA class II antigens are transmembrane proteins that are expressed by antigen 
presenting cells, including B-cells, macrophages, and cytokine stimulated endothelial cells They are 
recognized by CD4+ T-cells 
I d i o t y p e · The antigenic characteristic of the variable region of an antibody 
I F N s · Interferons Interferons are a group of mediators, glycoproteins of cellular origin produ­
ced by eukaryotic cells, which increase the resistance of cells to viral infection, and act as cytokines 
by their effects on cell growth and differentiation 
I n t e r f e r o n g a m m a · A protein produced by activated Τ cells, and natural kdler cells It acts as 
a positive feedback signal it activates T-cells further 
IgG index · Q IgG/ Q albumin = ({CSF IgG concentration χ 107 scrum IgG concentration}/ 
{CSF albumin concentration χ lO'/serum albumin concentration}) 
I m m u n o g l o b u l i n · A general term for all antibody molecules Immunoglobulins are serum 
glycoproteins produced by cells of the B-cell lineage They are bifunctional molecules One part, 
which is extremely variable between different immunoglobulins, is responsible for binding to the 
many different antigens the body may encounter (Fab fragment), while the second, constant portion 
(Fc fragment) binds to the Fc receptors on cells and also activates complement Each immunoglo­
bulin molecule is made up of two identical polypepnde heavy chains and two identical light chains 
(kappa or lambda) The type of the heavy chain determines the immunoglobulin isotype, ι e IgG, 
IgA, IgM, IgD or IgE 
I n t e r l c u k i n s · Hormone like compounds, preferably called cytokines because they are not ex 
clusively produced by and for leucocytes They are involved in signalling between cells, and may ef­
fect the cell of origin (autoenne effect), cells in the microenvironment (paracrine effect), and distant 
cells (endocrine effect) Interleukins IL-1 through IL-12 thus have various actions including lymph­
ocyte stimulation, activation of macrophages, Chemotaxis, cell growth, induction of fever especial­
ly by IL-1, and mediation of inflammation They bind to specific receptors, the best understood of 
which are the IL-1 receptor (IL -IR) and the IL 2R 
IL-1 · Interleukin-1 A protein secreted in response to damage, infection or antigen by macroph­
ages, endothelial cells, astrocytes and others It acts on T-cells and В cells by potentiating their re­
sponses to other cytokines It is also synthesized and released from neurons and glial cells and is an 
endogenous inducer of fever and slow-wave sleep 
IL-2 · Interleukin-2 Soluble substance released by Τ cells which promotes proliferation of other 
T-cells, and potentiates В cell growth IL-2 causes also soporific effects and EEG changes 
I n t r a c t a b l e · Intractable in the strict sense refers to the resistance of epilepsies to antiepileptic 
drug treatment, it is frequently used as synonymous with malignant 
IVIg · Intravenous immunoglobulin, a preparation consisting of pooled human polyclonal im­
munoglobulin (IgG) 
L G S · Lennox-Gastaut syndrome is a severe childhood epilepsy syndrome, usually beginning be­
tween 1 and 8 years of age, and characterized by multiple seizures, diffuse slow spike wave dischar­
ges ('petit mal variant') m the intenctal EEG, and cognitive dysfunction 
XV 
М Н С · Major histocompatibility complex, a genetic region found in all mammals whose pro­
ducts, expressed on the surfaces of a variety of cells, are primarily responsible for the rapid rejection 
of grafts between individuals It functions in signalling between lymphocytes and cells expressing 
antigen The human major histocompanbihty complex situated on chromosome 6 is called HLA 
Q a l b u m i n · CSF albumin concentration χ 10s/serum albumin concentration 
R E M s leep · A sleep stage characterized by rapid eye movements (REM), low voltage EEG pat­
terns, and generally reduced muscle activity, it is associated with dreaming 
SLE · Systemic lupus erythematosus, an autoimmune disease of humans usually involving anti-
nuclear antibodies 
T R H · Thyrotropin releasing hormone 
W S · West syndrome is a severe childhood epilepsy syndrome also known as infantile spasms, 
usually beginning at age 4-7 months, and characterized by infantile spasms, a typical intenctal EEG 
pattern called hypsarrhythmia and arrest of mental development 
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General introduction 
The CNS and the immune system 
The CNS (central nervous system) has been characterized immunologically as a 
site of limited reactivity. This concept of so-called immune privilege, was developed 
from classical studies which showed that allografts usually fare better in the brain 
than in more conventional sites. In addition, the CNS lacks for the most part a lym-
phatic system that drains the tissues and captures potential antigens, the blood-
brain barrier (BBB) poses a more substantial and complex barrier to extravasation 
of immune cells than other tissues, and the CNS cells express very low levels of 
antigens coded by the MHC genes, whose products play a fundamental role in the 
induction and regulation of immune responses. It is based on these three features 
that the brain received its immunological privileged status. Immune responses in 
the CNS have been regarded as representing the "intrusion of an ill-behaved mob 
of leucocytes into the well-ordered and organized domain of thought and rea-
son'"7. It may be supposed that it is beneficial for the organism not to turn the 
retina of the eye, or the brain, into an inflammatory battlefield, for the immuno-
logical response is sometimes more damaging than the antigen insult that pro-
vokes it6. 
However, a growing body of literature has accumulated over the past few years 
suggesting that communication exists between cells of the immune system and 
CNS, even under normal conditions. Far from being an immunological privileged or-
gan, the brain can regulate or shape immune responses7,17 and immune responses 
alter neural functions'1,22. The fact "that" of the immune-neuroendocrine interac-
tion is now readily accepted, the "how", the tools, the functional connections that 
are being used in the interaction between the immune and neuro-endocrine sys-
tems have only recently been the subject of a rapidly expanding research. There 
is abundant receptor and ligand promiscuity (Table 1). The neuroendocrine and 
immune system share neuropeptides and cytokines. Neuroendocrine hormones 
of the CNS can influence leucocyte function and leucocyte cytokines can influ-
ence the CNS417,22. Thus, the immune system and the brain speak a common bio-
chemical language*, which is particularly interesting because similarities have of-
ten been noted between the two in terms of the total number of cells and mem-
* Although it is important to note that all lymphoid organs are innervated by neurons and therefore neurologi-
cally 'hardwired'9, this thesis will focus on humoral connections between the immune and nervous systems 
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ory function4. In addition, the immune system can be conceived as a sensory ca-
pacity for noncognitive stimuli. Stimuli that are not recognized by the senses of 
sight, touch, smell or hearing, such as antigens, bacteria and viruses, are convert-
ed into biochemical information in the form of peptide neurotransmitters, hor-
mones and cytokines. This information is then perceived by the neuroendocrine 
system and a physiological response ensues5. 
Table 1. Molecular communication between the immune and neuroendocrine systems expressing 
ligand- and receptor promiscuity 
Immune system <Ç-
Neuro (endocrine) ~ ^^ Peptide hormones 
system Peptide neurotransmitters 
In conclusion, a bidirectional interaction, a crosstalk between the CNS and immune 
system, is generally accepted4·22 (Table 1). But it remains controversial if such in-
teractions might also be of importance in the epilepsies. 
Epilepsy and the immune system 
The present study is a neuroimmunological approach to some therapy-resistant 
childhood epilepsies. In the traditional concept, immunology might seem to have 
little to do with epilepsy1,2, but scattered in the immunological, neurological, and 
paediatric literature several indications supportive for interactions between the immune 
system and the CNS in epilepsy have been reported (Table 2). These interactions, 
however, have not yet been firmly explained and the most fundamental questions 
concerning these interactions remain unsolved. Firstly, immunological factors 
may contribute to the development of epilepsy. Secondly, it is possible that as a re-
sult of seizures, CNS antigens may become exposed to and trigger the immune 
system. Thirdly, another possibility is misregulation of the immune system in 
epilepsy, due to a common genetically determined susceptibility or underlying bi-
ological process that during development concurrently gives rise to immune mis-
regulation and to CNS disturbances leading to epilepsy20'26. 
Therapeutic possibilities in epilepsies due to immune-neuro-endocrine 
interactions 
In this thesis interactions between the immune system and the CNS in some ther-
apy-resistant epilepsies are further investigated. Because of the interactions and 
-5». Cytokines 
- ^ 
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the common biochemical language between the immune and neuroendocrine 
system it would be inconceivable if severe epilepsies would not influence the im-
mune and endocrine systems as well. The question is if this common biochemi-
cal language can also have therapeutic potentiah. In experimental animals it has 
been shown that several areas in the brain respond to immune substances with al-
tered electrical activity15,25. Can the human immune system be used as a target for 
treatment to prevent seizures? This question was studied in two severe childhood 
epilepsy syndromes, the West syndrome (WS) and the Lennox-Gastaut syndrome 
(LGS), both named after the doctors who first described them. 
Table 2. Reported interactions between the immune system and CNS in epilepsies 
Interactions m patients 
Reported immunogenettc abnormalities in patients with epilepsy 
Increased incidence of antibodies to brain tissue20 
Association with certain HLA alleles'2 
Impaired immunity (IgC¡ and IgA deficiencies)" '°, increased humoral or cellular immunity' ' 
Anticonvulsants such as phenytoin and carbamazepine can suppress the immune system (IgC2 and IgA) 
or precipitate SLE in some patients' г 
Vigabatnn interferes with the cellular immune response" 
Immunosuppressive drugs such as ACTH or corticosteroids can show an anticonvulsant effect, espe­
cially in otherwise intractable childhood epilepsies like West syndrome (WS) or Lennox Gastaut syn­
drome (LGS)" 
Clinical experience of exacerbations and also remissions of epilepsy after viral infection"" 
Some immunological mediated diseases such as SLE and myasthenia gravis are associated with epilep 
sy more often than would be expected by chance' 
Patients with gliomas (and epilepsies) present with suppression of humoral and cellular immunity" 
Rasmussen's encephalitis (hemiparesis, mental retardation, epilepsia partialis continua) is the combi 
nation of an immunologically mediated cortical lesion with epilepsy" 
Interactions m experimental animais 
Epileptiform discharges can be recorded after intracerebral injection of anti brain antibodies to neu­
ronal cell membrane components2 " 
Electroconvulsive shock induces production of anti brain antibodies2" 
Electrically and chemically induced convulsions modulate experimental allergic encephalomyelitis and 
other immune inflammatory reactions2* 
Anti brain autoantibodies from rats exposed to electroconvulsive shock show neuromodulating activi-
t y " 
Genetically epilepsy-prone rats show immune dysfunction (decreased IgM concentrations, increased 
IgG concentrations)2' 
The immune response evokes changes in brain noradrenergic neurons' 
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The elements: Intractable childhood epilepsies, 
especially West syndrome and Lennox-Gastaut 
syndrome 
What is epilepsy? 
Epilepsy has been described since ancient times. The Hippocratic writings include 
full clinical descriptions and a clear recognition of the brain as the site of the dis-
order12. Although the expression of epilepsy is most commonly perceived as a ton-
ic-clonic convulsion, its actual clinical presentation is quite variable, ranging from 
a convulsion to simple brief lapses in awareness with many other behaviours be-
tween these extremes. Because of this diversity of the clinical expression of epilep-
sies, the classification of epilepsies is of major concern (Table 3), and the question 
"what is epilepsy?" is nowadays usually answered referring to the underlying phys-
iological disorder. Since Hughlings Jackson (1863) epilepsy is primarily defined 
physiologically, "as an episodic disorder of the CNS arising from the excessively syn-
chronous and sustained discharge of a group of neurones"17. In this view, the clin-
ical definition of epilepsy is derived from the physiological one, and involves a 
paroxysmal and transitory disturbance of brain function that develops suddenly, 
terminates spontaneously, and exhibits a tendency to recur10. 
One may realize that the above definition is only one of the possible defini-
tions, and that a phenomenological approach of epilepsy taking into account the 
experience of the patient and his or her relatives is of the utmost importance both 
for understanding the essence of epilepsy and for direct paticntcare. The present 
thesis, nevertheless, will focus on epilepsy as a brain dysfunction because a (rela-
tively new and non-conventional) biological treatment approach is investigated. 
The frequency of epilepsy 
Although it is difficult to obtain accurate information and statistical data on fre-
quency and distribution of epilepsy, it is generally estimated that 1-2% of the pop-
ulation will be classified as having epilepsy at some time in their lives. About half 
of these will have it as long as they live. 
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Table 3. International classification of epilepsies, epileptic syndromes and related seizure disorders 
(adapted from Epilepsia9) 
Î. Localization related (focal, 
local, partial) 
2. Generalized 
Idiopathic 
(primary) 
Cryptogenic 1 2 
Symptomatic 
(secondary) 
1 3 
Benign childhood epilepsy 
with centro-temporal spike 
Childhood epilepsy with 
occipital paroxysms 
Primary reading epilepsy 
Defined by seizure type, 
clinical features, etiology, 
anatomical localization 
2 1 Benign neonatal familial convulsions 
Benign neonatal convulsions 
Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy (pyknolepsy) 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy (impulsive 
petit mal) 
Epilepsies with grand mal seizures 
(GTCS) on awakening 
Other generalized idiopathic epilepsies 
Epilepsies with seizures precipitated by 
specific modes of activation 
2.2 Cryptogenic or symptomatic: 
West syndrome (Infantile spasms) 
Lennox-Gastaut syndrome 
Epilepsy with myodonic-astatic seizures 
Epilepsy with myoclonic absences 
Temporal lobe epilepsies 
Frontal lobe epilepsies 
Parietal lobe epilepsies 
Occipital lobe epilepsies 
Chronic progressive epilepsia 
partialis continua of childhood 
Nonspecific etiology: 
Farly myoclonic encephalopathy 
Early infantile epileptic encephalopathy 
with suppression bursts 
Other symptomatic generalized epilepsies 
Syndromes characterized by 
seizures with specific modes 
of precipitation 
3. Undetermined epilepsies 
3.1 
2 3 2 Specific syndromes· 
Epileptic seizures may complicate many 
disease states 
4. Speculi syndromes 
3 2 
With both generalized 
and focal seizures: 
Neonatal seizures 
Severe myoclonic epilepsy in 
infancy 
Epilepsy with continuous 
spike waves during slow 
wave sleep 
Acquired epileptic aphasia 
(Landau-Kleffner syndrome) 
Other undetermined epilepsies 
Without unequivocal 
generalized or focal features 
4 1 Situation-related seizures. 
Febrile convulsions 
Isolated seizures or isolated 
status epilepticus 
Seizures occurring only when there is an 
acute metabolic or toxic event due to factors 
such as alcohol, drugs, eclampsia, 
nonkctonic hyperglycaemia 
INTRACTABLE CHILDHOOD EPILEPSIES 9 
A far greater number, perhaps as many as 5% of the general population, will have 
an isolated seizure at some time3. The incidence of WS varies between 18-40 per 
100,000 children. WS counts for 3-15% of all seizure disorders during childhood, 
and for 52% of all afebrile seizure disorders diagnosed during the first year of life12. 
LGS represents 3-10% of all epilepsies in childhood12. 
Seizures, epilepsy, the epilepsies and epileptic encephalopathies 
A seizure or ictus is a single event that results in an altered state of brain function. 
If someone persists in having multiple seizures, then the word "epilepsy" is appro-
priate to describe the condition, when at least an underlying structural or physio-
logical change in the brain is presupposed3,10. A seizure is a symptom, a finite event 
in time with a distinct beginning and end, epilepsy is a chronic syndrome with re-
current symptomatology or seizures. Therefore, in the WHO-definition epilepsy 
is a chronic brain disorder characterized by recurrent seizures. Epilepsy is not one 
single disease, it consists of a group of different syndromes or clinical seizure pat-
terns. To take into account and emphasize this heterogeneity of epilepsy, the term 
the epilepsies™ is more appropriate. 
In some cases, seizures are the only expression of the brain disorder and the pa-
tient is symptom-free between the seizures. In other cases the patient presents 
with a variety of other symptoms of a more or less widespread brain disorder and 
epilepsy is only one of the symptoms. Apart from the seizures mental retardation 
can be another expression of the underlying encephalopathy. Frequent seizures by 
itself can also influence mental development in a negative way. WS and LGS 
belong to the latter group of epileptic encephalopathies. Delineating such epilepsy 
syndromes or epileptic encephalopathies permits a greater precision of diagnosis 
and prognosis than simply classifying seizure types. In the recent classification of 
epilepsies the term epileptic syndromes has been introduced. 
Ictogenicity as a characteristic of the brain 
Seizures are not dependent on a specific disease process. Almost any condition 
(genetic, metabolic, toxic, traumatic, infectious, hypoxic, vascular, neoplastic or 
degenerative) that disturbs normal brain function can result in a lowering of the 
seizure threshold of the brain and contribute to the pathogenesis of seizures or 
epilepsies. It is important to realize that abnormal neuronal discharges or seizures 
result only from the electrical discharge of living cells. Living neurons are the fi-
nal common pathway of seizures. Dead or necrotic tissue and scar tissue around 
a lesion may promote seizure activity of the surrounding living neurons. From 
this concept it is understandable that seizures can even be induced in normal brain 
by convulsive agents, electric shock, or alterations in metabolic environment. 
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Thus, the production of seizures is a property of the normal brain when put into 
abnormal situations. One of the characteristics of the living brain L· to be ictogenic 
ana epilepsy-prone. 
Epilepsies in childhood; idiopathic, cryptogenic and symptomatic 
epilepsies; intractable epilepsies 
Most epilepsies have their onset in childhood and 78% of childhood epilepsies are 
reported to begin within the first 3 years of life23. It has been estimated that 3-10% 
of children under five years old may have at least one convulsion of one type or 
another6. The child's brain is more "icto-sensible" than a mature brain (Table 4). 
The immature state of the child's brain enhances the generation as well as the phe-
notypic expression of seizures. Animal data show that early postnatal develop-
ment is a period of increased susceptibility to seizures. The cause is probably a 
combination of enhanced excitation (overabundance of excitatory postsynaptic 
potentials [EPSP], increased density and sensitivity of N-methyl-D-aspartate [NM-
DA] binding sites, high number of neurons involved in a network of recurrent ex-
citation), and diminished inhibition (low GABA levels and receptors), as well as de-
velopmental differences in subcortical circuits (such as the substantia nigra-mediat-
ed seizure-suppression system). Several other factors have been proposed. Immature 
neurons have high input resistance and thus, small currents may lead to large volt-
age changes (Ohm's law, V=IxR); increases in axonal myehnation may provide 
more effective communication among cells; ephaptic influences may facilitate 
neuronal synchronization; and delayed development of glia may allow potassium 
to accumulate which contributes to hyperexcitability22. All these age-dependent 
factors may contribute to an increased incidence of seizures and epilepsy in child-
hood. 
Table 4. Possible reasons why the immature brain L· more "icto-sensible" 
Enhanced excitation (overabundance of excitatory postsynaptic potentials, 
increased density and sensitivity of N methyl-D-aspartate binding sites, high number of 
neurons involved in a network of recurrent excitation) 
Diminished inhibition (low GABA levels and receptors) 
Developmental differences in subcortical circuits (such as the substantia 
nigra-mcdiated seizure suppression system) 
Immature neurons have high input resistance and thus, small currents may 
lead to large voltage changes (Ohm's law, V=[xR) 
Increases in axonal myehnation may provide more effective communication 
among cells 
Ephaptic influences may facilitate neuronal synchronization 
Delayed development of glia may allow potassium to accumulate which 
contributes to hyperexcitability 
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The term cryptogenic, from the Greek kryptos genos (hidden origin) relates to 
epilepsies in which a cause is supposed but cannot be identified9. The major goal 
in cryptogenic epilepsies is to identify the hidden lesion, its topography and its na-
ture". In symptomatic epilepsies an etiology can be determined, or there is evi-
dence of brain damage, which is supposed to be related to a lower seizure thres-
hold. The term idiopathic, from the Greek idios pathos (disease produced by itself, 
and which has no other cause than itself) relates to epilepsies without any brain 
damage, the condition is purely functional. It develops at a specific age and leaves 
no sequelae". 
Because many of the epilepsies in infancy and young childhood are difficult to 
treat and are frequently associated with mental retardation and/or mental re-
gression, the term malignant has been used in contrast to the benign childhood 
epilepsies27. Although the term intractable in the strict sense refers to the resistance 
to treatment, it is frequently used as synonymous with malignant. 
Table 5. Definitions of cryptogenic, symptomatic and idiopathic epilepsies 
Cryptogenic relates to epilepsies in which a cause is supposed but cannot be identified 
Symptomatic relates to epilepsies in which an etiology can be determined, or where there 
is evidence of brain damage, which is supposed to be related to a lower 
seizure threshold 
Idiopathic relates to epilepsies without any brain damage, the condition is purely 
functional 
The epilepsy syndromes of West and Lennox-Gastaut 
The child's brain is a continuous evolutionary process of developmental and matura-
tional changes. Despite this continuity, maturation during infancy and childhood 
is not a smooth and steady growth but is characterized by stepwise development at 
critical ages23. This idea of stepwise development fits with the classification of dif-
ferent (but connected) epileptic syndromes based on differences in age of onset. 
A certain seizure pattern manifests itself in a certain age range and a specific 
epilepsy is observed in a specific age range24. Each of these age-clamped epileptic 
conditions show characteristic clinical and EEG features in spite of etiological he-
terogeneity and topographical differences in brain lesions. Vice versa, a certain eti-
ology can cause various types of epileptic syndromes at successive ages. 
The term age-dependent epileptic encephalopathy combines the concept of an un-
derlying maturational continuity with different age-related epileptic phenotypes. 
According to Ohtahara, the age-dependent epileptic encephalopathy is a general 
term for 3 syndromes, namely early infantile epileptic encephalopathy (EIEE) 
with suppression-burst (Ohtahara syndrome), WS, and LGS23. Ohtahara distin-
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guishes the following characteristics: (1) age dependence, (2) characteristic minor 
seizures, (3) high seizure frequency, (4) almost continuous and severe epileptic 
EEG abnormalities, (5) polyetiology, (6) frequent association with mental defect, 
and (7) intractability and grave prognosis. Meanwhile, each of these 3 types is an 
independent "electro-clinical" entity with its own age-dependent clinical and EEG 
characteristics, and constitutes an independent epileptic syndrome. The present 
study will focus on the most frequent and the most clearly delineated and widely 
accepted childhood epileptic disorders, WS and LGS. 
Transition from West syndrome to Lennox-Gastaut syndrome 
Because of the frequent transition from WS to LGS and the close mutual rela-
tionship between both age-dependent epileptic encephalopathies, both patients 
with WS and LGS were included in the present thesis. WS can precede LGS in 20-
30% of the cases1. Evolution of WS to LGS has been reported in 23% to 57% of 
patients1213. 
The West syndrome/Infantile spasms 
West syndrome has been recognized since its early description by West in 1841. 
The syndrome is also known as infantile spasms, which term however both indi-
cates a seizure type and a syndrome with multiple causes1. WS is characterized by 
the triad 1) infantile spasms occurring in series, 2) a typical interictal EEG pattern, 
called hypsarrhythmia, in awake stage, and 3) arrest of mental development, men-
tal retardation or deterioration19. The incidence of infantile spasms has been esti-
mated to be 1 per 3000 to 1 per 6000 live births. The onset is usually in the age 
group 4-7 months27. 
Table 6. Characteristics of West Syndrome 
1 Infantile spasms occurring in senes 
2 A typical intenctal EEG pattern, called hypsarrhythmia, in awake stage 
3 Arrest of mental development, mental retardation or deterioration 
Infantile spasms are generalized brief (fraction of a second to several seconds) 
myoclonic contractions of muscles of the neck, trunk and extremities, occurring 
both as a single seizure and as a series of seizures. Spasms are more or less bilat-
eral symmetric even when focal cerebral lesions are present. Three main photo-
types of spasms can be recognized: flexor (35%), extensor (20%), or mixed (45%). 
They frequently occur upon arousal or when unexpected auditory or tactile stim-
uli occur. They might be interpreted as the expression of a disturbed interaction 
between cortex and subcortical structures and have some resemblance with the 
Moro-reflex. 
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The pathophysiology of WS remains unknown. Any pathophysiological hypothesis 
has to be compatible with the unique features of this seizure disorder. Some of 
these are: How can a single entity have diverse causes? Why does WS arise only in 
infancy? Why is it associated with profound and lasting cortical dysfunction? Why 
does it respond to ACTH and corticosteroids? 
Table 7. Reported pathophysiological hypotheses of WS 
Immune anomalies (certain HLA associations)" 
Developmental "arrest" in a period of maximum cerebral development (development of dendritic 
spines, mitotic activity, myelin)18 
Brainstem dysfunction (REM-sIeep abnormalities)13 
Unihemispheric dysfunction8 
The interictal EEG is characterized by hypsarrhythmia, particularly in younger 
infants. Hypsarrhythmia is a mix of continuous irregular polymorphous theta and 
delta waves and spikes, and sharp waves with variable localization. This typical 
pattern can be modified by the states of wake or sleep, by age and by etiology. 
Fragmentation of hypsarrhythmia can be seen in NREM-sleep and disappearance 
in REM-sleep; in younger infants an increase of hypsarrhythmia in sleep can oc-
cur. The most common EEG-event associated with spasms is a high-voltage, gen-
eralized, slow-wave transient, followed by a general attenuation of background 
activity that may last from one to many seconds. 
While infantile spasms are age-related phenomena and tend to disappear six to 
twelve months after onset of the disease, and although mental development after 
a first decline may normalize after arrest or control of spasms in 10 to 30% of the 
cases, in all other cases severe mental retardation with dyspraxia and dysgnosia, 
dysphasia and autistic behaviour are the dramatic outcome. WS can be classified 
according to etiology in idiopathic (5%), cryptogenic (15%) and symptomatic 
(80%). The number of cryptogenic cases decrease in favour of the symptomatic 
ones because of the improved technical possibilities. The characteristics and prog-
nosis of these three forms of WS are difFerent. Prognosis is best in idiopathic cas-
es. 
The main causes of WS according to Aicardi1, are listed in Table 8. This list of 
causes is not exhaustive but dearly indicates how diverse causes can be. Brain dys-
genesis, neurocutaneous syndromes (mainly tuberous sclerosis) and chronic ac-
quired lesions account for the majority of symptomatic cases. From their patho-
logical studies, Meencke and Gerhard21 found no detectable pathology in only 
11% of 107 cases. Most cases are related to diffuse lesions, but unilateral lesions 
may also be responsible. 
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Table 8. Main causes of WS (adapted from Awardi') 
Neurocutaneous syndromes 
Tuberous sclerosis 
Neurofibromatosis 
Sturge-Weber syndrome 
Incontinentia pigmenti 
Linear naevus syndrome 
-Brain malformations 
Aicardi syndrome 
Agyna-pachygyna 
Holoprosencephaly 
Hemimegalencephaly 
Heterotopias and other migration disorders 
Down syndrome 
Fragile X syndrome 
Metabolic diseases 
Phenylketonuria 
Non ketone hyperglycinaemia 
Hyperornithinaemia hyperammonaemia-homocitrullinaemia 
Histidinaemia 
Leigh disease 
Pyndoxine dependency 
Degenerative diseases of unknown cause (polrodystrophy, leukodystrohpy) 
Toxic 
Sequelae of neonatal hypoglycaemia 
Lithium toxicity 
Hypoxic ischaemic encephalopathy 
Prenatal, perinatal or postnatal 
Cerebral infarcts 
Near drowning 
Trauma and haemorrhage 
Neonatal haemangiomatosis 
The issue of therapy is still under debate. ACTH and corticosteroids have re-
mained for over 35 years the most active drugs for treating infantile spasms al-
though their mode of action remains unknown. In 1958, Sorel and Dusaucy-
Bauloye31 were the first to report excellent results of a therapy with 4-10 units of 
ACTH-retard during 10-25 days, depending of the age of the child (5 weeks-
27 months). Subsequently, many publications on hormonal therapy have ap-
peared, reporting different results while using a variety of products and dosages. 
Some authors proclaim high doses of ACTH during several months while others 
prescribe low doses of ACTH during a few weeks. In a retrospective study, Renier 
and Le Coultre26 have demonstrated that, independent of the type of therapy 
(conventional anticonvulsant drugs, low dose ACTH or high dose ACTH), there 
is a good result in approximately 10% of the infants. Severe or fatal complications 
occurred only in the high dose ACTH group. One of the best studies is the dou-
ble blind and 24-hours polygraphic/video monitoring study of Hrachovy et al14. 
This study demonstrates that the response to hormonal therapy is all or none, that 
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only a short course (2 weeks) of therapy is required and that there is no major dif-
ference in therapeutic efficiency between ACTH (20-30 units/day) and pred-
nisone (2 mg/kg/day). In their opinion etiology and treatment delay are not use-
ful predictors of response and normalization of the EEG is not an absolute crite-
rion for clinical outcome or prognosis. 
Of the conventional anticonvulsant drugs, valproate (25-50 mg/kg/day) has 
been reported to be effective and is still a first choice drug. Liver enzymes and 
thrombocytes have to be checked carefully in infants with mental retardation un-
der treatment with valproate. In mitochondriopathies valproate should be avoid-
ed. In symptomatic types of infantile spasms, especially tuberous sclerosis, viga-
batrin (40-80 mg/kg/day) has been promoted as a drug of first choice, but focal 
seizures can be activated. In the cryptogenic types the results are less pro-
nounced30, and half of the responders later relapsed2. 
Occasionally a high dose of pyridoxine (200-400 mg/day) produces clinical and 
EEG improvement. Beneficial results have been described with intravenous im-
munoglobulins (IVIg), with thyrotropin-releasing hormone (TRH) and with 
methysergide and alpha-methyl-paratyrosine. The study of Chugani et afdemon-
strates that in infants with cryptogenic spasms, positron emission tomography can 
identify those due to unsuspected focal cortical dysplasia, for which resective 
surgery may offer a better prognosis. For more details on therapy we refer to Re-
nier27. 
The Lennox-Gastaut syndrome 
The classical Lennox-Gastaut syndrome (LGS) is characterized by the triad: 1) 
characteristic multiple seizures (axial tonic, atypical absences, atonic seizures) pos-
sibly associated with generalized tonic-clonic seizures and complex partial 
seizures, 2) interictal diffuse slow (less than 3/s) spike and wave discharges in the 
awake EEG, and 3) cognitive dysfunctions with personality disorders and behav-
ioural problems5. The age of onset of epilepsy is between 1 and 8 years. There is 
a male:female ratio of 1,5: l27. 
Short tonic, atonic and myoclonic seizures may lead to frequent drop attacks. 
The clinical characteristics of LGS varies with age of onset and neurological de-
fects. Tonic fits are more frequent in symptomatic cases, whereas myoclonic at-
tacks and atypical absences are more frequent in cryptogenic cases. 
Interìctal EEG shows slow background activity, slow (1-2,5 Hz) spike wave com-
plexes while awake, polyspikes while asleep, and fast rhythms of 10/sec during 
sleep; in REM-sleep the paroxysmal activity decreases markedly. 
Behaviour problems in LGS are nonspecific. Hyperkinetic motor behaviour, 
short attention span, slow mental speed, perseveration, stereotyped behaviour 
and progressive mental retardation are frequently found. Mental retardation is 
present before seizure onset in approximately 60% of the cases. 
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Table 9. Characteristics ofLennox-Gastaut syndrome 
1 Characteristic multiple seizures (axial tonic, atypical absences, atonic seizures) possibly associated 
with generalized tonic-clonic seizures and complex partial seizures 
2 Incenerai diffuse slow (less than 3/s) spike and wave discharges in the awake EEG 
3 Cognitive dysfunctions with personality disorders and behavioural problems 
The causes of LGS are multiple, and the same brain insults that produce WS 
(Table 8) can be responsible for LGS. Brain malformations, however, are less com-
mon in LGS1. The pathophysiology of LGS still remains to be elucidated. A poor 
dendritic arborization of the inner layers of the cerebral cortex has been found in 
supposedly "cryptogenic" cases25'29. Diffuse or more localized hypometabolism on 
the interictal PET-scan can be demonstrated1. 
Sodium valproate and benzodiazepines (clonazepam, nitrazepam, clobazam) 
are the anticonvuhant drugs most often used in LGS: valproate being the drug of 
first choice that should be tried. Hyperactivity and dysphoria can occur as side-ef-
fects of the medication. Sometimes a combination of valproate and benzodi-
azepines proves to be more effective than a monotherapy of either drug. In that 
case benzodiazepines should be added to the initial valproate treatment. The 
dosage of both drugs is best evaluated by clinical observation of seizure frequen-
cy, alertness, and side-effects. 
Benzodiazepines commonly show an initial and quick reduction of seizure fre-
quency ("honeymoon response") followed, after several months, by tolerance. 
Change of the product or alternate day medication can be tried in such cases, how-
ever without guarantee of success. Starting with a low dose and a higher dose at 
bedtime is to be advised. Drowsiness or paradoxical hyperactivity, lack of con-
centration, problems with short memory functions, hypotonia, increased 
bronchial secretion and drooling, limit the use of benzodiazepines in young chil-
dren. Because alertness and active wakefulness are usually associated with fewer 
seizures, a reduction of sedative drugs can give better results. Exceptionally, a ton-
ic status epilepticus can be provoked by benzodiazepines. For all these reasons 
these should, if possible, be used only in acute situations with no respiratory dis-
tress and for a short period of time. Phénobarbital, primidone and phenytoin are 
usually ineffective. They have side-effects on memory and behaviour during 
chronic use. Nevertheless, primidone and ethosuximide can be used if other drugs 
fail. Carbamazepine can be helpful in older children who have more generalized 
tonic-clonic and complex partial seizures associated with mood disturbances. Oc-
casionally carbamazepine can provoke non-convulsive and/or myoclonic 
seizures. Lamotrigine is a promising new drug but more longterm experience is 
needed. 
Although their effect is even more questionable than in WS, ACTH or corti-
costeroids can be tried in a period of deterioration, frequendy a period of physi-
cal growth27. This add-on treatment is given during 5 or 10 days, the benefit is of-
ten only temporary. The best results are observed in children under the age of four 
years, and in cryptogenic cases. 
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Because treatment with conventional AED's in many cases is disappointing, alter­
native treatment regimens have been tried. There is no proof that treatment with 
special diet (ketogenic diet, oligo-antigenic diet, food without additives) is of help 
in children with an allergic constitution or with hyperactivity and behaviour 
problems27. Thyrotropin-releasing hormone (0,5-1,0 mg i.v. or i.m. for 1 or 4 
weeks) is reported to have beneficial but transient effect in half of the cases20. High 
dose of intravenous immunoglobulins have been used by clinical researchers. 
LGS may have a waxing and waning course. This is the reason that treatment 
trials are difficult to perform and to evaluate. On the other side, because of the 
severity and frequent intractability of the epilepsy syndrome, small results have 
their value and all new treatments should be fully exploited. This thesis will fur­
ther explore the effect of human intravenous immunoglobulin (IVIg) on WS and 
LGS. 
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The elements: The human polyclonal 
immunoglobulin preparation 
Introduction 
Human polyclonal immunoglobulin for intravenous use (IVIg) has some charac-
teristics in common with a Swiss army knife: it is relatively expensive but can be 
used for multiple purposes. And indeed, IVIg is used for multiple purposes, it 
serves as an expensive panacea for an increasing amount of diseases11,19. It is met 
with enthusiasm by some, but with suspicion by many, for we do not know if it 
works in most of these different conditions, and when it works we do not know 
how it works. Several years of clinical utilization and therapeutic success in some 
autoimmune diseases have not sufficed to establish the mode of action of normal 
human polyclonal immunoglobulin administered intravenously at high doses (See 
the following special issues of: Clin Exp Immunol 1994;97, Immunol Reviews 
1994;139, J Neurol Neurosurg Psychiatry 1994;57). Only recently IVIg managed to 
make the desired transition from clinical "bedside" to the laboratory "bench". 
Table 1. Use of IVIg in neurological diseases (Thornton & Griggs19) 
Effective in randomized GuiUain-Barré syndrome 
controlled trials: Dermatomyositis 
Probably effective: Polyneuropathy with IgG or IgM paraprotein 
Multifocal motor neuropathy 
Myasthenia gravis 
Chronic idiopathic demyelinating polyneuropathy 
Possibly effective: Lambert-Eaton myasthenic syndrome 
Polymyositis 
Inclusion-Body myositis 
Immunoglobulins, especially IgG 
Immunoglobulins are glycoproteins synthesized by cells of the B-cell lineage. 
They are bifunctional with a recognition function (binding antigens), and an ef-
fector function (initiating a variety of biological activities like adherence of phago-
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cytes). All immunoglobulins consist of 2 identical polypeptide light chains linked 
to 2 identical heavy chains. According to the size, charge, amino acid composition 
and carbohydrate content of the heavy chain, immunoglobulins are divided in 5 
classes: IgG, IgA, IgM, IgD, and IgE. IgG is the main immunoglobulin class and ac­
counts for 80% of serum immunoglobulins (Table 2). The predominant role of 
IgG in antibody-mediated immunity, together with its remarkable long half-life 
(18-32 days) in adults as well as in children4, led to many attempts to use it as a 
therapeutic agent. 
Table 2. Some properties of human immunoglobulin classes' 
Property 
Usual molecular 
form 
Molecular formula 
Subclasse* 
Molecular weight 
Mean Serum level (g/l) 
Percentage of 
total serum 
immunoglobulin 
Mean Half life (days) 
IgG 
Monomer 
κ,γ2 or 
КУі 
IgG,. IgG,, 
IgC3.lgG4 
150,000 
12 
75 85% 
23 
IgA 
Monomer 
dimer 
(κ2α2)„ or 
(λ2α2)η 
IgA„IgA2 
160,000 
1 8 
7-15% 
6 
IgM 
Pentamer 
(κ,μΛ or 
(λ,μ2). 
900,000 
10 
5-10% 
5 
IgD 
Monomer 
К A or 
λΑ 
180,000 
0 03 
0 1% 
3 
IgE 
Monomer 
κ,ε, or 
Ke-i 
200,000 
0 0003 
0 003% 
2 
The first immunoglobulin preparations only suitable for intramuscular ad­
ministration, have initially been used for substitution of immunodeficiency 
states'. Safe human polyclonal immunoglobulin preparations for intravenous use 
became available some ten years later (Barandun3; see also page 24). Another 20 
years later Imbach showed that human polyclonal intravenous immunoglobulin 
can also rapidly remedy the platelet deficiency in (autoimmune) idiopathic throm­
bocytopenic purpura". This success opened up for IVIg administration an unex­
pectedly wide scope in the treatment of autoimmune diseases". 
Characterization of IVIg 
IVIg is a biological product and differs in many respects from classical chemically syn­
thesized pharmaceuticals. There is no defined chemical formula to be checked, 
100% purity is never achieved, and the composition of the various immunoglobu­
lins may differ from preparation to preparation or even from batch to batch. 
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Content of IVIg 
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Fig 2. Some components of the complex IVIg 'soup' 
The IVIg preparation used in this thesis is, except for one experiment (Chapter 13), 
manufactured by the Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service (CLB) Amsterdam. This preparation contains mainly (>95%) 
pooled human IgG in a form that is safe for intravenous administration. In addi-
tion it is kwown to contain other immunoglobulins (1% IgA, traces of IgM and 
IgE), other proteins (soluble CD4, CD8, HLA-molecules, interferon gamma), and 
additives: sodium (25-50 mmol/1), and glucose (160-300 mmol/1). 
Production of IVIg 
IVIg is produced by (1) creating large pools of plasma from several thousands of 
blood donors (2) cold alcohol (Cohn) fractionation to precipitate IgG, and (3) a 
"finishing step" that removes aggregated IgG and other complement-activating 
material19. Each of the 3 steps will be discussed successively. 
Table 3. Production of IVIg 
1 Creating large pools of plasma from several thousands of blood donors 
2 Cold alcohol (Cohn) fractionation to precipitate IgG 
3 A "finishing step" (chromatography, ion exchangers, pH reduction, enzymatic or chemical modifica-
tion) that removes aggregated IgG and other complement-activating material 
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(1) Creating large pooh of plasma 
Large donor pools maximize the diversity of antibodies in the final product, such diversity may be important for 
the therapeutic effect Careful selection of donors is necessary for safety from infection Emphasized is the im 
portance of voluntary, unpaid blood donation (hepatitis infection correlates with the number of paid blood 
donors), the medical examination of every individual donor, and the precise introductory screening of every in­
dividual blood donation'7 
(2) Cold alcohol (Cohn) fractionation 
Cold ethanol fractionation of plasma was introduced during World War II to generate large volumes of safe plas 
ma products that could be stored and shipped for use by military services1'1 Described by Cohn10, the process 
was based on the theory that various plasma proteins precipitate at a pH near the isoelectric point, as governed 
by an increasing ethanol gradient The Cohn fractionation leads to removal of viruses to a very high degree At 
the present time, cold ethanol fractionation is based on the methods of Cohn and Ondey in the United States, 
and on modifications of this method m Europe" These fractionation processes use a muluvanable system, with 
specified ethanol and protein concentrations, pH s, ionic strengths, and temperatures, to precipitate plasma in 
to its serial 'Cohn fractions A single donation of 500 ml whole blood yields only about 2 3 ml of im 
munoglobulin, 9 ml albumin, <1 ml fibrinogen, and 3ml of a combination of > 100 different proteins (Table 4) 
(3) a "finishingstep" that removes aggregated igG 
The Cohn fraction contains monomers, dimers, and aggregates of immunoglobulins, as well as trace amounts 
of non immunoglobulin serum proteins Although safe for intramuscular administration, further processing is 
necessary to make the product safe for intravenous use 
Safe IVIg preparations became available some 30 years ago, when Barandun1 reported that the adverse re 
actions of intravenous injection of the conventional intramuscular immunoglobulin preparation were due to 
spontaneous activation of the complement system by a small part of the aggregated immunoglobulin molecules 
Additional processing is needed to inhibit or remove aggregates Two methods of purification are currently 
employed These methods include techniques for (3a) reduction of the natural ability of immunoglobulin to ac 
Table 4. Cold alcohol (Cohn) fractionation for the production of immunoglobulins out of whole blood, 
(adapted from1"') 
Blooddonor — 5»- 500 ml whole blood Js>- red blood cells 
platelets V 
250 ml plasma 
Ψ 
15 ml plasma proteins 
pH 7 2/8% ethanol 
i 
Supernatant I 
I pH 5 85/19% ethanol 
1/ 
\ I Precipitate A 
Albumin (9 ml) 
v 
pH 4 8/2% ethanol 
pH 5 1/12% ethanol 
Supernatant II 
pH 7 2/25% ethanol 
Y ν 
Supernatant III Precipitate В (Immunoglobulins, 3 ml) 
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tivate complement via enzymatic or chemical modification and (3b) elimination of aggregates by chromatogra­
phy or ion exchangers or by pH reduction14 
In method 3a aggregate formation of the immunoglobulin product can be reduced by enzymatic modifica­
tion for example by pqmn the Fc fragment is completely split off, the binding site for the complement compo­
nent Clq is destroyed, and the residual F(ab)2 fragment is still bivalent and may precipitate and agglutinate with 
antigens The preparation is well tolerated and safe because formation of spontaneous complement activity is 
no longer possible On the other hand, in vivo half-life is dramatically reduced to less than 10%, and IgGj sub 
class proteins are broken down" Complement activation may also be eliminated by Летка} modification of the 
immunoglobulin molecule for example by modification of the Fc fragment with beta propiolactone As with en­
zymatic cleavage the in vivo half life is reduced, showing that the body no longer recognizes the molecule as na­
tive 
Many attempts have been made to eliminate aggregates (method 3b) Chromatography, ion exchangers or pH 
reduction may produce good tolerability as well as stable immunoglobulin preparations The processing used by 
the Swiss Red Cross Central Laboratory Transfusion Service (Sandoglobulin, distributed by Sandoz Pharma 
ceuticals) as well as by the CLB (The Netherlands) for their IVIg preparation consists of a mild acid pH, which 
enables a non-modification purification that prevents or inhibits aggregate formation, without physically re­
moving any constituent Traces of pepsin improves stability of the preparation and the reproducibility of the 
technique This liquid preparation is well tolerated, but it has to be stored in the cold, and sometimes precipita 
Dons form during storage Further improvements have been introduced and excellent stability at room tem­
perature is achieved by freeze drying" 
In conclusion, this finishing step (3) is different for various IVIg preparations cre­
ating differences in the final product that could affect biological activity. The dif­
ferences in finishing step have led to the generation of IVIg products that are sim­
ilar in immunoglobulin composition, but which vary in antibody activity and in 
content of other proteins716. As yet, however, there are no clear indications that 
differences in IVIg preparations cause differences in therapeutic effect or toxicity. 
Cost of IVIg 
The price of 9000 milligrams IVIg is some Fl 600,-. In the treatment of autoim­
mune diseases, dosages range from 100-1000 mg/kgbodyweight per day. The cost 
of IVIg administration in the treatment of adult autoimmune diseases is general­
ly (100-1000 mg) χ (80 kg) χ (Fl 600,-/9000 mg IVIg) = Fl 500,- to Fl 5000,- per day. 
For children with WS or LGS (10-30 kg) the cost of IVIg can be estimated between 
Fl 60,- and Fl 2000,- per day. For prophylactic treatment in immune deficiency 
states lower dosages (300 mg/kg/3 weeks) are used. 
Side effects 
IVIg is generally considered to be safe, complications are known to occur in less 
than 10% of cases', but caution is urged when there is cardiac or renal disease. 
Table 5 comprises the generally infrequent and infusion rate dependent side ef­
fects, and also the rare but major side-effects of IVIg6,8,12. Viral safety, especially for 
hepatitis С remains of major concern. 
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Table 5. Side-effects oflVIg 
Rare side effects: 
Headache 
Myalgia 
Vasomotor symptoms 
Fever 
Skin rash 
Extremely rare but major side effects (especially in older people): 
Congestive heart failure, Hypotension 
Deep venous thrombosis, stroke 
Renal failure 
Aseptic meningitis 
Neutropenia 
Hepatitis С infection 
Anaphylactoid reactions (IgA deficiency) 
Mechanisms of action 
IVIg is not a treatment searching for a disease, it is a treatment searching for its 
mechanisms of action. Several recent reviews on IVIg in medicine11, and neuro­
muscular diseases19, and entire volumes dedicated to IVIg (Clin Exp Immunol 
1994;97, Immunol Reviews 1994;139, J Neurol Neurosurg Psychiatry 1994;57) 
have shown the broad applicability of IVIg. IVIg is complex material, in different 
diseases different mechanisms of action might be present. Undoubtedly, no single 
mechanism accounts for the immune modulating effects of IVIg, even in one spe­
cific disease. 
Table 6. Some possible mechanisms of action of IVIg in non-immune deficient states 
1 Anti-idiotype activity 
Neutralization of toxin superantigens 
2 Fc receptor blockade 
Complement binding 
3 Immunomodulation (CD8+ T<ells, В cells, cytokines) 
4 Effect of "contaminating" proteins 
Human polyclonal immunoglobulin is complex material. Made from plasma of 
several thousands of donors, it contains at least 108 different immunoglobulin 
(IgG) molecules recognizing 10е different epitopes. Some of these IgG molecules 
recognize and bind to epitopes on IgG molecules from the receiving patient (an­
ti-idiotype interaction, Table 6). Other IgG molecules react with bacterial toxins 
from Staphylococcus and Streptococcus organisms. These toxins stimulate a large 
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fraction of the Τ cell population without requiring prior sensitization and are 
called superantigens™. The other side of the IgG molecule, the Fc fragment, can 
block the Fc receptors of the reticuloendothelial cell system and mononuclear 
phagocytes, and bind to biologically active complement components. Even more 
complex mechanisms of action of IVIg are described: immunomodulation by en­
hancement of CD8+ Τ cells, inhibition of В cell function, and inhibition of cy­
tokine production. Finally, IVIg contains in addition to IgG molecules, other "con­
taminating" proteins like HLA antigens, soluble CD4 and CD8 molecules, and cer­
tain cytokines (e.i. gamma interferon16). 
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Part i 
Clinical aspects 

[4] 
Immunoglobulin treatment in epilepsy, 
a review of the literature 
Summary 
The purpose of this study is to ascertain possible efficacy and to understand pos-
sible mechanisms of action of intramuscular or intravenous immunoglobulin 
(IVIg) in the treatment of intractable epilepsy, through a review of all identifiable 
articles on this topic. In 24 studies, none with a placebo controlled design, 368 pa-
tients with epilepsy receiving IVIg were identified. Patients' ages ranged from < 1 
to 35 years, mean 7.3 years. Female/male ratio was 0.6. All patients were report-
ed to suffer from intractable epilepsy. The average percentage of patients with an 
IgG2 deficiency was 25%. The total dose of IVIg varied between 0.3 and 6.8 g/kg 
for a period of 0.15 to 12 months. Whenever reported, adverse effects of IVIg were 
minimal. None of the studies reported the need of cessation of IVIg administra-
tion due to adverse effects. On the average, the mean clinical seizure reduction and 
the mean EEG improvement were 52% and 45%, respectively. On the average the 
percentage of patients with complete seizure remission and the percentage of pa-
tients with behavioral improvement were 23% and 63%, respectively. Cumulative 
meta-analysis of the identified articles is not possible due to the lack of controlled 
studies, the heterogeneity of the available studies, and the possible publication 
bias of unpublished negative data. Given these pitfalls, this literature study never-
theless allows some conclusions: (i) There is no formal proof of efficacy of IVIg 
treatment in epilepsy, and the present review underscores the need of controlled 
clinical trials before firm conclusions concerning efficacy can be drawn. The un-
controlled clinical observations discussed in this "state-of-the-art" review gener-
ate suggestive evidence at best. They suggest that IVIg might be effective in some 
patients with intractable epilepsy, and may be considered as a safe add-on med-
ication in various types of idiopathic and symptomatic intractable epilepsy, (ii) Re-
view of the literature did not help in explaining intractable epilepsy or the mech-
anism of action of IVIg, but did permit some inferences that could serve to design 
future clinical and experimental approaches to IVIg administration in epilepsy. 
30 CHAPTER 4 
Introduction 
The first immunoglobulin (I VIg)* preparations only suitable for intramuscular ad-
ministration, were initially used for substitution of immunodeficiency states17. 
Some years later Imbach et al. showed that high doses of IVIg also can rapidly 
remedy the platelet deficiency in (autoimmune) idiopathic thrombocytopenic 
purpura38. This success opened up for IVIg administration an unexpectedly wide 
scope in the treatment of autoimmune diseases8'13,2628'29,42'45. In a recent review ar-
ticle, IVIg therapy has been reported to be beneficial in more than 35 diseases, 
thought to be produced by immunopathology26. 
IVIg treatment in intractable epilepsy remains controversial, although in-
tractable epilepsy is one of the oldest applications of IVIg in neurology. It started 
empirically and the results were published as early as 19774', 4 years before the pa-
per of Imbach38. Pechadre et al4' reported that children with epilepsy who were 
treated with IVIg for recurrent upper respiratory tract infections experienced a de-
crease in the frequency and severity of their seizures. Most other workers con-
firmed these findings (Table I), and the old allergic approach to epilepsy21 was re-
vived and transformed in an immunological one. The hypothesis emerged that 
immune mechanisms may play a role in triggering, maintaining or even improv-
ing (intractable) epilepsies1'18,32,43'62. 
In the present paper we systematically studied the available data regarding IVIg 
administration in intractable epilepsy. Major questions were: (i) What are the da-
ta to support the efficacy of IVIg in epilepsy, and why is its use still controversial? 
(ii) If IVIg seems effective in some patients with epilepsy, what could be its im-
munological mechanism of action, or does IVIg have direct anticonvulsant prop-
erties by a non-immunological mechanism of action? 
Patients and methods 
Data identification and extraction 
An English, German, and French-language literature search was done using MED-
LINE (1966-1993), meeting reports were reviewed, and extensive hand search of 
bibliographies of identified articles were conducted. All identified articles were 
examined and assessed for specific descriptive information concerning population 
(number of patients studied, age ranges, mean age, sex, and percentage of patients 
with IgG2 deficiency), epilepsy (type of epilepsy, percentage of idiopathic etiolo-
gy), IVIg treatment (intramuscular or intravenous administration, total dose, and 
duration of IVIg administration), and outcome measurements (mean percentage 
of clinical seizure reduction, mean percentage of EEG improvement, percentage 
* For reasons of convenience, the abbreviation "IVIg" will be used for human polyclonal immunoglobulin prepa-
rations administered both by the intramuscular and intravenous route 
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of patients with complete clinical seizure remission, and percentage of patients 
showing behavioral improvement). 
To compare the IVIg treatment regimes in the various studies, we calculated 
the total dose of IVIg and the duration of treatment in each study. In the various 
studies most of the results are reported as the percentage of patients with a fa-
vorable response, whereas a favorable response has been defined differently by dif-
ferent authors. To correct for this variability we compared the study outcomes (ex-
cept behavior and complete seizure remission) by estimating in each study the 
mean percentage of seizure reduction, and EEG improvement (epileptic dis-
charges and/ or background). Concerning a particular item, total results of the rel-
evant studies on IVIg in epilepsy were assessed by averaging the mean results of 
the studies that included that particular item. For behavioral improvement and 
complete seizure remission the percentage of patients were estimated in each 
study. 
IVIg 
The predominant role of IgG in antibody-mediated immunity, and its remarkably 
long half-life (18-32 days) in adults as well as in neonates13, led to many attempts 
to use it as a therapeutic agent. Commercial IVIg is human polyclonal IgG pre-
pared from the pooled plasma of 2000 to 10000 or more donors. Considering that 
the antibody repertoire of the species is much greater than in an individual patient 
with 108 different immunoglobulin proteins, IVIg is a complex material63. Toxici-
ty could potentially arise from particular antibody specificities in IVIg, as nonspe-
cific effect of increased IgG levels, or as an unintended consequence of the man-
ufacturing process (impurities, stabilizing agents). The most frequent side effects 
of IVIg administration, occurring for example, in 4% of adult patients treated for 
Guillain-Barre syndrome, seems to be fever, malaise, myalgia, and headache dur-
ing or within hours of completing the infusion64. These symptoms often respond 
to a reduction in the infusion rate. In children (with human immunodeficiency 
virus infection) adverse reactions to IVIg were equally minor and occurred in 17 
of 3199 infusions (0.5%)"*. Far less frequent but more severe reactions to IVIg 
(which contains a slight amount of IgA) are reported in IgA deficient patients with 
anti-IgA antibodies. Some rare but severe idiosyncratic reactions are reported: 
alopecia, aseptic meningitis, and retinal necrosis (for review63). Nephrotoxicity 
was until recently an unrecognized side effect of IVIg administration and is prob-
ably due to sucrose, a stabilizing agent in some IVIg preparations61. No docu-
mented instance of human immunodeficiency virus transmission by IVIg has ever 
been reported, but viral safety, also concerning hepatitis virus, remains an impor-
tant concern63. 
Results 
In 24 studies 368 patients with epilepsy receiving IVIg were identified (Table 1). 
None of the studies had a double blind placebo controlled design, one study was 
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an add-on placebo controlled single blind trial37. Three publications on IVIg in 
epilepsy were excluded, one because it described a single case-report19, another be-
cause of the lack of quantitative data71. The third study was an abstract primarily 
on the mechanism of action of IVIg in two Lennox-Gastaut (LGS) patients6 show-
ing that intact IgG (containing the Fc fragment) gave a complete clinical remis-
sion, whereas pepsin-treated IgG (mainly composed of the F(ab)2 fragment) was 
ineffective. 
Patients' ages ranged from <1 to 35, with a mean age of 7.3 years. About 2/3 
were male and 1 /3 female (overall female/male ratio is 0.6). All patients suffered 
from intractable epilepsies, and 9 studies reported on a more homogeneous sub-
group of intractable epilepsies like West syndrome (WS) or LGS or both. In-
tractability was nearly never exactly defined. On the average the percentage of id-
iopathic (and cryptogenic) cases in all studies was 45%. 
In general, immunological investigations were not carried out extensively. From 
the papers that included these investigations on the average a prevalence of 25% 
of IgG2 deficiencies appeared. 
Total dose of IVIg (intramuscular or intravenous administered) varied between 
0.3 and 6.8 gm/kg for a period of 0.15 to 12 months. Usual single dose was 100 to 
400 mg/kg administered using several schedules with and without a "booster" 
dose. One study observed a positive correlation between dose and response: after 
reducing IVIg from 400 to 200 mg/kg once every 21 days, deterioration of the 
EEG was noted25. No studies evaluated the lot-to-lot consistency of treatment ef-
fect among various lots of IVIg used, and no studies investigated the relation be-
tween serum or cerebrospinal fluid (CSF) IgG concentration and effect. Instead of 
native IVIg consisting of intact IgG molecules, one study used a plasmin-treated 
preparation containing separate Fc and Fab fragments27. Despite the different con-
tent of this preparation the outcome of this study seems to be comparable with 
that of other studies (Table 1). 
Adverse effects were seldom specified. In two studies a mild rise in temperature 
was noted only during the first injection30,50. None of the studies reported the need 
of cessation of IVIg administration due to adverse effects. IVIg appears not to af-
fect the plasma levels of anticonvulsant drugs12,33,59. 
On the average the percentage of patients with complete seizure remission was 
23%: from the total of 368 patients in the reviewed literature, it is mentioned ex-
plicitely of 89 (23%) that they became seizure free. However, the follow-up peri-
ods only rarely permit one to judge whether there were true remission periods of 
over 3 years: in the majority of studies it was unclear if the complete seizure re-
mission was a permanent effect or if it was a honeymoon response lasting only for 
the duration of IVIg administration (mean duration 4 months). On the average 
the mean percentage of seizure reduction, and on the average the mean percentage 
of EEG improvement was 52% and 45%, respectively. On the average the percent-
age of patients with behavior improvement was 63%. Various improvements in some 
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patients were seen immediately (within hours'0) or within a few days27,33, whereas 
in others there was a delayed treatment effect of weeks to even months12,2"'60. On-
ly 2 studies with less than 10 patients each, reported no treatment effect at all34,53, 
whereas in 2 studies without specific differences compared to the other studies10,37 
seizure frequency even increased in some patients after IVIg administration. 
Discussion 
Efficacy of IVIg 
Cumulative meta-analysis of the identified articles is not possible due to the het-
erogeneity in study designs, patients' characteristics, treatment regimens, and out-
come definitions. In many studies even difficulties concerning data extraction ex-
ist. Other difficulties in meta-analysis are the unsettled question of whether or not 
to assign a weight to the included studies according to some measure of their qual-
ity, and the lack of agreement about which statistical methods to use40. In total 368 
patients with epilepsy have been reported having received IVIg, but it is possible 
that small series of non-responders have not been published, resulting in publica-
tion bias. Therefore, the conclusions about efficacy may not reflect exactly the 
outcome of the IVIg therapy in practice. 
None of the 24 studies on intractable epilepsy were double blind placebo con-
trolled. We can understand why, if we realize that the patient population consists 
mainly of children, and IVIg is administered via the intramuscular or intravenous 
route for several times over a period of weeks to months. A placebo controlled de-
sign in such a setting was possibly considered unethical, and a cross over design 
was problematic because there was a lack of anticonvulsant drugs without major 
side effects that could be administered intravenously, like IVIg. Comparing the ef-
fectiveness of IVIg and that of ACTH was not possible for this reason. Most stud-
ies have to be considered as pilot studies performed to find out whether it may be 
worthwhile to carry out a more extended and controlled trial in the future. Based 
on the present reports on IVIg treatment in epilepsy, and because now ACTH dé-
rivâtes without major side effects are available, time seems ripe to set up a con-
trolled study on the efficacy of IVIg in homogeneous groups of patients with in-
tractable epilepsy. Such a design is important just in intractable epilepsies like WS 
and LGS to correct for their variable and still unsettled prognosis concerning 
seizure frequency and mental state11,39. 
The effectiveness of IVIg has been proven in monophasic diseases like idiopath-
ic thrombocytopenic purpura and its indication is now settled for this disease8. Ap-
plication of such an expensive treatment - even if its efficacy was proven - in a 
chronic disease like epilepsy is more problematic. However, when one of five pa-
tients (23%) with intractable epilepsies and 43-64% with WS would indeed be-
come seizure free within 4 months and remain seizure free, this would suggest 
that in such a subgroup IVIg has a place, certainly when it also improves behavior 
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and lacks severe adverse effects. Considering the data on IVIg treatment in epilep-
sy it seems that "when it works it works", and the same situation of a subgroup 
showing a favorable response after IVIg treatment has been described in chronic 
demyelinating polyneuropathy65. In view of this, the search for predictive mark-
ers defining such a subgroup showing a favorable response, seems very important. 
Most but not all studies reported that cryptogenic etiology seems a favorable pre-
dictive marker7,27,30,24, but this is difficult to interpret from uncontrolled studies, be-
cause in general the natural history of the cryptogenic compared to the sympto-
matic types of epilepsy is better". The various study results were not consistent 
concerning other predictive markers like serum IgG2 deficiency10,12""'27,30,60, low 
serum IgA values5,7,27'67, duration of epilepsy5,24,27,3335, or seizure type. In one study 
generalized seizures seem more sensitive to treatment than partial seizures with 
secondary generalization12, in another study the opposite has been reported50. In 
a third study only minor seizures like absences and drop attacks decreases after 
treatment". The average female/male ratio (0.6) in all studies on IVIg treatment 
in epilepsy is comparable with that found in large epidemiological studies on 
epilepsies in children and adolescents20. 
The interpretation of the average 23% complete seizure remission remains dif-
ficult. Due to the publication bias it is possible that the subgroup with a favorable 
treatment response is smaller in practice. Comparison of the IVIg effect with the 
natural outcome or with that of another treatment is hardly possible: the natural 
outcome of the various intractable epilepsies concerning seizure frequency and 
mental state is not exacdy known"3 ' , and the treatment effect of ACTH in the var-
ious epilepsies is unsettled. For WS, ACTH has been described as the most effec-
tive treatment3,23 with 20 to 70% of patients stop having seizures (for review3) but 
different dose regimes have been advised by different authors. In the 4 studies on 
IVIg treatment in WS total cessation of seizures occurred in 0%, 43%, 64%, and 
64%. Concerning LGS, only a few reports on ACTH treatment exist. They show 
cessation of seizures in 51% and 61% of the patients (for review"). But the use of 
ACTH in LGS remains controversial because 70 to 90% of patients will suffer a re-
lapse of seizures during the ACTH taper58. Therefore, most authors consider 
ACTH indicated only to tide the patient over bad periods of very active epilepsy 
or status". The natural outcome of complete seizure-free recovery in LGS is rare 
and is reported in 0% to 6.7% of patients11. In the 3 studies on IVIg in LGS total 
cessation of seizures was 10%, 14%, and 44%. From these studies on WS and LGS, 
IVIg seems to be an alternative for ACTH treatment in these types of intractable 
epilepsy, since the anticonvulsant treatment effect is comparable, whereas ACTH 
lacked an effect on mental deterioration and induced significant, and occasional-
ly fatal, side effects54,58. 
In conclusion, the answer to our first question in the "Introduction" appears to 
be that there is no formal proof of efficacy of IVIg treatment in epilepsy, and the 
present review underscores the need of controlled clinical trials before firm con-
clusions concerning efficacy can be drawn. The uncontrolled clinical observations 
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discussed in this "state-of-the-art" review generate suggestive evidence at best. 
They suggest that IVIg might be effective in some patients with intractable epilep-
sy, and may be considered as a safe add-on medication in various types of idio-
pathic and symptomatic intractable epilepsy. Intractability defined as insufficient 
control of epilepsy by adequate dosages of antiepileptic drugs like valproate, ni-
trazepam or vigabatrin. 
An immunological mechanism of action of IVIg? 
The mechanism of action of IVIg in epilepsy is usually interpreted as an im-
munological one despite the lack of a well established immunological mechanism 
in epilepsy, and although from the various studies on IVIg in epilepsy no definite 
immunological mechanism of action could be defined69. One of the most fre-
quently discussed mechanisms of action of IVIg is the compensation of an ¡gGi 
ííefгdenςyш,12'24·27•,0','0. Such an IgG2 deficiency is believed to predispose to some 
form of viral encephalitis triggering immune mechanisms leading to intractable 
epilepsy2447. This mechanism of action suggested by Duse et al.24 has more re­
cently been abandoned by the same group", because all 5 children with in­
tractable childhood epilepsy and associated IgG2 deficiency responded to IVIg 
treatment and relapsed or worsened after discontinuation of IVIg, whereas IgG2 
levels returned to subnormal pretreatment values in only 2 of the 5 children. An­
other study10 concerning 14 children with myoclonic seizures (of whom 10 with 
frequent infections and IgG2 deficiency) reported normalization of IgG2 levels and 
elimination of frequent infections during the IVIg period without obvious 
changes in seizure frequency. This is also not in favor of a second suggested mech­
anism of action of IVIg, i.e. suppression of infections, influencing seizure frequency 
indirectly19. Third, because there is no proof from review of the literature that all 
human epilepsies are more or less immune mediated2, IVIg may only be effective 
in a distinct subgroup of epilepsies, by interfering with a distinct (for example au­
toimmune) pathogenesis. It has even been suggested that involvement of the im­
mune system in epilepsy is a factor that contributes to intractability1016'18. When 
this hypothesis will turn out to be true, treatment with IVIg might be effective just 
in the subgroup of immune dysregulated, i.e. intractable epilepsies. In this view, 
IVIg may neutralize pathogenic auto-antibodies by anti-idiotypic interaction, i.e. the 
anti-idiotype antibodies contained in the IVIg preparation bind to the variable re­
gion of the circulating autoantibodies of the patient22. An increased incidence of 
antibodies against frontal cortex has indeed been reported in epilepsy52'44. Several 
other immunological mechanism of action of IVIg have been proposed, like in­
terference with cytokine production. The suggested effectiveness of IVIg in post­
encephalitic epilepsy" and in Rasmussen s syndrome (chronic encephalitis with 
epilepsy)72 favors the assumption of such an immunological mechanism of action 
of IVIg. 
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A поп-immunological mechanism of action of IVIg? 
The various studies on IVIg in epilepsy could not provide an indication for an im­
munological mechanism of action, whereas the immediate treatment effect in 
some patients suggests a non-immunological (perhaps direct neuromodulating) 
effect. In addition, the immediate treatment effect was present not in one single 
type but in various types of idiopathic and symptomatic epilepsies, i.e. in epilep­
sies with etiologic heterogeneity and multifactorial pathogenesis. This suggests 
direct interference with the final common pathway of the epileptic brain distur­
bance at the cellular level, by a direct anticonvulsant effect. Although it has been 
stated without published data that IVIg lacks such neuromodulating properties8, 
IVIg did show a direct anticonvulsant effect in an animal epilepsy model of kin­
dled cats36. If such an anticonvulsant effect of IVIg will indeed be confirmed in 
clinical and experimental studies, this may, for a second time, broaden the applic­
ability of IVIg. The first time this occurred when IVIg, initially used in clinical 
medicine in 1952 to treat immunodeficiency conditions17, was increasingly used 
in a variety of auto-immune conditions13. The idea that specific IVIg with distinct 
IgG populations could in the future be envisaged for pathological states other than 
immunodeficiency and autoimmunity, is in accordance with recent immunologi­
cal theories on the role of immunoglobulins, not only in the regulation of the im­
mune system but also in the general homeostasis of the organism9,70. It is evident 
that with such an objective and to be able to choose the adequate IgG populations, 
we have to know and understand in much greater depth than today the link be­
tween the immune system and nervous system, including the role of specific im­
munoglobulins in both. 
In conclusion, review of the literature shows that cumulative meta-analysis of 
the identified articles is not possible due to the lack of controlled studies, the het­
erogeneity of the available studies, and the possible publication bias of unpub­
lished negative data. Given these pitfalls, this literature study nevertheless allows 
some conclusions: (i) There is no formal proof of efficacy of IVIg treatment in 
epilepsy, and the present review underscores the need of controlled clinical trials 
before firm conclusions concerning efficacy can be drawn. The uncontrolled clin­
ical observations discussed in this "state-of-the-art" review generate suggestive ev­
idence at best. They suggest that IVIg might be effective in some patients with in­
tractable epilepsy, and may be considered as a safe add-on medication in various 
types of idiopathic and symptomatic intractable epilepsy, (ii) Review of the liter­
ature did not help in elucidating the mechanisms behind the intractability of 
epilepsy or the mechanism of action of IVIg, but did permit some inferences that 
could serve to design future clinical and experimental approaches to IVIg admin­
istration in epilepsy. Relevant in this respect are: 
-1- Clinical trials to investigate efficacy of IVIg in homogeneous groups of patients, 
with a randomized and controlled design or at least correcting for a lack of this; 
uncontrolled clinical observations generate suggestive evidence, at best. 
-2- Immunological studies (i) in serum and CSF to investigate if a subgroup could 
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be defined that shows a favorable effect on IVIg administration; (ii) CSF examina­
tions to investigate if IVIg crosses the blood-CSF barrier and significantly increas­
es the CSF IgG concentration. 
-3- Experimental studies on the cellular and animal model level concerning espe­
cially a possible пеиготоаиЫпщ or anticonvulsant effect of specific components 
in the various immunoglobulin preparations; efficacy of IVIg is not necessarily 
mediated by its main component, the IgG molecules15. Without insight in the spe­
cific mechamsms, progress in this area will be slow45. 
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[5] 
High-dose intravenous immunoglobulin 
treatment in cryptogenic West and Lennox-
Gastaut syndrome; an add-on study 
Summary 
In an add-on pilot study, a group of 15 children with cryptogenic and intractable 
West syndrome (WS, 3) and Lennox-Gastaut syndrome (LGS, 12) received intra-
venous immunoglobulin (IVIg, 0.4 g/kg body weight per day for 5 consecutive 
days, followed by the same dose once every 2 weeks for 3 months). Five patients 
had been treated previously with adrenocorticotropic hormone (ACTH) with-
out success. The reduction in clinical seizures averaged 70 percent. Electroen-
cephalographic (EEG) recordings revealed a mean reduction in epileptic dis-
charges of 40 percent. In all 15 patients, acceleration of EEG background activity 
occurred, and psychomotor development improved. Prior to IVIg administration, 
cerebrospinal fluid (CSF) examinations were within normal ranges. After IVIg ad-
ministration, the serum total IgG concentration increased by an average of 76%, 
and the CSF IgG concentration by 44%. According to our data, IVIg crosses the 
blood-CSF barrier, and might be effective in the treatment of WS and LGS. We 
suggest it should be considered when other treatments, such as ACTH, have 
failed. 
Introduction 
Early childhood epilepsies can be serious because of their severe developmental 
consequences and high percentage of therapy resistance. Most intractable child-
hood epilepsies belong to the group of WS and LGS16, which have been well de-
fined by their clinical and EEG characteristics'1·1115·16·30·36·17. 
In 1977, Pechadre et al38 reported that children with epilepsy who were treated 
with intramuscular injections of immunoglobulin for recurrent upper respirato-
ry tract infections experienced a decrease in the frequency and severity of their 
seizures. Since then, the hypothesis has emerged that immune mechanisms may 
play a role in triggering, maintaining or even improving (intractable) epilep-
sies1,32 35A1. The favourable results of immunosuppressive drugs like ACTH and 
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corticosteroids, in epilepsies usually of the WS type but also LGS, have favoured 
an immunological approach, and many studies have reported generally successful 
IVIg treatment in epi leps ies 6 8 1 0 1 2 1 7 1 9 " 2 9 3 ' 4 2 4 3 4 5 4 6 Nevertheless, heterogeneity 
concerning patient inclusion entena, types of epilepsy, route and schedule of IVIg 
administration, follow-up penod and entena for the evaluation of the response, 
makes the vanous results difficult to interpret 
According to the "Guidelines for Clinical Evaluation of Antiepileptic Drugs"13, 
the present study is an add-on pilot study, conducted in order to determine 
whether high-dose IVIg administered to a homogeneous group of children with 
cryptogenic WS and LGS reduces seizures clinically as well as electroencephalo 
graphically, and improves behaviour compared to the pretreatment situation As 
the study was uncontrolled, we attempted, at least partially, to correct for this by 
analysing the EEG data in a blinded manner Furthermore, we investigated some 
immunological parameters in serum and CSF in order to detect possible patho­
physiological mechanisms and markers of a favourable response 
Patients and Methods 
Study population 
Fifteen patients (six boys, nine girls) were enrolled, 12 with intractable, crypto 
genie LGS (four of whom started with WS) and three with intractable, crypto­
genic WS (Table I) All completed the tnal The mean age at time of enrollment 
was 3 6 years (range 1 0 to 6 0 years), the mean duration of epilepsy pnor to start 
of the study 2 years (range 0 2 to 5 5 years) 
Study Design and Entry Criteria 
Cryptogenic aetiology was defined as epilepsy of unknown cause in infants or 
young children with unremarkable neuromental development pnor to onset of 
seizures Physical examination was normal, there were no abnormalities on cere 
bral CT or MR imaging, except for a slight dilatation of ventndes, no known men 
tal retardation syndromes, chromosomopathy, or inborn errors of metabolism 
(normal unnary organic acids, amino acids, purines, pynmidines, mucopolysac-
chandes, oligosacchandes, and neuraminic acid, normal serum amino acids, lac­
tate, normal lysosomal enzymes in leucocytes) Other exclusion entena were 
ACTH treatment within 6 weeks before start of the study, other diseases or inter­
current infections, and IgA deficiency An intractability score of at least five on 
Schmidt's intractability score modified by Aicardi3 was a prerequisite for entry in 
to the study, ι e seizures persisted despite treatment with more than one first-line 
drug at a maximum tolerable dose, possibly combined with second-line drugs All 
patients received valproate either as monotherapy or in combination with other 
anti-epileptic drugs, especially benzodiazepines Using the treatment regimen as 
recommended by Hrachovy and Frost28, five patients had previously received 
ACTH, all without success 
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WS was defined by the triad: 1) infantile spasms occurring in series, 2) inter-ictal 
hypsarrhythmic EEG in awake stage, 3) arrest of mental development, mental re-
tardation or deterioration, and by the onset of epilepsy before 1 year of age30. LGS 
was defined by the triad: 1) typical epileptic seizures (axial tonic, atypical absences, 
atonic seizures) possibly associated with generalized tonic-clonic seizures and par-
tial seizures, 2) inter-ictal slow spike-waves (less than 3 per second) in awake EEG, 
3) mental retardation or deterioration with personality disorders, and by age of 
onset of epilepsy between 1 and 8 years". True myoclonic epilepsies characterized 
by a predominance of myoclonic seizures and fast (>2.5 Hz) activity in the EEG, 
were excluded2,5,25. Because of the frequent transition from WS to LGS (in the pre-
sent study four of 12 patients with LGS started with WS), and the close mutual re-
lationship between both age-specific epileptic encephalopathies, patients with 
both WS and LGS were included151636·37. 
The children served as their own controls and time relation was assessed. Prior 
to IVIg administration, and 3 months later, exactly 14 days after the last IVIg ad-
ministration, all children were evaluated with regard to the parameters listed be-
low. All tests were performed on day 89 after the start of the study, at the same 
time of the day to avoid circadian variability. In addition, every 14 days the parents 
were interviewed concerning clinical seizure frequency and psychomotor devel-
opment of their child. 
Evaluation criteria 
The following criteria were used to evaluate the effect of IVIg administration: 
(1) Clinical characteristics of seizures. Type, frequency and duration of seizures 
were registered by the parents for 2 days in four samples of 1 hour, according 
to oral and written instructions11. Identification of various types of seizure was 
improved by asking all parents to view photographs of reference examples. In 
some cases the parents' registration was checked using data from videotapes of 
their child. A baseline period of 3 months was assessed in order to compensate 
for seizure variability. During the treatment period, seizure frequency was as-
sessed once every week. Frequencies of infections and fever were assessed, as 
well. 
(2) The Denver Developmental Screening Test (DDST) covering four functions 
(gross motor, language, fine motor-adaptive, and personal-social) was assessed 
by a single independent investigator. In addition, behaviour of each child was 
observed for a 30-minute period on 2 consecutive days. 
(3) Electroencephalography (EEG) for one hour, at the same time in the morning 
using a 21-channel EEG machine and electrode placement according to the In-
ternational 10-20 System. Two qualified neurophysiologists carried out a blind 
routine evaluation of all paired EEG's independently, measured the number of 
spikes and polyspikes, the number of spike-wave complexes, the number of 
generalized epileptic discharges, and the percentage of dominant background 
activity (alpha, beta, theta, delta) blindly in 18 samples of 10 seconds. From 
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these data they assessed which of the two paired EEG's showed the lesser 
epileptic abnormalities. 
(4) Immunological parameters in serum: immunoglobulin classes and subclasses, 
percentage of B-cells and CD3+ cells, CD4/CD8 ratio, and proliferation of pe­
ripheral blood lymphocyte stimulation to phytohaemagglutinin and pokeweed 
mitogen; antibodies against CNS tissue (human cerebellar Purkinje cells). 
White blood cell count with differential count and C-reactive protein (CRP). 
In cerebrospinal fluid (CSF): cell number, total protein, Q albumin (CSF albu­
min concentration χ IO5/ serum albumin concentration), IgG, IgA, IgM, and 
oligoclonal bands (on isoelectric focusing). 
Methods of Immunological Determination 
Serum total IgG, IgA and IgM concentrations were determined as described ear-
lier25'26. Serum IgG subclass concentrations were determined by radial immuno­
diffusion, and calibrated against standard serum containing 6.2 g/L IgG^ 2.4 g/L 
IgG2; 0.64 g/L IgG3; and 0.46 g/L IgG„ (HOO-020, Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service, Amsterdam, NL). Percentages 
of B-cells were determined by immunofluorescence microscopy using anti-hu­
man immunoglobulin antisera (Kallenstad Lab.Inc,Austin (TX), USA). The per­
centages of CD3, CD4, and CD8 positive T-cells were determined using mono­
clonal antibodies (OKT3, OKT4, OKT8, respectively; Coulter Co., Hialeah (FL), 
USA). 
Serum antibodies against cerebellar Purkinje cells were assessed using an indi­
rect immunofluorescent technique24. CSF was investigated as described else­
where21. 
Treatment protocol 
The study protocol was reviewed and approved by the institutional review board 
of our hospital. Written informed consent was obtained from each child's parent 
prior to entering the study. IVIg from different lots was produced from the plas­
ma of more than 3000 Dutch blood donors by ethanol fractionation, treated at pH 
4 with a low concentration of pepsin (Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service, Amsterdam, NL). It was administered in a dose 
of 0.4 g/kg body weight per day for 5 consecutive days, followed by the same dose 
once every 2 weeks for 3 months (11 infusions in total). The initial and maximal 
infusion rates were those recommended by the manufacturer. The dose of the 
concomitantly administered conventional anti-epileptic drug medication re­
mained unchanged throughout the study period. 
Statistical analyses 
The results of the various immunological investigations were compared with 
those of an earlier described normal control group consisting of 114 healthy chil­
dren aged 1 month to 16 years25,26. All immunoglobulin concentrations were cor-
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rected for age by subtracting the expected value as calculated from the data of the 
reference group from the actual value found. Statistical analysis was performed 
using the Kruskal-Wallis test. Spearman correlation coefficients (p) between im­
munological and outcome parameters were measured to assess prognostic factors 
for a good response. 
Because of multiple variables, Ρ < 0.01 was considered statistically significant. 
Results 
Seizures 
Following IVIg treatment, 13 out of 15 children had at least a 50% reduction of to­
tal clinical seizure frequency (Table 1 ). The mean reduction for the whole group 
was 70%. In one patient with WS (patient number 13) there was total cessation of 
seizures (the duration of WS was only 0.3 years), whereas another patient with 
WS (patient number 10) showed a slight increase in seizure frequency. The third 
patient with WS showed an intermediate response, like 11 of the 12 patients with 
LGS. Seizure reduction became apparent on average after 6 weeks of treatment. 
Clinical seizure reduction showed a significandy positive correlation (p = 0.7; Ρ 
= 0.003) with EEG background improvement, and a significantly negative corre­
lation with serum IgM concentration after IVIg treatment (p - -0.7; Ρ = 0.008). A 
trend existed for a negative correlation between clinical seizure reduction and the 
serum IgM concentration before treatment (p = -0.6; Ρ = 0.02). 
Psychomotor development 
At entry into the study, all 15 patients were mildly/moderately to severely retard­
ed, according to the WHO classification on degree of mental retardation. After 3 
months of IVIg, behaviour improved and developmental delay was reduced in all 
15 patients, even in the two children who did not show a favourable response in 
clinical seizure frequency (Table 1). From the 30-minute-period of behavioural ob­
servation, the clinical impression (confirmed by the parents) was that all children 
showed better eye contact and greater attentiveness, perceptivity and social ad­
justment, sometimes before any evidence of seizure reduction. 
Improvement of psychomotor development correlated significantly positively 
with EEG background improvement (p = 0.8; Ρ - 0.001), whereas a trend existed 
for a negative correlation with age (p = -0.6; Ρ - 0.04). 
Electroencephalographic changes 
Of each child's paired EEG's, the EEG that was rated by the neurophysiologists as 
the one with the lesser epileptic abnormalities, turned out to be the EEG after IVIg 
treament! Eleven patients had a reduction of spike-wave complexes, spikes and 
polyspikes, and generalized epileptic discharges of 30 percent or more (Table I). 
Mean reduction was 40 percent. In all 15 patients acceleration of background ac­
tivity occurred. Normalisation of the EEG occurred in one patient with WS. 
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There was no significant disagreement between the independent interpretations 
of the two blinded neurophysiologists. 
Acceleration of background activity on EEG correlated significantly positively 
with clinical seizure reduction (p = 0.7; Ρ = 0.003), and with behavioural improve­
ment (p = 0.8; Ρ = 0.001). No positive correlation was found between reduction of 
epileptic discharges on EEG and clinical seizure reduction (p - 0.5; Ρ = 0.09). 
Immunological parameters 
Serum total IgG, IgA, IgM concentrations, and kappa/lambda ratios of IgG, IgA, 
IgM before IVIg treatment have been described previously". In the group as a 
whole, the total IgG concentration was significantly increased, whereas none of 
the subclass concentrations reached a statistical significant difference with the ref­
erence values derived from the previously described normal control group (all Ρ 
> 0.1)2S. According to these reference values, 2 of the 15 children showed an IgG2 
deficiency (concentrations below the P5 level), and 3 showed an IgG3 deficiency. 
The percentage of B-cells (mean 10.6, range 3 - 21), CD3+ cells (mean 65.8, range 
52 - 79), and the CD4/CD8 ratio (mean 3.3, range 1.5 -10.0) did not differ signifi­
cantly from the normal controls. 
Serum antibodies against cerebellar Purkinje cells were negative in each pa­
tient. 
CSF examinations including cell count (mean 3.4; range 0 - 14/3mm3), total 
protein concentration (mean 234; range 157 - 358 mg/L), albumin concentration 
(mean 110; range 62 -192 mg/L), Q albumin (mean 242; range 137 - 405), and con­
centrations of IgG (mean 12; range 6 - 19 mg/L), IgA (mean 1.0; range 0.3 - 1.8 
mg/L), and IgM (mean 0.3; range 0.1 - 0.5 mg/L) were all within normal ranges. 
No oligoclonal bands were found on iso-electric focussing in any of the patients. 
An extensive description of the CSF data can be found elsewhere21. 
After IVIg administration, serum total IgG increased in all patients and ranged 
5 to 186% (mean 76%, percentage of IgG increase was significantly negatively cor­
related with age), (in five of five patients, IgG„ IgG2, and IgG3 concentrations rose 
by an average of 72%, 427% and 34%, respectively); CSF IgG increased in all but 
one patient, and ranged 22 to 89% (mean 44%). The delta increase in serum IgG 
( = serum IgG after treatment minus serum IgG before treatment) ranged from 
0.8 to 10.3 g/L. The delta increase in CSF IgG ( = CSF IgG after treatment minus 
CSF IgG before treatment) ranged from -1 to 11 mg/L. Patient number 3, who 
showed no CSF IgG increase also showed no clinical seizure reduction. After IVIg 
treatment, no significant differences occurred in serum IgA concentrations, IgM 
concentrations, percentage of B-cells, CD3+ cells, or the CD4/CD8 ratio. 
Serum IgM before treatment showed a significantly positive correlation with 
the pre-treatment concentration of serum IgG (p = 0.7; Ρ = 0.008), and a trend to­
wards a negative correlation with seizure reduction (p = -0.6; Ρ = 0.02) and be­
havioural improvement (p = -0.5; Ρ = 0.04). After IVIg treatment, the delta CSF 
IgG increase correlated significantly positively with Q albumin before treatment 
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(ρ = 0.9; Ρ = 0.0003). The CSF IgG increase was not correlated with serum IgG in­
crease (ρ = 0.3; Ρ = 0.3), nor with seizure reduction (ρ = -0.07; Ρ = 0.8). 
Adverse reactions 
Adverse reactions to IVIg did not occur in the 165 infusions performed in 15 chil­
dren. In none of the children cessation of treatment was required. Clinical signs 
such as malaise, fever or skin rash reported in the literature in a small percentage 
of patients, or clinical and CSF signs of aseptic meningitis were not found9. 
Discussion 
Although intractable epilepsy is one of the first neurological disorders for which 
immunoglobulin was administered38, it has never been investigated by a double-
blind, placebo controlled study. Most studies like the present one can be consid­
ered as pilot studies, performed to find out whether it may be worthwhile to car­
ry out a more extended and controlled trial in the future. A controlled design is 
important in intractable epilepsies like WS and LGS to correct for their variable 
and still unsetded prognosis1'16'30. In the present study, we attempted, at least par­
tially, to correct for this deficiency by analyzing the EEG data in a blinded man­
ner, and by using videotapes in some cases to check parents' registration. 
In the present uncontrolled add-on pilot study, the clinical and EEG improve­
ments were time-related to administration of high-dose IVIg, suggesting that the 
observed improvements were related to IVIg treatment. Moreover, these im­
provements, evaluated by independent investigators and concerning various as­
pects of brain function (clinical seizures, EEG, behaviour), showed remarkable 
correlations. Furthermore, no spontaneous remission was seen in any child before 
IVIg treatment, and five patients had previously been treated with ACTH without 
success. 
Despite the heterogeneity of earlier studies (including administration sched­
ules) on IVIg treatment in patients with epilepsy, an overall rate of responsiveness 
of about 50 percent has been reported22. The improvement observed in our 15 pa­
tients is relatively high. Possible explanations could be the entry criterion of cryp­
togenic types of WS and LGS, and the way IVIg was administered (short interval 
of administration, high dose, and long duration of IVIg treatment). The manner 
of IVIg administration in the present study was based on a preliminary study and 
data from the literature on IVIg. In this preliminary study, we administered IVIg 
with a longer interval between applications (monthly instead of every 2 weeks) af­
ter the same booster dose used in the present study (0.4 g/kg body weight per day 
for 5 consecutive days). Our experience was that clinical seizure frequency in­
creased shortly before the monthly IVIg administration. Using EEG results, Duse 
also observed a positive correlation between dose and response. After reducing 
IVIg from 400 mg/kg every 21 days to 200 mg/kg, she observed a deterioration in 
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the EEG18. Both Steno46 and Bedini12 reported a delayed clinical and EEG im-
provement in some patients, who initially did not respond to IVIg administration 
over a 5-week or 6-week period, respectively, suggesting that a long duration of 
treatment could be beneficial in some patients. 
After IVIg treatment, acceleration of EEG background activity correlated sig-
nificantly positively with improvement of psychomotor development, and also 
with clinical seizure reduction. This is in agreement with the data obtained by 
Bedini12. The correlation between EEG background activity and psychomotor de-
velopment has already been described by Dodrill14. As suggested by others12, it is 
possible that a greater level of concentration and attentiveness, accompanying the 
reduction in seizure number, is responsible for the behavioural improvement. In 
the present study, like that of Pechadre38, however, the clinical impression existed 
that behavioural improvement was even noted in some patients without or prior 
to seizure reduction. The lack of a significantly positive correlation between clin-
ical seizure reduction and reduction of epileptic discharges on EEG, has also been 
reported by others12,38. 
We could not confirm previous reports concerning markers predicting a 
favourable IVIg response, like IgG2 deficiency17,39,46, duration of epilepsy6, low 
serum IgA values6,43 or low CD4 values43. However, a trend for a negative correla-
tion existed between serum IgM concentration, and both clinical seizure reduc-
tion and behavioural improvement. The lower the serum IgM concentration the 
better the outcome. 
The mechanisms by which IVIg acts to ameliorate epilepsy are poorly under-
stood. From the present study it seems unlikely that IVIg acts by simple substitu-
tion, for example by compensating for an IgG2 deficiency. Such a mechanism of 
action previously suggested by Duse et al17 was more recently abandoned by the 
same group", because all five children with intractable childhood epilepsy and as-
sociated IgG2 deficiency responded to IVIg treatment and relapsed or worsened 
after discontinuation of IVIg, whereas IgG2 concentrations returned to subnormal 
pretreatment values in only two of the five children. Another study10 concerning 
14 children with myoclonic seizures (10 showing frequent infections and IgG2 de-
ficiency) reported normalisation of IgG concentrations and elimination of fre-
quent infections during the IVIg period without obvious changes in seizure fre-
quency. Again, this finding does not favour a second possible mechanism of action 
of IVIg, suppression of infections, influencing seizure frequency and behaviour in-
directly. In addition, in the present population we did not find any indications, ei-
ther clinically or in laboratory tests of serum and CSF, of an increased infection 
incidence prior to IVIg administration. Furthermore, none of the children showed 
signs of a bacterial or viral infection as underlying aetiology, and none was affect-
ed by slow virus infections like subacute sclerosing panencephalitis or progressive 
rubella encephalopathy, in which immunological mechanisms are involved and 
IVIg might have some logical foundation12. Nor could a third possible immuno-
logical mechanism of action of IVIg (interference with antibrain-auto-antibodies 
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as in autoimmune diseases) be confirmed by the present study. We did not find au-
to-antibodies against cerebellar Purkinje cells. (These were measured because 
neuropathological examinations of cryptogenic types of epilepsy, especially LGS, 
showed predominant cerebellar atrophy with destruction of the Purkinje cell 
type"34'40.) In addition, the delayed onset of the treatment effect (6 weeks) is not 
in accordance with the acute effect encountered in autoimmune diseases like id-
iopathic thrombocytopenic purpura31. Another factor which fails to support an id-
iotype-anti-idiotype interaction is the report of two patients with LGS, in whom 
pepsin-treated IgG mainly composed of the F(ab)2 fragment was ineffective, 
whereas intact IgG (containing the Fc fragment) gave a complete clinical and EEG 
remission7. Nevertheless, this mechanism of action could not be totally excluded 
because absence of evidence is not the same as evidence of absence. 
Thus, in the present study the effect of IVIg could not easily be explained by its 
accepted broad immunomodulatory action44. Instead, and although it has been 
frequently stated that IVIg has no anticonvulsant properties", our clinical data do 
not exclude the possibility of a neuromodulator influence33, which is in accor-
dance with the anticonvulsant effect of IVIg in the animal epilepsy model of kin-
dled cats27. Further studies of animal models of epilepsy may contribute to the 
elucidation of the exact mechanisms of action of IVIg. Whatever the mechanism 
of action of IVIg in epilepsy might be, from the present study it is clear that IVIg 
administration increases serum and CSF IgG concentrations, and that it could 
reach at least certain parts of the brain adjacent to the CSF. In this respect it is re-
markable that the patient (no 3) with the lowest Q albumin (which represents the 
lowest blood-CSF permeability), showed no increase in CSF IgG after IVIg treat-
ment, and did not show a clinical seizure reduction. These findings may be com-
patible with a possible anticonvulsant effect of IVIg on the neurochemical net-
work of the brain23,41. 
From the present study of cryptogenic WS and LGS, and the study of the lit-
erature on cryptogenic and symptomatic cases of intractable childhood epilep-
sies20, we think that IVIg could have a place in the treatment of otherwise in-
tractable childhood epilepsies of the WS and LGS type, particularly when ACTH 
has failed. The use of ACTH, especially in LGS, is controversial11. Although fur-
ther pathophysiological and clinical studies are required, IVIg seems to offer many 
advantages compared to ACTH: good tolerance, infrequent and mild side effects, 
and no increase in infections9. The present study suggests that IVIg treatment has 
a favourable effect even in patients previously treated unsuccessfully with ACTH. 
The only drawback of IVIg is its cost. We must, however, underscore the fact that 
the potential ambulatory use of IVIg may avoid an expensive hospital stay for sel-
dom uncomplicated ACTH treatment. 
In conclusion, our data suggest that IVIg is effective in treating intractable WS 
and LGS, and should be considered when other treatments have failed. A number 
of issues still need to be clarified, including dose, duration, and long term effect. 
To answer some of these questions and to test the results of the present pilot 
study, it is now worthwile to perform a controlled and randomized study. 
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Part 2 
CSF aspects 

[6] 
Age-related changes of neuron-specific enolase, 
S-100 protein, and myelin basic protein 
concentrations in cerebrospinal fluid 
Summary 
Studies on cerebrospinal fluid (CSF) concentrations of neuron-specific enolase 
(NSE), S-100 protein, and myelin basic protein (MBP) in patients with neurologi­
cal lesions indicate a quantitative relation between the degree of cell damage in de 
central nervous system (CNS) and the concentration of these CNS-specific pro­
teins in CSF. Thus NSE, S-100, and MBP could be of use as markers for destruc­
tive processes in de CNS. We collected 937 specimens of CSF from children and 
adults (from newborns to age 91 years) who were undergoing a diagnostic lum­
bar puncture for several clinical indications. Of these, 79 samples from subjects 
ranging in age from 0,7 to 66 years could be used retrospectively to construct a ref­
erence interval according to our criteria. In these 79 samples no sex dependency 
existed. The relative increase of NSE, S-100, and MBP with age was similar (1% 
per year), suggesting a common underlying mechanism. These results emphasize 
the necessity of using age-matched reference values when the CNS-specific pro­
teins are to be evaluated in neurological diseases. We also present three case his­
tories to discuss the possible clinical relevance of the measurement of NSE, S-100, 
and MBP in children and adults. 
Introduction 
The clinician dealing with neurological disorders has to answer three questions. 
Is there a disease involving the nervous system? If so, where is the disease locat­
ed? What kind of disease is it, and what is its pathological nature? The first ques­
tion is often the most difficult one to answer. To answer it, but also the third ques­
tion, the assessment of damage to the central nervous system (CNS) by determi­
nation of neuron-specific enolase (NSE), S-100 protein (S-100), and myelin basic 
protein (MBP) in cerebrospinal fluid (CSF) may be helpful. 
NSE, S-100 and MBP are regarded as nervous-system-specific proteins. NSE, 
the γ,γ-isoenzyme of enolase, is a soluble cytoplasmic protein localized mainly in 
neurons'. S-100, named after its solubility in 100% saturated ammonium sulphate 
58 CHAPTER 6 
at neutral pH, constitutes a major component of the cytosol predominantly of 
glial cells2,3. MBP is detectable in developing Oligodendroglia and is bound to cel­
lular membranes of central and to a lesser extent peripheral myelin45. Thus, in­
creased concentrations of NSE, S-100, and MBP in CSF indicate CNS damage and 
may help to identify the cell type or part (neuron, glia, or myelin) affected by the 
pathological process. NSE, S-100, and MBP can now be measured in CSF with suf­
ficient sensitivity by immunoassays14. However, data on sex- and age-related ref­
erence values are lacking. 
We measured the concentrations of NSE, S-100, and MBP in CSF from 937 chil­
dren and adults, ranging in age from newborn to 91 years, who were undergoing 
a diagnostic lumbar puncture for several clinical indications. To establish possible 
sex- and age-related effects in the concentrations of NSE, S-100, and MBP, we ret­
rospectively selected, according to certain criteria, 79 of the patients as a reference 
group. 
We also present three case histories to discuss the possible clinical relevance of 
the measurement of NSE, S-100, and MBP in CSF. 
Materials ana Methods 
Reference Group 
From 1985 to 1988, 937 CSF samples were obtained form patients undergoing a 
diagnostic lumbar puncture for conventional clinical indications such as suspect­
ed CNS infection or neurological disorder. 
Of each CSF sample, 0,5 mL was used for the present investigation. Retro­
spectively, we were able to use 79 of the samples (from 37 females and 42 males, 
ages 0,7-66 years) for the formation of reference ranges. These samples were se­
lected according to the following criteria: no use of medication; no evidence of an 
organic neurological disorder; and normal concentration of total protein in CSF. 
The diagnoses selected in this way, comprise predominantly somatoform disor­
ders6. 
To get normal control subjects in a hospital population remains a problem: al­
though we started with nearly 1000 cases, only 79 could be used for the formation 
of reference ranges. Relaxing our entry criteria led to qualitative differences in the 
reference ranges; e.g., when we included patients with migraine, the overall ref­
erence ranges significantly increased. So we used strict entry criteria. 
Determinations in CSF 
NSE in serum and CSF were determined by RIA according to instructions of as­
say manufacturer (Pharmacia Diagnostics AB, Uppsala, Sweden). This double-an­
tibody assay contains human NSE as antigen and rabbit anti-human antiserum. 
Sepharose-anti-rabbit IgG raised in sheep is used as precipitating reagent. The de­
tection limit for NSE is 2 μg/L. 
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S-100 concentrations in CSF were determined by a particle-counting immunoas­
say (PACIA), essentially as described by Sindic et al.3. The S-100 immunoassay kits 
were received from C.J.M. Sindic of the Department of Experimental Medicine, 
University of Brussels. The detection limit is 0.5 μg/L. 
MBP was determined by a double-antibody RIA kit according to the instruc­
tions of the manufacturer (cat. no. DSL 1500; Diagnostic System Lab., Webster, 
TX). Human MBP (whole molecule) is used as the antigen and rabbit anti-human 
MBP as antiserum. Goat anti-rabbit gamma globulin is the MBP precipitation 
reagent. The detection limit is 0.2 μg/L. 
Statistics 
After logarithmic transformation, we performed a regression analysis to yield age-
related reference intervals for NSE, S-100 and MBP. We estimated the median val­
ue and the reference limits as the 5th and 95th percentiles. P-values for sex and age 
dependency were calculated. 
The scatter diagrams of NSE and MBP against age contained no clear outliers. 
The scatter diagram of S-100 against age contained one clear outlier (7 μg / L at age 
7 years), which we removed before calculating the reference interval for S-100. 
Results 
Age and Sex Dependency 
NSE, S-100, and MBP in CSF increase with age. Table 1 lists the age-related refer­
ence intervals ^g/L) and Figure 1 illustrates the NSE, S-100, and MBP concentra­
tions as functions of age (years). The P-values for age-dependency were 0.03 for 
NSE, <0.001 for S-100, and 0.001 for MBP. The 95% confidence intervals for the 
relative increase of NSE, S-100, and MBP with age overlapped and were as follows 
(percentage increase per year): NSE, 0.1-1.4%, S-100, 0.4-1.5%, MBP 0.5-1.9%. 
There were no significant differences between males (n=42) and females 
(n=37) in age or in NSE, S-100, and MBP concentrations (0.20 < Ρ < 0.80). There­
fore, we combined the data for further analysis. 
Table 1. Reference values (\lg/L)for NSE, S-100, and MBP in CSF 
Age 
(years) 
1 
20 
40 
60 
NSE 
PS 
2 2 
2 7 
3 1 
3 8 
P50 
5 0 
5 8 
6 5 
7 8 
P95 
10 2 
12 0 
13 8 
16 0 
S 100 
P5 
0 9 
1 1 
1 3 
1 6 
P50 
1 5 
18 
2 2 
2 7 
P95 
2 6 
3 3 
4 0 
50 
MBP 
P5 
0 12 
0 17 
0 22 
0 30 
P50 
0 30 
0 40 
0 52 
0 70 
P95 
0 72 
0 95 
1 21 
1 57 
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Fig. 1. Scatter diagram of CSF concentrations fag/L) as a function of age (years) for reference sample patients: (top) NSE, 
(middle) S100, (bottom) MBP. Solid lines indicate 5-95% confidence limits and median valves. 
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Table 2. Detaih of Clinical Case Histories 
Patient and Age (years) 
Diagnosis 
Acute transverse myelopathy 
1 Borrelia 6 
Myelopathy 
2 Adenovirus 10 
myelopathy 
(untreated) 
Acute panencephalitis 
3 Herpes 1.5 
encephalitis 
Duration of 
Sickness 
(days) 
5 
Treatment started 
13 
27 
11 
23 
10 
Treatment started 
24 
40 
49 
Concentrations ^ g / L ) 
NSE 
(2.2-10.2)* 
7.3 
7.2 
9.7 
3.9 
7.3 
44.8 
11.0 
8.1 
5.9 
S-100 
(0.9-2.6) 
2.8 
3.1 
2.1 
2.2 
2.5 
8.6 
1.9 
1.3 
1.5 
MBP 
(0.12-0.72) 
20.0 
10.9 
0.4 
12.9 
1.1 
8.7 
2.9 
4.2 
* Reference interval (5th-95th percentiles) given in parentheses 
Clinical Examples 
Serial analysis of NSE, S-100, and MBP in CSF has been recommended in the lit-
erature as a very sensitive but unspecific screening variable for pathological or-
ganic CNS processes2'4,7'9. In our opinion, these measurements have even greater 
clinical relevance and potentials. To illustrate this, we present three case histories 
(Table 2). 
Transverse myelopathy. Patients with an acute transverse myelopathy show dis-
tinct nervous-system-specific protein profiles in CSF, depending on the different 
underlying causes and corresponding to different prognosis. 
Patient 1, with acute transverse myelopathy after infection with Borrelia 
burgdorferi treated with penicillin G, and patient 2, affected after adenovirus in-
fection, show MBP values solely above the reference interval. The values of NSE 
and S-100 in the acute stage of the disease are within the respective reference in-
tervals. This combination indicates acute and isolated demyelination. If this 
process terminates spontaneously (patient 2) or after treatment (patient 1), re-
myelination and clinical recovery occur. No neurological deficit remains because 
there was no irreversible damage to the neuron compartment. 
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In these cases, the determination of NSE, S-100, and MBP may serve to assess 
which compartment (neuron, glia or myelin) is affected. By elucidating which 
functional structure is involved in an acute neurological disorder, the CNS-specif-
lc proteins can serve as a diagnostic but also as a prognostic tool 
Panencephalitis. In the CSF of a child (case 3) with an acute disease with fever, 
focal epilepsy, and hemiparesis, we found clearly increased values for NSE, S-100, 
and MBP Such an acute and severe panencephalitis has to be treated as a herpes 
encephalitis The remarkably high values of NSE correspond to a very bad prog­
nosis when therapy is delayed After therapy was started, NSE and S-100 values 
decreased in our patient (Table 2) Thirty days after the start of the therapy, MBP 
was still clearly above the reference interval, indicating ongoing demyehnation 
In this case, the CNS-specific proteins may again serve as a diagnostic and prog­
nostic tool Another possible use is for evaluation and measurement of the effect 
of therapeutic interventions. 
Discussion 
NSE, S-100 and MBP in these CSF samples increased with age from 0 7 until 66 
years It is remarkable that the relative increases of NSE, S 100, and MBP with age 
are similar The 95% confidence limits of the relative increases of NSE, S-100, and 
MBP overlap The median increase of the CNS-specific proteins is 1% per year 
We found no prior reports on age dependency of CNS specific proteins in the 
literature 
A supposed age-dependent increase m blood brain barrier permeability, result­
ing in an increase in CSF total protein with age, cannot be the explanation for the 
age-dependency of the CSF CNS specific proteins Because they originate from 
the nervous system, there is no transudation of these proteins from the serum to 
CSF across the blood-brain barrier At least three explanations for increases in 
NSE, S-100, and MBP with age are possible (a) the age-dependency reflects in­
creasing cell and myelin loss with age, (b) the NSE, S-100, and MBP concentrations 
in the cells and myelin increase with age, whereas the turnover of the cells and 
myelin remains constant, or (c) the same relative increase of NSE, S-100 and MBP 
(1% per year) with age could be the result of a common underlying mechanism, 
e g , an increased half-life attributable to reduced CSF bulk flow at older ages The 
CSF bulk flow reportedly decreases with age10, resulting in a synchronous increase 
of the concentrations of proteins'"u. 
Some investigators have reported about NSE, S-100, and MBP in CSF of chil­
dren and adults in relation to various neurological diseases head injury2 9, CNS tu­
mours
4 7 B 1 3 1 5
, cerebral ischemia, including stroke2 7 8 н 16, inflammatory diseases of 
the CNS, such as encephalitis or myelitis3 7"1 4, multiple sclerosis'78, Guillam-
Barré syndrome37, epilepsies814, migraine8, cervical myelopathy"8, amyotrophic 
laterosclerosis , Huntington disease17; Creutzfeldt-Jacob disease18, dementia8, and 
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subarachnoidal and intracerebral bleeding or haematoma2'7. We shall discuss the 
clinical potentials and restrictions of the CNS-specific proteins in relation to neu-
rological diseases more in general. 
Many modern imaging techniques yield important information concerning 
the status of the brain or spinal cord but cannot distinguish between irreversibly 
damaged brain or spinal cord (infarcts) on the one hand and reversible changes in 
viable tissue (edema) on the other. Although the neurological deficit depends on 
the size as well as on the site of the lesion - a small strategically placed lesion can 
lead to substantial clinical deficit - quantification of CNS-specific proteins may 
contribute to a more-detailed estimation of the actual structural and irreversible 
brain or spinal cord damage in various clinical situations". Therefore assessment 
of CNS-specific proteins can be of diagnostic and prognostic value2,7'9. 
Markers of CNS cell damage can also be of clinical value in evaluating the ef-
fect of therapeutic measures to reduce cerebral cell damage caused by vascular re-
construction, hemodilution, hyperventilation, and treatment with barbiturates, 
calcium blockers or mannitol2. 
Although the nervous-system-specific proteins are very sensitive indexes", nor-
mal values for NSE, S-100, and MBP do not exclude disease. The time of CSF sam-
pling in relation to the ictus of the cytolytic process is of crucial importance: in is-
chemic stroke patients, concentrations of NSE and S-100 were increased only be-
tween 18 h and 4 days after the ictus2. In demyelinating diseases, MBP is cleared 
within 5-7 days after the ictus'. Therefore, serial measurements can elucidate the 
dynamics of the pathological process in relation to therapy. 
From our own clinical examples and review of the literature, we think the sig-
nificance of the assessment of NSE, S-100, and MBP in clinical (child)neurology 
could be 
- to help to determine if the disease is involving the nervous system; 
- to differentiate between damage to the glia or neuron compartment (clinical 
symptoms and signs, neuroradiology, and neurophysiology also contribute to 
this differentiation but in a less direct and specific way); 
- to differentiate between irreversible damage or reversible changes in nervous 
tissue (in addition to a diagnostic value, there is a potentially prognostic one); 
and 
- to help in evaluating the effect of treatment. 
In this study we obtained reference values for NSE, S-100, and MBP in children 
and adults of different ages and both sexes. The availability of these age-matched 
reference values allows interpretation of CNS-specific proteins in CSF of patients 
with different neurological disorders, perhaps leading to a better understanding of 
their basic mechanisms. 
In a second paper20 we used age (but not sex) -matching to investigate whether 
the CNS-specific proteins behave independently and show distinct profiles in var-
ious neurological disorders. 
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Cerebrospinal fluid examinations in cryptogenic 
West and Lennox-Gastaut syndrome before and 
after intravenous immunoglobulin 
administration 
Summary 
Before and after administration of intravenous immunoglobulin (IVIg), cere-
brospinal fluid (CSF) was examined in a homogeneous group of 15 patients with 
cryptogenic types of West syndrome (WS) and Lennox-Gastaut syndrome (LGS). 
The purpose of the present CSF study was: (i) to elucidate possible etiological fac-
tors and consequences of these severe forms of epilepsy, and (ii) to elucidate 
mechanisms of action and adverse effects of IVIg. Hypotheses concerning etio-
logical factors like central nervous system (CNS) infections, neuroimmunological 
disorders, or disturbances in neurotransmitter metabolites could not be con-
firmed. These normal CSF findings are in accordance with the concept of a cryp-
togenic etiology of the epilepsies in the reported patients. Nor could we confirm 
hypotheses concerning seizure consequences, such as increased blood-CSF per-
meability, increased markers of brain cell destruction, or increased metabolic 
components. Following IVIg administration in these patients, all with an on the 
whole undisturbed blood-CSF barrier permeability as measured by Q albumin, 
the CSF IgG concentrations increased significantly and proportionally to the Q al-
bumin level. No signs of adverse effects of IVIg such as aseptic meningoen-
cephalitis were found in 165 infusions of IVIg performed in the 15 children. 
Introduction 
WS and LGS are etiologically nonspecific. They are described in association with 
numerous pre-, peri-, and postnatal complications (symptomatic types), and are 
also observed without apparent associated cerebral pathology (socalled idiopath-
ic or cryptogenic types)2'5·21'2''. Despite the various etiologies and pathophysiolog-
ical mechanisms that have been suggested to explain these conditions, it is re-
markable that WS and LGS show such distinct clinical characteristics and exhibit, 
to a certain extent, a homogeneous age-related epileptic phenotype. WS and LGS 
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can be considered to be the developing brain's relatively uniform answer to the dy-
namic interaction between genetics, maturation, and environmental factors48. 
The cerebrospinal fluid (CSF) is appropriately viewed as the clinician's (indi-
rect) access to the brain and is capable of reflecting pathophysiological changes in 
brain function and metabolism11". Therefore, we studied CSF in a homogeneous 
group of patients with WS and LGS in an attempt to understand certain elements 
of the age-specific answer of these developing brains. In order to rule out con-
founding etiological factors, only patients with WS and LGS of cryptogenic etiol-
ogy were investigated. Results are compared to a group of normal controls and 
discussed (i) by reviewing the literature on etiological factors of epilepsy (such as 
neurological infections, neuroimmunological disorders, disturbances of neuro-
transmitter metabolism), and (ii) by reviewing the literature concerning conse-
quences of epilepsy (like increased blood-CSF permeability, increased markers of 
brain cell destruction, and increased metabolic components). 
In addition, the effect of human polyclonal IVIg on CSF examinations was in-
vestigated. A number of reports has appeared on the usually successful IVIg treat-
ment of epilepsy (including WS and LGS), whereas hardly anything is known 
about the mechanism of action of IVIg in epilepsy45. Whether it crosses the blood-
CSF barrier, enters the CSF, and significantly increases CSF IgG in patients with 
epilepsy has never been investigated. Thus, CSF examination before and after IVIg 
administration may not only reveal pathophysiological mechanisms of WS and 
LGS, but may also detect adverse effects and elucidate mechanism of action of 
IVIg. 
Patients and Methods 
Study population 
The children eligible for the study were outpatients, well known to the clinical in-
vestigators (BvE, WR). Fifteen patients (six boys, nine girls) were studied, 12 with 
cryptogenic LGS (four of whom initially had WS) and three with cryptogenic WS. 
The mean age was 3.6 yrs (range, 1.0 to 6.0 yrs), the mean duration of epilepsy 
prior to the start of the study 2 yrs (range, 0.2 to 5.5 yrs). All patients received val-
proate either as monotherapy or in combination with other anti-epileptic drugs, 
especially benzodiazepines. Written informed consent was obtained from each 
child's parent prior to sampling of blood and CSF for diagnostic purposes. 
Cryptogenic etiology was defined as epilepsy of unknown cause in infants or 
young children with unremarkable neuromental development prior to onset of 
seizures. Physical examination was normal; there were no abnormalities on cere-
bral computed tomography or magnetic resonance imaging, except for a slight di-
latation of ventricles; no known mental retardation syndromes, chromosomopa-
thy, or inborn errors of metabolism (the following laboratory tests were per-
formed, in urine - organic acids, amino acids, purines, pyrimidines, mucopolysac-
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chandes, oligosaccharides, and neuraminic acid; in serum - amino acids and lac-
tate; in leukocytes - lysosomal enzymes). Any abnormality excluded the child 
from entry into the study. Other exclusion criteria were adrenocorticotrophic hor-
mone (ACTH) treatment within 6 weeks prior to start of the study, other diseases 
or intercurrent infections, and IgA deficiency. IgA-deficient patients may have an-
ti-IgA antibodies which can cause an anaphylactic reaction with the IgA antibod-
ies in the IVIg preparation43. An intractability score of at least five on Schmidt's in-
tractability score, modified by Aicardi, was a prerequisite for entry into the study, 
i.e. seizures persisted despite treatment with more than one first-line drug at a 
maximum tolerable dose, possibly combined with second-line drugs1. 
WS and LGS, epileptic encephalopathies with characteristic ages of peak inci-
dence, were defined (i) by the occurrence of severe epilepsy (resistant to most or 
all currently available drugs) with infantile spasms in WS and with multiple types 
of frequent generalized seizures in LGS; (ii) by their typical interictal electroen-
cephalographic patterns; and (iii) by their association with cognitive /behavioral 
problems and their early onset, usually during infancy or the first years of child-
hood5'24. Because of the frequent transition from WS to LGS (in the present study 
four of 12 patients with LGS started with WS), and the close mutual relationship 
between both time-locked epileptic encephalopathies, patients with both WS and 
LGS were included13. 
The age- and sex-matched control group consisted of 16 normal controls de-
rived from a previously published reference group of 79 healthy children and 
adults46. Normal controls were selected according to the following criteria: no use 
of medication; no evidence of an organic neurological disorder, an inherited 
metabolic disease, or a malignant disease; and normal concentration of total pro-
tein in CSF. The diagnoses selected in this way, comprise predominantly somato-
form disorders. Due to an insufficient volume of CSF, not all investigations could 
be carried out in all patients or in all normal controls. 
Methods 
CSF and serum values obtained from patients before IVIg administration and 3 
months later, exactly 14 days after the last dose of IVIg, were compared to those 
of the normal control group. Commercially available IVIg (Central Laboratory of 
the Netherlands Red Cross Blood Transfusion Service, Amsterdam), containing 
more than 95% IgG, was administered in a dose of 0.4 gm/kgbody weight per day 
for 5 consecutive days, followed by the same dose once every 2 weeks during 3 
months (11 infusions in total). 
Peripheral venous blood and CSF samples were drawn simultaneously at the 
same time of day (10.00 a.m.) according to standard procedures, in the L3/L4 or 
the L4/L5 interspace. Samples of serum and CSF were stored within 30 minutes 
at -70 °C until assayed. Analyses were performed on a standard volume of CSF, 
e.g. proteins in the first 5 mL, neurotransmitter metabolites in the second 5 mL. 
The leukocyte count in CSF was performed using a Fuchs Rosenthal chamber, and 
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a Sayk sedimentation chamber with May-Grunwald-Giemsa staining for leuko­
cyte differentiation. The CSF and serum concentrations of albumin, IgG, IgA, IgM 
and the detection of CSF and serum oligoclonal bands by means of isoelectric fo­
cussing on commercial Polyacrylamide PAG plates were measured as described 
previously'8. We used the following ratios or indices in our study: Q albumin = 
CSF albumin concentration χ 10s/ serum albumin concentration; IgG index = Q 
IgG/ Q albumin = ({CSF IgG χ IO5/ serum IgG} / Q albumin); the IgA index and 
IgM index were calculated analogous to the IgG index. The CSF concentrations of 
neuron specific enolase (NSE), S-100 protein (S-100), and myelin basic protein 
(MBP), were assessed as described in our previous study46. CSF concentrations of 
the dopamine metabolite homovanillic acid (HVA), serotonin metabolite 5-hy-
droxyindoleacetic acid (5-HIAA), lactate and total protein were measured as de­
scribed previously27. 
Data from the normal control group, as well as the data obtained from the 
study population before and after IVIg administration, were compared using the 
Wilcoxon's signed rank test. Relationships between the CSF data were calculated 
by means of Spearman's correlation coefficient ( ρ ). Hypotheses were tested two 
sided and significance was set at Ρ < 0.01 because of multiple variables. 
Results 
CSF components in the group of WS and LGS patients before IVIg administration 
No significant differences in the various CSF components were found between the 
patient group before IVIg administration and the control group (Table 1). 
With regard to correlations between various markers in CSF, a significant (P < 
0.01) correlation (in normal controls ρ = 0.7; in patients ρ = 0.9) was found be­
tween the Q albumin level and CSF total protein concentration. In addition, in 
both patients before IVIg administration and in normal controls, there was a re­
markable significantly positive correlation between CSF IgM and CSF NSE, and 
between CSF IgM and CSF S-100 (both ρ in normals = 0.9, in patients ρ = 0.5). 
CSF components in the group of WS and LGS patients after IVIg administration 
After 3 months of IVIg administration, no significant differences were found in 
the various CSF components in the patient group compared to the normal con­
trols, except for a significant lower Q albumin level in patients compared to nor­
mal controls (Table 1). 
Following IVIg administration, CSF lactate, serum total IgG and CSF IgG were 
significantly increased compared to the pretreatment values. Serum total IgG in­
creased in all patients ranging from 5 to 186% (mean 76%). CSF IgG was elevated 
in all but one patient, the only one who did nor clinically, nor electroencephalo-
graphically respond at all. The CSF IgG increase ranged from 22 to 89% (mean 
44%). The delta increase in CSF IgG ( - CSF IgG after treatment minus CSF IgG 
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Table I. Comparison of CSF components in the group of WS and LGS patients (n—15) before and 
after IVIg treatment with those of normal controls (n=16), * significant difference (P < 0.01) 
I 
и 
m 
IV 
V 
CSF examinations 
Blood-CSF 
barrier 
parameters: 
Brain сей 
destruction 
parameters: 
Neuro-
immunological 
parameters: 
Metabolic 
components: 
Neurotransmitter 
metabolites: 
Components 
Total protein 
Q Albumin 
NSE 
S-100 
MBP 
Leukocyte no 
IgG 
IgA 
IgM 
IgG index 
IgA index 
IgM index 
Units 
mg/L 
Mg/L 
Mg/L 
Mg/L 
/3mm' 
mg/L 
mg/L 
mg/L 
Oligoclonal bands 
Glucose 
Lactate 
HVA 
5ΗΙΛΑ 
mmol/L 
μιηοΙ/L 
nmol/L 
nmol/L 
Patients 
before IVIg 
Mean ± SD 
234 ± 50 
242 ± 78 
5.5 ±2.0 
2.1 + 0.8 
0.42 ±0.38 
3.4 ±3.6 
12.0 ± 4.1 
1.0 ±0.5 
0.3 ± 0 . 1 
0.46 ±0.06 
0.36 ±0.13 
0.05 ± 0.03 
0 
2.5 ±0.37 
1552 ± 139 
584 ±157 
232 ± 97 
after IVIg 
Mean ± SD 
222 ± 61 
245 + 56 
5.3 ±2.6 
3.8 ±2.5 
0.37 ±0.31 
4.2 ±3.4 
16.6 ± 6.0* 
0.8 ±0.5 
0.2 ± 0 . 1 
0.50 ± 0.08 
0.38 ± 0.25 
0.06 ± 0.02 
0 
2.5 ±0.29 
1640± 176* 
543 ±150 
190 ± 72 
Controls 
Mean ± SD 
259 ± 5 1 
301 ± 74* 
7.1 ±2.6 
1.8±0.8 
0.37 ±0.17 
2.9 ±2.4 
13.2 ± 5 . 7 
1.0 ±0.2 
0.3 ± 0.3 
0.47 ±0.07 
0.35 + 0.11 
0.08 ±0.10 
0 
2.6 ±0.36 
1558 ±234 
5 5 1 ± U 5 
174 ± 4 4 
before treatment) ranged from 5 to 11 mg/L. In two patients, CSF IgG was not 
only measured after 3 months but also after 6 weeks of IVIg treatment. CSF IgG 
levels before, after 6 weeks, and after 3 months of IVIg were, respectively: 9,17,14 
mg/L in one, and 12,21,15 mg/L in the other patient. 
Concerning correlations, the delta increase in CSF IgG correlated significantly 
positive ( ρ = 0.9) with Q albumin (a measure of blood-CSF permeability) (Fig. 1). 
The correlation between Q albumin before and after IVIg did not reach statistical 
significance (P = 0.02, ρ = 0.7), neither did the IgG index before and after IVIg (P 
= 0.08, ρ = 0.6). After IVIg, no CSF signs of an adverse reaction like an aseptic 
meningoencephalitis8 were found. 
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Discussion 
In the present study on patients with cryptogenic WS and LGS, the various CSF 
examinations did not contribute to the elucidation of possible etiological factors 
or consequences of these severe forms of epilepsy, because CSF findings did not 
significantly differ from those of normal controls. This is in keeping with the gen-
eralization that the CSF is normal in idiopathic or cryptogenic epilepsy17. An in-
creased CSF white cell number or an increased CSF total protein concentration 
has been described in symptomatic epilepsy secondary to a structural lesion in the 
brain adjacent to the CSF pathways, and also during the postictal period17. In the 
reported patients with severe forms of cryptogenic epilepsy and frequent seizures 
(up to several hunderd each day in some patients), we had expected an increased 
white cell number and total protein concentration12 because of their chronic pos-
tictal state. 
We shall discuss the results of the present study in more detail and compare 
them to literature data on CSF examinations in epilepsy. 
Markers of blood-CSF barrier permeability 
In agreement with a study on normal blood-CSF permeability in cryptogenic WS 
and increased permeability in symptomatic WS38, we did not find indications for 
an overall increased permeability in the present study on cryptogenic WS and 
LGS. This does not, however, exclude regional or focal increases in permeability 
as reported in the hippocampus of patients with epilepsy32; nor is it incompatible 
with regionally increased permeability in cases of experimental epilepsy occur-
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ring particularly in the hypothalamus and midbrain tegmentum but also in the 
thalamus, hippocampus, cerebellum and neocortical brain areas depending on the 
specific convulsant used34'11. 
Markers of brain cell destruction 
Neuropathological reports of patients with idiopathic or cryptogenic types of 
epilepsy, including LGS, have consistently described an appreciable degree of neu-
ronal loss accompanied by a glial reaction, especially in the hippocampus and cere-
bellum, in more than half the patients29,37. NSE, S-100 and MBP are considered to 
be markers of neuronal, glial, and myelin damage, respectively46. In the present 
study group as a whole, NSE, S-100 and MBP did not differ from normals, and 
none of the patients showed elevated NSE concentrations (according to our age-
related reference values46), whereas 3 showed an S-100 elevation, 2 of whom also 
had an increased MBP concentration. Although the markers of cell destruction 
are very sensitive parameters, normal values do not exclude disease or damage to 
the brain. In acute diseases, the amount of tissue damage, and the time of CSF 
sampling (within the first 1 to 2 weeks) in relation to the ictus of the (cytolytic) 
process is of crucial importance. In chronic diseases, markers of cell destruction in 
CSF are nearly always within reference ranges, with the exception of a few se-
verely encephaloclastic processes like metachromatic leukodystrophy, globoid cell 
leukodystrophy (Krabbe's disease), and GMl gangliosidosis46. 
Markers of infections or neuroimmunological disturbances 
Benson et al4 reported elevated IgG indices, a sign of intrathecal IgG production, 
with a normal CSF cell number and normal CSF total protein concentration in 5 
patients with WS. In a group of 8 patients, most of whom had LGS, Ariizumi et 
al3 observed elevated IgG indices. Intrathecal IgG production, oligoclonal bands 
and viral antibodies in association with a normal Q albumin level have been de-
scribed23 and also rejected28 in progressive myoclonus epilepsy. It has also been 
postulated that therapy resistant epilepsy may be related to persistent virus infec-
tions", and that cryptogenic WS may be caused by unrecognized viral encephali-
tis33. Porter35 even stated that an unrecognized infection is a prominent cause of 
epileptic disorders in a significant percentage of patients with seizures of 'un-
known etiology', especially in children. Our findings and those of others36,38 do 
not support hypotheses concerning neurological infections (normal white cell 
number) or neuroimmunological disturbances (no intrathecal immunoglobulin 
synthesis because of normal IgG, IgA and IgM indices, and no oligoclonal bands) 
as etiological factors in cryptogenic WS and LGS. Nor could a postictal pleocyto-
sis be confirmed12. 
Metabolic components 
Metabolic abnormalities, just like increased cell numbers, could either be a con-
sequence of a seizure or an indication of an etiological factor contributing to the 
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seizure. Concerning the latter, decrease of CSF glucose and CSF lactate in chil-
dren with seizures and delayed milestones has recently been described as a sepa-
rate syndrome. This syndrome has been attributed to a genetic defect of the glu-
cose transporter I protein of the blood-brain barrier endothelial cells, which re-
sults in cerebral glucopenia17. Recognition of this syndrome could be important 
because it responds well to a ketogenic diet. In the present study on patients who 
showed a similar clinical syndrome of seizures and delayed milestones, no de-
crease of CSF glucose or lactate was found. Although several studies provide evi-
dence that status epilepticus and even a single tonic-clonic seizure can lead to a rise 
in CSF lactate*'7, we could not confirm this in the present study on children with 
frequent seizures. This lack of CSF lactate elevation is in accordance with a study 
on children who had suffered a single seizure of less than 30 minutes duration; 
raised CSF lactate levels were only reported in 4 of 31 patients40. 
Neurotransmitter metabolites 
Lumbar CSF concentrations of HVA and 5-HIAA are influenced by age, diet, 
drugs, state of physical activity, diurnal rhythms, and manner of storage of CSF". 
These factors may account for the wide range of normal values and contradicto-
ry results reported in the literature. Effects of age, diurnal rhythms, volume of the 
CSF sample, and manner of storage of CSF are excluded in the present study. Most 
studies, including the present one, showed reduced or normal CSF levels of the 
dopamine metabolite HVA in children or adults with epilepsy25,39,51. Chadwick et 
al' reported normal CSF HVA concentrations in untreated patients with epilepsy, 
and a trend toward higher values in patients on antiepileptic drugs. In the study 
by Zimmer et al52, treatment with valproate elevated GABA, cAMP and HVA lev-
els in patients. With regard to the serotonin metabolite, 5-HIAA, low lumbar CSF 
concentrations are reported in both children and adults with epilepsy39,47,5 '. Chad-
wick et al9 demonstrated normal CSF 5-HIAA concentrations in untreated pa-
tients with epilepsy, and elevated lumbar CSF 5-HIAA concentrations in patients 
treated with phenytoin and phénobarbital. In animal studies, rat brain serotonin 
levels increased following administration of phenytoin, phénobarbital, diazepam 
and sodium valproate51. In the present study, involving patients usually on val-
proate in combination with benzodiazepines, concentrations of 5-HIAA before 
IVIg administration were possibly increased, but without reaching statistical sig-
nificance. 
Concerning correlations between the various CSF variables, it was not sur-
prisingly to find a significant positive correlation between Q albumin level and 
CSF total protein concentration in both patients and controls'". More remarkable 
was a significant correlation in CSF between IgM and NSE, and between IgM and 
S-100 in the patient group before IVIg as well as in normal controls. Vlajkovic et 
al49 recently detected significantly higher levels of autoantibodies to NSE, S-100, 
and MBP in the sera of rats with experimental epilepsy Although the autoanti-
bodies were also present in normal control rats (admittedly, in smaller amounts), 
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it was suggested (i) that they were either the consequence of the repeated elec­
troconvulsive shocks or (ii) that they are potentially epileptogenic and contribute 
to the pathogenesis of epilepsy. Due to the remarkable correlation found in the 
present CSF study between IgM and NSE, and between IgM and S-100 in the pa­
tient group before IVIg administration, we could not exclude suggestion (ii) that 
CSF IgM may consist of pathogenic autoantibodies to NSE and S-100. Neverthe­
less, because these correlations were also present in normal controls, we can spec­
ulate that the CSF IgM in the presented patients may be a consequence of seizure-
induced increased antigen presentation, and might play a role in phagocytosis of 
endogenous debris22. (Micro)trauma of nervous tissue may provoke increased 
antigen presentation and increased autoreactive Τ and В cell responses, as has 
been demonstrated in patients with polyneuropathy after (compared to before) 
sural nerve biopsy42. 
The effect of IVIg administration on CSF examinations 
In the present study, IVIg significantly increased serum and CSF IgG concentra­
tions. Moreover, the delta increase in CSF IgG correlated significantly positively 
with Q albumin. As Q albumin in individual patients can be used as a measure for 
the individual blood-CSF barrier permeability14, a higher Q albumin should in­
deed be associated with a higher IgG transfer from blood into CSF across the 
blood-CSF barrier. In the present patients, all of whom had normal Q albumin lev­
els, which means a generally undisturbed blood-CSF barrier permeability, IVIg is 
able to increase CSF IgG (except in one patient). This is in accordance with the 
normal situation of transfer of IgG from blood to the CSF1"'19'44. Whereas the 
blood-brain barrier with its endothelial tight junctions represents a virtual block 
to faster and measurable protein transfer, the blood-CSF barrier with its porous, 
fenestrated capillaries can be conceived as a small-pore microfilter generally al­
lowing comparatively easy passage of IgG and even the largest serum proteins16. 
The filtration sites of the blood-CSF barrier reside within the choroid plexus16. 
Currently, there is no readily available technique to investigate directly the 
composition of the interstitial i.e. extracellular fluid of the human brain. But, first­
ly because no restrictive barrier appears to exist between CSF and the extracellu­
lar fluid of the brain31,50,51 at least within short diffusion distances, and secondly be­
cause IgG crosses the blood-CSF barrier, IgG could probably reach certain parts of 
the brain and may have an effect on its epileptic activity, e.g. by favorably altering 
neuronal excitability. Areas of the brain and brainstem adjacent to the CSF are sus­
pected to be involved in WS and LGS5,29. In this respect it is remarkable that the 
one patient who did not show any increase in CSF IgG concentration after IVIg 
administration, was the only patient who did not show any clinical seizure reduc­
tion after IVIg. A second possible mechanism whereby IgG can reach the epilep­
tic brain is that IgG focally penetrates the seizure-induced focally destructed 
blood-brain barrier as has been shown for albumin in experimental epilepsy 34,41. 
The specific or unspecific mechanisms of action of IVIg remain unknown, and 
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this study can only exclude some possible mechanisms, for instance an effect of 
IVIg by suppression of a chronic meningoencephalitis. 
In the present study, we did not find indications for reported adverse effects of 
IVIg like an aseptic meningoencephalitis8. We do not have a biological explanation 
for the increase in CSF lactate after IVIg administration (although lactate concen­
trations remained within reference limits). IVIg was administered in a booster 
dose of 0.4 gm/kg body weight per day for 5 days, followed by the same dose once 
every 2 weeks during 3 months. In two patients, CSF IgG concentrations were 
measured prior to, and 6 weeks and 3 months after IVIg administration, each time 
exactly 14 days after the last IVIg injection. In both patients, the CSF IgG concen­
tration was higher after 6 weeks than after 3 months of IVIg administration, pos­
sibly due to the booster effect. 
To summarize, extensive CSF studies only confirmed the cryptogenic charac­
ter of WS and LGS in the present group of patients. We conclude that, on the clin­
ical level in individual patients with these types of epilepsy, CSF examinations 
could serve to exclude associated disorders (symptomatic forms of epilepsy) and 
potentialy treatable causes of infectious or metabolic origin. Concerning more fon­
damental aspects of WS and LGS, we could exclude some etiological factors and 
consequences in the present patient group. If, even in these severe forms of epilep­
tic encephalopathy, no CSF abnormalities can be found, it can be speculated that 
epilepsy is hidden in the neurochemical network of the brain with only micro-ar­
chitectonic or focal metabolic abnormalities. The CSF composition reflects, at 
least in a general way, the sum total of metabolic activity within the CNS. Focal 
CSF abnormalities may be missed in lumbar CSF because of turnover and equili­
bration of focal metabolic abnormalities. In the larger context of a neurochemi­
cal network-analysis of epilepsies, future studies on CSF and brain extracellular 
fluid (by intracranial dialysis) may focus on neuronal and glial growth factors, 
cytokines, and electrolytes. It remains intriguing to investigate the potential role 
of CSF and brain extracellular fluid in synaptic cell-cell interaction ("wiring 
transmission"), but especially in non-synaptic, cell-cell interaction ("volume trans­
mission") in the epileptic brain20. 
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Part3 
Immunological aspects 

[8] 
Serologic HLA typing in cryptogenic 
Lennox-Gastaut syndrome 
Summary 
Serologic HLA typing was performed on 12 patients with cryptogenic Lennox-
Gastaut syndrome and compared to a normal control group of 1661 Caucasians. 
In the Lennox-Gastaut group we found a significant increase in the frequency of 
DR5 antigen (55%, chi-square = 5.6), and an indication of a decrease in the fre­
quency of DR4 antigen (0%, chi-square = 3.0) as compared with controls (20% and 
28%, respectively). No significant differences existed in the frequencies of HLA-A, 
B, and С antigens between the Lennox-Gastaut group and the controls. These 
findings contribute to the hypothesis that immunogenetic mechanisms may play 
a role in triggering or maintaining cryptogenic Lennox-Gastaut syndrome. 
Introduction 
The Lennox-Gastaut syndrome (LGS) is an uncommon, unexplained, au­
tonomous, epileptic syndrome, which looks rather like a diffuse encephalopathy 
with a tendency to become chronic2. The distinct characteristics of cryptogenic 
LGS clearly differentiate it from the diversity of other childhood epileptic syn­
dromes and provide, to a certain extent, a homogeneous phenotype, a major is­
sue when dealing with common complex diseases. Various pathophysiologic 
mechanisms have been suggested to explain this condition, including the hypoth­
esis that it results from aberrant immune function17,21. Indications supportive for 
this hypothesis include the demonstration of antibodies to brain tissue in the sera 
of patients with LGS17, and the effect of intravenous immune globulin in patients 
with LGS13,23. A third indication is the impaired humoral immune response to a 
primary antigen (haemocyanin)2" which has also been described in an auto-im­
mune disease like systemic lupus erythematosus. To investigate further the possi­
bility that LGS of cryptogenic aetiology may be associated with autoimmune ab­
normalities, we performed serologic HLA-A, B, C, and especially HLA-DR and 
DQ typing studies on a homogeneous group of patients with this disorder. 
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Patients and Methods 
We studied 12 unrelated Caucasian patients with cryptogenic LGS. LGS was de­
fined by the triad: (1) typical epileptic seizures (axial tonic, atypical absences, aton­
ic seizures) eventually associated with generalized tonic-clonic seizures and par­
tial seizures, (2) inter-ictal slow spike-waves (less than 3 per second) in awake EEG, 
(3) mental retardation or deterioration with personality disorders, and by age of 
onset between 1 and 8 years2. True myoclonic epilepsies characterized by a pre­
dominance of myoclonic seizures and fast (>2.5 Hz) activity in the EEG, were ex­
cluded1,2. Cryptogenic aetiology was defined as epilepsy of unknown cause in in­
fants or children with unremarkable neuromental development before onset of 
seizures; normal physical examination; no abnormalities on cerebral CT or MR 
imaging, except for a slight dilatation of ventricles; no known mental retardation 
syndromes, chromosomopathy, or inborn errors of metabolism. The control pop­
ulation consisted of 1661 normal Caucasian individuals (blood donors). 
HLA typing was performed for serological WHO defined HLA antigens in the 
Tissue Typing Laboratory of the Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service, Amsterdam, using the NIH microcytotoxicity 
assay for HLA-A, В, С typing, and the two colour fluorescence test for HLA-DR 
and DQ typing3. 
HLA antigen frequencies of patients and controls were compared using the chi-
square test. Ρ < 0.05 was considered significant. 
Results 
There were no significant differences in frequencies of HLA-A, B, and С antigens 
(including B7) between the LGS group and controls. Concerning the HLA class II 
antigens in the LGS group however, a significant increase in the frequency of DR5 
antigen (55%, chi-square = 5.6, Ρ = 0.025) was found. In addition, none of the LGS 
patients showed the DR4 antigen, whereas 28% of the normal population did 
(Table I), which is an indication (not reaching statistical significance) of a decrease 
in frequency of DR4 antigen (chi-square = 3.0). 
Discussion 
A number of epilepsies have been reported to have an association with a specific 
HLA allele, and a few conditions appear to show genetic linkage with the HLA lo­
cus on chromosome 6p25. Nevertheless, comparison of the present data with pre­
vious studies on HLA antigen association in patients with LGS is difficult since on­
ly few studies have examined patients with this type of epilepsy (Table I), and none 
of the studies tested for both HLA class I molecules (HLA-A, B, and С antigens), 
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Table I. HLA studies in Lennox-Gastuut syndrome, West syndrome and idiopathic types of other 
epilepsies. 
Type of 
epilepsy 
Lennox 
West 
Idiopathic 
Study* 
Smeraldi2' 
Westphal* 
Monaghan" 
Hashimoto10 
Present Study 
Howitz" 
Hrachovy" 
Hashimoto10 
Hafez' 
Minev" 
Antigen 
B7 
B7 
B7 
BW60 
B7 
DR4 
DR5 
B7 
DRw52 
BW60 
A2 
A9 
DR4 
DRS 
Frequency of antigen (%) 
Patients 
45 Î 
18 ns 
53 ns 
30 ns 
33 η 
0 ns 
55 Τ 
32 ns 
90 Τ 
55 Τ 
15 i 
46 Τ 
6 ns 
53 Τ 
Controls 
10 
46 
31 
12 
27 
28 
20 
27 
72 
12 
38 
5 
14 
27 
Number of 
Patients 
22 
49 
19 
10 
12 
12 
12 
19 
29 
11 
52 
50 
50 
Controls 
443 
916 
253 
no 
1661 
1661 
1661 
1967 
218 
110 
120 
200 
200 
* see references 
Τ significantly increased in patients 
X significantly decreased in patients 
ns not significant 
as well as HLA class II molecules (e.g., HLA-DR and HLA-DQ antigens). We 
found, in contrast to some studies410,21 but in accordance with other studies16,26, no 
increased incidence of HLA-B7 in LGS compared to controls. It must be noted 
however, that there is a remarkable difference in the frequency of HLA-B7 in the 
control groups of the various studies7. In the West syndrome, which has a fre­
quent transition to, and a close mutual relationship with LGS5,619, Howitz and 
Platz11 reported also no abnormalities in HLA class I antigens. 
Concerning HLA class II antigens however, no studies on LGS are available, 
whereas Hrachovy et al12 reported a significant increase in frequency of the HLA-
DRw52 antigen in West syndrome (presumably of idiopathic as well as sympto­
matic types). In the present study on LGS patients we could only detect abnor­
malities in HLA class II antigens. It involved an increase in the frequency of DR5 
antigens and an indication of a decrease in DR4 antigens. This is in accordance 
with the report of Minev et al1! on a group of children with mostly primary gen­
eralized epilepsy (of unknown origin) demonstrating a significant increase in 
HLA-DR5 antigen. In addition, and in accordance with the present study, their da­
ta also suggest a decrease (not reaching statistical significance) of DR4 antigen in 
this type of epilepsy. 
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Eeg-Olofsson et al8 were the first to stress the importance of a deficiency of a cer-
tain haplotype in epilepsy. This concerned the A1-B8 haplotype in patients with 
different types of primary epilepsies including benign epilepsy of childhood" and 
absences. In the present study on cryptogenic LGS we could not confirm the lack 
of this A1-B8 haplotype. Eeg-Olofsson et al8 suggested that this haplotype A1-B8 
must offer some kind of biological advantage, for example carrying 'protecting' 
genes against certain noxious mechanisms, whereas lack of this haplotype may ex-
plain a lowered immunologic defense mechanism, resulting in increased risk for 
the appearance of seizure disorders. Although these authors suggested a link be-
tween a certain HLA haplotype and an immunological significance, they tested 
only for HLA class I molecules, which are of lesser importance for the immune 
response, but not for HLA class II molecules, which are identical with the classi-
cal immune response determinants. HLA class II molecules are critical to the im-
mune response, since they differentially bind certain peptide antigens and thus se-
lect determinants presented by accessory cells to T-cells, although both classes of 
HLA molecules act as restriction structures on the cell surface and regulate co-op-
eration between different types of cells18. 
The significantly increased frequency of the DR5 antigen (despite the small 
number of patients studied), and the indication of a deficiency in DR4 antigen in 
patients with LGS of cryptogenic aetiology are compatible with the involvement 
of immunogenetic factors in this type of epilepsy, since different alleles of class II 
HLA molecules have been highly associated with several autoimmune diseases 
(DR3 with systemic lupus erythematosus; DR4 with rheumatoid arthritis), and al-
so with several neurological diseases with autoimmune characteristics (DR2 with 
multiple sclerosis and optic neuritis; DRl with D-Penicillamine induced myasthe-
nia gravis)20. In general, these HLA associated conditions are not inherited as such, 
but certain inherited class II antigens make some individuals susceptible to devel-
opment of a disease when exposed to various factors such as viral infections20. 
Correspondingly, individuals with a certain genetic background (e.g. the presence 
of HLA-DR5 antigen) and exposed to exogeneous factors during a certain stage of 
the maturation and development of their central nervous system22, could be sus-
ceptible to the development of LGS. 
It remains intruiging how to explain positive or negative associations between 
HLA alleles and disease development1,1. One possibility is that the positive or neg-
ative HLA association is related to the selection of the T-cell repertoire during T-
cell ontogeny in the thymus. In this view, T-cells involved in the development of 
disease (e.g. LGS) are positively or negatively selected according to the HLA anti-
gen association, creating a T-cell repertoire with potential harmful T-cells. Ac-
cording to another hypothesis, HLA molecules function as or interfere with re-
ceptors for pathogens, hormones, transmitters, and drugs14. Concerning neuro-
logical diseases like LGS, it could even be speculated that some Class II HLA mol-
ecules are directly involved in as yet unknown neurotransmitter mechanisms20. 
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Light chain ratios and concentrations of serum 
immunoglobulins in children with epilepsy 
Summary 
Serum immunoglobulin G,A and M concentrations and their respective kappa/ 
lambda (Κ/λ) light chain ratios were studied in 26 children with epilepsy. Fifteen 
had cryptogenic West syndrome or Lennox-Gastaut syndrome and 11 had other 
forms of childhood epilepsy. The results were compared to the data of a reference 
group of healthy children. The mean serum IgG and IgM concentrations were re­
spectively 2.2 g/1 (P=0.016) higher in the 26 children with epilepsy compared to 
the reference group. The Κ/λ ratios of total serum immunoglobulins, IgG and 
IgM were respectively 0.10 (P=0.057), 0.20 (P=0.001) and 0.14 (P=0.005) lower in 
the children with epilepsy than in the reference group. IgA concentration and IgA 
Κ/λ ratio were nog affected. There were no significant differences between the 
Κ/λ ratios of the West and Lennox-Gastaut epilepsy and the other types of child­
hood epilepsies. The results are further evidence of reciprocal interaction be­
tween the nervous system and the immune system in childhood epilepsies. 
Introduction 
In animal experiments, epilepsy may be caused or maintained by autoimmune 
processes indicating a role of immune or autoimmune mechanisms in the patho­
genesis of this disorder". Immunological disturbances have also been described in 
patients with West and Lennox-Gastaut syndromes (WS/LGS)1624 as well as in 
other types of epilepsies1620. Especially, a high incidence of IgG2 deficiency has 
been published16. Treatment with intravenous immunoglobulins has been report­
ed to be beneficial in intractable epilepsies, including WS/LGS,1"16·24·25. 
The total serum κ/λ ratio has been found to be abnormal in various immune 
and autoimmune disorders as well as in some infectious diseases91317,21. The total 
κ/λ ratio of serum immunoglobulins and of cerebrospinal fluid immunoglobu­
lins has been found to be raised in patients with various neurological diseases such 
as multiple sclerosis, amyotrophic lateral sclerosis, polyneuropathies and viral en­
cephalitis3,4. Recently, a raised serum total κ/λ ratio was reported in children with 
intractable epilepsies12. The serum κ/λ ratio reflects primarily the Κ/ λ ratio of the 
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most abundant immunoglobulin, usually IgG. Therefore, this ratio may over­
shadow light chain abnormalities in other immunoglobulins. Until now, no study 
has evaluated the κ/λ ratio separately in IgG, IgA and IgM in epilepsies. We there­
fore conducted a study on the serum total κ/λ as well as the separate Κ/λ ratios 
of IgG, IgA and IgM in children with epilepsies. Special attention was given to the 
group of children with cryptogenic WS and LGS. The results were compared to 
those of a reference group of healthy children and young adults6. 
Patients and methods 
Patients 
Twenty-six children with epilepsy were enrolled in the study, aged 1-5.2 years ex­
cept for one who was 12.2 years. Three had cryptogenic WS and 12 patients had 
cryptogenic LGS. Eleven children suffered from other types of epilepsy (OTE). All 
patients in the WS/LGS group were taking antiepilectic drugs (valproic acid as 
monotherapy or in combination with nitrazepam) at the time of the study. The 
children in the OTE group were receiving various regiments of antiepileptic ther­
apy except two patients who were without medication. The reference group6 con­
sisted of 114 healthy children aged 1 month to 16 years, and 20 adult blood donors. 
Informed consent was obtained from all the children's parents. 
The diagnosis of the age-related WS/LGS was established by the triad of typ­
ical epileptic seizures, mental retardation or deterioration and characteristic EEG 
pattern. All WS/LGS were classified as cryptogenic, because of uncomplicated 
development until onset of epilepsy, normal neuroradiological, biochemical and 
chromosomal studies and no signs of infections in the central nervous system. 
Immunological studies 
The immunoglobulin G,A and M concentrations were measured by ELISA5. The 
total Κ/λ ratio was measured by nephelometry as described earlier17 using laser 
nephelometry with anti-K and anti-λ antibodies. The κ/λ ratios of polyclonal IgG, 
IgA and IgM were measured by using a solid phase ELISA sandwich method5. All 
serum samples were kept frozen until measured. 
Statistical analyses 
The results of the determination of IgG, IgA and IgM concentrations, and of the 
separate κ/λ ratios were compared to the reference group. Moreover, the 
WS/LGS and the OTE groups were compared separately to the reference group. 
Finally, the WS/LGS group was compared to the OTE group. All κ/λ ratios as 
well as immunoglobulin concentrations were corrected for age and the expected 
value as calculated from the data of the reference group6 was subtracted from the 
actual value found. Statistical analysis was done with the Kruskal-Wallis test. As 
the patient group was compared to the same reference group as used for several 
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Table I. Mean differences and Ρ values (in parentheses) (Kruskal-Wallis tests) of κ/λ ratios and 
immunoglobulin 
(n=134)6. 
Total group 
WS/LGS 
OTE 
η 
26 
15 
11 
concentrations in ¿ь 
Total κ/λ 
-0.10 
(0.057) 
0.05 
(0.250) 
-0.16 
(0.091) 
[gGK/λ 
-0.20 
(0.001) 
-0.10 
(0.132) 
-0.34 
(0.0004) 
children with epilepsy 
IgAK/λ 
-0.02 
(0.799) 
-0.04 
(0.538) 
0.01 
(0.752) 
IgM Κ/λ 
-0.14 
(0.005) 
-0.17 
(0.006) 
-0.10 
(0.288) 
compared 
IgG 
(g/L) 
2.2 
(0.007) 
2.8 
(0.005) 
1.4 
(0.322) 
to a reference group 
IgA 
(g/L) 
0.02 
(0.513) 
0.1 
(0.166) 
-0.1 
(0.562) 
IgM 
(g/L) 
0.4 
(0.016) 
0.3 
(0.188) 
0.6 
(0.019) 
other patient groups, a significance level of 0.01 should be regarded on statistical 
grounds as a safe assumption. 
Results 
Immunoglobulin concentrations 
The total group of children with epilepsy had a mean concentration of IgG that 
was 2.2 g/L higher (P=0.007) and of IgM that was 0.4 g/L higher (P=0.016) than 
in the reference group (Table I). IgA was unaffected (Fig.l). 
The patients with WS/LGS had raised IgG, IgA and IgM concentrations com­
pared to the reference group. This difference was only significant for IgG 
(P=0.005). The OTE group had raised IgG and IgM concentrations, the mean dif­
ference for IgM being 0.6 g/1 (P=0.019) (Fig.l) (Table I). 
The difference between the WS/LGS group and the OTE group was not sig­
nificant. 
No significant sex difference was found. 
Kappa/hmbda ratios 
The total group of 26 children with epilepsy had values of total κ/λ ratio, IgG 
Κ/λ ratio and IgM κ/λ ratio lower than the reference group (Fig.l). The differ­
ence for the total κ/λ was 0.10 (P=0.057), for the IgG κ/λ 0.20 (P=0.001) and for 
the IgM κ/λ ratio 0.14 (P=0.005) (Table I). For the IgA κ/λ ratio there was no dif­
ference. In the WS/LGS group the IgG κ/λ ratio was 0.10 (P=0.132) lower than 
in the reference group and the IgM κ/λ ratio was 0.17 lower (P=0.006) Table I). 
The differences of the total κ/λ ratio and of the IgA κ/λ between the WS/LGS 
group and the reference group were nog significant (Fig.2). 
The 11 patients with OTE had an IgG κ/λ ratio which was 0.34 (P=0.0004) low­
er than in our reference group (Table I). Total Κ/λ ratio and IgM κ/λ ratio tend-
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Fig 1 Immunoglobulin concentrations m patiens with childhood epilepsies as compared to the reference values. The lines rep­
resent 5%, 50% and 95% confidence values. · . cryptogenic West and Lennox-Gastaut syndromes, O. other types of child­
hood epilepsies 
ed to be lower as compared to the reference group although this difference was 
not significant. The IgA κ/λ ratio did nog differ from the reference group (Fig.2). 
The differences in κ/λ ratios between the WS/LGS group and the OTE group 
were not significant. 
Discussion 
Humoral immunological disturbances have been demonstrated in patients with 
epilepsies16,20, in particular a decreased serum IgA concentration21020,22,23. These 
changes have been explained as a result of antiepileptic therapy10,20,22 but can also 
be present before the start of treatment20,25. In the present study of children with 
epilepsies, we found increased levels of serum IgG and IgM, but decreased serum 
total Κ /λ, IgG Κ/ λ and IgM κ/ λ ratios as compared to the age-related healthy ref­
erence group. IgA concentration and IgA κ/λ ratio were nog affected in our study. 
In the current study, a drug effect cannot be entirely ruled out but seems un­
likely because various therapy regimens were used. Moreover, in the WS/LGS 
group, valproic acid and nitrazepam were used, drugs that are not known to have 
an effect on immunoglobulins. 
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Fig 2 Immunoglobulin light d u m rattos inpatients with intractable epilepsies as compared to t/i£ reference values. The lines 
represent 5%, 50% and 95% confidence values. · cryptogenic West and Lennox Gastaut syndromes; O. oilier types of 
childhood epilepsies 
Earlier data on raised serum total κ/λ ratios in children with intractable epilep­
sies12, are in contrast with our findings. The clear discrepancy between these two 
studies may reflex the different patient groups, age of the children or treatment. 
A raised total serum κ/λ ratio has been described in some infections and in au­
toimmune disorders9,13,17,21 as well as in children with intractable epilepsies12. Cer­
tain antigens may produce light chain restricted antibody responses promoting ei­
ther К or λ chain synthesis714. Different light chain reactions for the various im­
munoglobulin classes to the same antigen have even been demonstrated in vitro7. 
The relatively increased λ synthesis in our study may represent a disturbed im­
mune response. It might also be possible that as yet unknown antigens stimulate 
relatively more λ production. 
The lower total κ/λ ratio in the epilepsy group (in our study) compared to age-
matched control children may be due to a delayed development of the immune sys­
tem as lower ratios are found in younger children6. The higher incidence of IgG2 
deficiency in children, with epilepsies16 points in the same direction as low IgG2 is 
more frequendy found in younger children. Elevated immunoglobulin concen­
trations, however, are not in accordance with this hypothesis, but might be the re-
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suit of recurrent infections. However, our children were investigated during in­
fection-free episodes and therefore elevated immunoglobulin concentrations may 
also be an expression of disturbed immunological mechanisms. In cryptogenic 
LGS a delay in development of cortical neuronal processes has been described by 
one of us18. All these are findings which may support the hypothesis of a con­
comitant developmental delay in immunopathophysiological and neuropatho-
physiological mechanisms in childhood epilepsies8 " . 
References 
1 Anizumi, M , Baba, К., Shiihara, H , Ogawa, К , Hibio. S , Hibio, Y, Ryo, S and Momoki, Τ , í ligh dose gam-
maglobulin for intractable childhood epilepsy, Lancet, u (1983) 162 163 
2 Bassani, M , Baez, A and Sotelo, J , Immunoglobulins in epilepsy, J Neurol Sci, 56(1982)275-281 
3 Bollengier, F, Rabinovitch, Ν and Lowenthal, A , Ohgoclonal immunoglobulins, light chain ratios and free 
light chain ratios in cerbrospinal fluid and serum from patients affected with various neurological diseases, 
J Chin Chem Clin Biochem 16(1978) 165 173 
4 Eickhoff, К and Heipertz, R , Determination of immunoglobulin content of CSF based on light chain char 
actenstics, Ann, Neurol, 3 (1978) 509 512 
5 Haraldsson, A , Kock Jansen, M J Η , Jammon, M, van Eck Arts, PBJ M , de Boo, Τ , Weemaes, С Μ R and 
Bakkeren, J A J M , Determination of kappa and lambda light chains in serum immunoglobulins G,A and M, 
Ann Clin Biochem, 28 (1991)461 466 
6 Haraldsson, A , Weemaes, С M R.KockJansen.MJH .vanEck Arts.PBJM , de Boo, T, Bakkeren, J A J M 
and Stoelinga, G В A , Immunoglobulin G,A and M ligh chain ratio in children, Ann, Clin Biochem , 29 
(1992)270 274 
7 Heilmann, С and Banngton, Τ , Distribution of к and 1 light chains isotypes among human blood un 
munoglobuhnsecreting cells after vaccination with pneumococcal polysaccharides, Scand J Immunol, 29 
(1989) 159 164 
8 Hrachovy.RA and Frost J D , Intaile spasms, Ped Clin North Am ,36(1989) 311-329 
9 Jasani, В, Immunohistologically definable light chain restriction in autoimmune disease, J Pathol, 154 
(1988)1 5 
10 Kanoh, Τ and Uchino, Η , Immunological side-effects of anticonvulsants, Lancet, ι (1976) 860-861 
11 Karpiak, S E , Graf, L and Rapport, M M , Annserum to brain gangliosides produces recurrent epileptiform 
activity, Science, 194 (1976) 735 737 
12 Lischka, A , Herkner, К and Pollak, A , Neuroimmunologische Parameter bei therapieresistenter Epilepsie 
im Kindesalter, Wien Kim Wochenschr, 8 (1990) 227-230 
13 McKelvey, Ε M and Fahey, J L , Immunoglobulin changes in disease, quantitation on the basis of heavy 
polypeptide chains, IghG (gG), IgA (gA) and lgM (gM), and of light polypeptide chains, type К (I) and type 
L (II), J Cl.in Invest, 44 (1965) 1778 1787 
14 Nussenzweig, V and Benacerraf В , Antihapten antibody specificity and I chain type, J Exp Med , 126 (1967) 
727 743 
15 Peechadre.J С , Sauvezie, В , Osier, С and Gilbert, J , Traitement des encephalopathies épüeptiques de l'en 
fant par les gamma-globulines, résultats préliminaires, Rev E E G Neurophysiol, 7 (1977) 443 447 
16 Plebani, A , Duse, M , Tiberti, S , Avanzini, M A , Monofo, V, Mencgati, E , Ugazio, A G and Burgio, G R, 
Intravenous g-globulin therapy and serum IgG subclass levels ion intractable childhood epilepsy, Monogr 
Allergy, 23 (1988) 204 215 
17 Renckens, A LJ M , Jansen, M J H , Van Munster, PJJ , Weemaes, С M R and Bakkeren, J A J M , Neph-
elometry of the kappa/lambda lighr chain ratio m serum of normal and diseased children, Clin Chem , 32 
(1986)2147 2149 
18 Renier, W O , Gabreels, FJ M andjaspar, H H J , Morphological and biochemical analysis of a brain biopsy 
in a case of idiopathic Lennox Gastaut syndrome, Epilepsia, 29 (1988) 644 649 
LIGHT CHAIN RATIOS AND IMMUNOGLOBULIN CONCENTRATIONS 91 
19 Rjikonen, R , Infantile spasms some new theoretical aspect. Epilepsia, 24 (1983) 159 
20 Seager, J, Jamison, D L, Wilson, J and Hayward, A R, IgA deficiency, epilepsy, and phenytoin treatment, 
Lancet, u (1975) 632 635 
21 Skvanl, F.Barandun, S , Morell, A and Probst, M , Imbalances of Κ/λ immunoglobulin light chain ratios in 
normal individuals and in immunodeficient patients In Η Peters (Ed ), 22nd Colloquium Bruges Protides 
of Biological Gluids, Pergamon Press, New York, NY, 1975, pp 415 420 
22 Sorrell, Τ С , Forbes. IJ, Bumess, F R and Rischbieth, R H С , Depression of immunological function in pa­
tients treated with phenytoin sodium (sodium diphenylhydantoin), Lancet, и (1971) 1233 1235 
23 Tartara, A , егп, A Ρ, Nespoli, L , Moglia, A and Botta, M G , Immunological findings in epileptic and 
febrile convulsion patients before and under treatment, Eur Neurol, 20(1981) 306 311 
24 Van Engelen, G G M , Renier, WO, Weemaes, С Μ R and Strengers, PF W, Treatment of idiopathic West 
and Lennox epilepsy with intrevenous immunoglobulins. Acta Neurol Scan , 133 (1990) 25 
25 Van Rijkevorsel Harmant, К, Delire, M and Rucquoy-Ponsar, Μ , Treatment of idiopathic West and 
Lennox Gastaut syndromes by intravenous administration of human polyvalent immuno globulins, 
bur Arch Psychiatr Neurol Sci, 236 (1986) 119 122 

[10] 
A dysbalanced immune system in cryptogenic 
Lennox-Gastaut syndrome 
Summary 
In children with cryptogenic Lennox-Gastaut syndrome we found a functionally 
impaired humoral immune response to a primary antigen (haemocyanin), despite 
signs of a triggered immune system consisting of elevated IgG concentrations 
This combination of immunological findings, considered to be the expression of 
a dysbalanced - triggered as well as functionally impaired - immune system, has 
also been described in an auto-immune disease like systemic lupus erythematosus 
in humans, and in genetically epilepsy-prone rats The interactions between the 
immune system and the nervous system in Lennox-Gastaut syndrome will be dis-
cussed 
Introduction 
The Lennox-Gastaut syndrome (LGS) is an unexplained, age-related epileptic en-
cephalopathy with a tendency to become chronic1 Various pathophysiologic 
mechanisms have been suggested to explain this condition including the hypoth-
esis that it results from an aberrant immune function Indications supportive for 
this hypothesis include the reports on antibodies to brain tissue2 3, the suggested 
effect of intravenous immunoglobulin1, and the reported associations with certain 
HLA class II alleles in patients with LGS5 The publications on humoral and cel-
lular immunity are conflicting, impaired immunity (predominandy IgG2 and IgA 
deficiencies)6 \ normal immunity', and increased humoral or cellular immunity710 
have been described Indirect suggestive evidence for reciprocal interactions be-
tween the immune and nervous system in epilepsies are the immunological al-
terations induced by proper anticonvulsant drugs like phenytoin and carba-
mazepine, and the anticonvulsant effect of immunosuppressive drugs like adreno-
corticotropic hormone and corticosteroids in otherwise intractable epilepsies (for 
review4) 
For the present study we attempted to select a relatively homogeneous group 
of cryptogenic LGS patients, and an epilepsy control group receiving the same an-
ticonvulsants In addition to studies on humoral and cellular immunity, we mea-
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sured the in vivo primary humoral immune response after subcutaneous injection 
of the neoantigen, α-Helix pomatia haemocyanin (HPH). The in vivo immune re­
sponse is a sensitive test of total immune responsiveness"12 measuring both the af­
ferent as well as the efferent arc of the immune system, and it is afunctional test 
which might be able to detect a possible modulating influence of the epileptic 
brain on immune responsiveness. The results in both epilepsy groups are com­
pared with those of normal controls and a possible misregulation of the immune 
system in LGS is discussed in the light of the conflicting data in the literature. 
Patients and methods 
Patients 
The study population consisted of 12 children (four girls, eight boys, mean age 4.4 
years) with cryptogenic LGS receiving valproate, either as monotherapy or in 
combination with other anticonvulsants, especially nitrazepam. An age and sex 
matched epilepsy control group consisted of seven children with other types of 
epilepsy13 [situation-related seizures (n=l), symptomatic generalized seizures 
(n=4), temporal lobe epilepsy (n=2)] receiving the same regimen of anticonvul­
sant drugs as the LGS group. The normal control group was derived from a pre­
viously published reference group consisting of 114 healthy children aged 1 
month to 16 years14. The study protocol was reviewed and approved by the insti­
tutional ethical review board of our hospital. Informed consent was obtained 
from the children's parents. 
LGS was defined by the characteristic triad: -1- multiple epileptic seizure types 
(axial tonic, atypical absences, atonic seizures) possibly associated with general­
ized tonic-clonic seizures and partial seizures; -2- inter-ictal slow spike-waves (few­
er than three per second) in awake electroencephalography (EEG); -3- mental re­
tardation or deterioration with personality disorders, with onset between 1 and 5 
years of age1. Cryptogenic aetiology was defined as epilepsy of unknown cause in 
infants or children with unremarkable neuromental development prior to onset 
of seizures; normal physical examination; no abnormalities on cerebral CT or MR 
imaging, except for a slight dilatation of ventricles; no known mental retardation 
syndromes, chromosomopathy, or inborn errors of metabolism. 
Immunological Studies 
Serum total IgG, IgA and IgM concentrations were determined as described ear­
lier14. Serum IgG subclass concentrations were determined by radial immunodif­
fusion, and calibrated against standard serum containing 6.2 g/L IgG,; 2.4 g/L 
IgG2; 0.64 g/L IgG,; and 0.46 g/L IgG4 (HOO-020, CLB, Amsterdam, NL). Pre-im-
munization anti-HPH titres were determined with an indirect ELISA technique 
and expressed as percentage of positive reference samples12. Afterwards, 1 mL (1 
mg) of HPH was given subcutaneously and serum was obtained 2 weeks (in LGS 
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patients also 4) and 6 weeks after immunization. HPH is a well characterized, eas­
ily available primary immunogen, whose safety has been documented11'12. One 
subcutaneous injection of 1 mL elicits a strong primary humoral (IgG, IgA, IgM) 
and cellular immune response in normal volunteers. Percentages of B-cells were 
determined by immunofluorescence microscopy using anti-human immunoglob­
ulin antisera (Kallestad Lab. Inc., Austin (TX), USA). The percentages of CD3, 
CD4, and CD8 positive T-cells were determined using monoclonal antibodies 
(OKT3, OKT4, OKT8, respectively; Coulter Co., Hialeah (FL), USA). Lymphocyte 
proliferation in vitro after stimulation by phytohaemagglutinin and pokeweed mi­
togen was studied by standard methods. 
All immunological studies were performed at a time when neither the patients 
nor controls showed any clinical signs of intercurrent infection. 
Statistical Analyses 
The results of the immunological investigations in the LGS group and the epilep­
sy control group were compared with each other and also with the normal con­
trol group. Concentrations of immunoglobulins and subclasses were corrected for 
age by subtracting the expected value as calculated from the data of the reference 
group1" from the actual value found. Anti-HPH titres measured in the LGS group 
and the epilepsy control group, were compared to those of previously described 
normal control children15. All group differences were evaluated using the Kruskal-
Wallis test. In addition, Spearman correlation coefficients were determined be­
tween IgG, IgA and IgM concentrations, and their respective anti-HPH titres. Sig­
nificance was set at Ρ = 0.05 (two-sided). In the case of multiple testing, the Bon-
ferroni correction was used. 
Results 
The only significant difference between the LGS group and the normal control 
group is an increased concentration of total IgG in the LGS group (P < 0.05). The 
epilepsy control group did not show significantly increased IgG concentrations 
compared to normal controls, whereas the difference between the epilepsy con­
trol group and the LGS group was not significant. IgG,, IgG2 and IgG3 concentra­
tions did not differ significantly between the LGS group and any of the control 
groups. 
The LGS group did not differ from any of the control groups with regard to 
percentage of B-cells (mean 11.3%, standard deviation (SD) 5.5; individual values: 
15, 14, 10, 17, 5, 21, 8, 14, 7, 6, 3, and 15%), CD3 positive cells (mean 64.5%, SD 
6.4; individual values: 66, 73, 65, 72, 70, 60, 60, 60, 70, 65, 61, and 52%) or 
CD4/CD8 ratio (mean 2.8, SD 0.9; individual values: 1.8, 5.2, 2.9, 2.8, 2.4, 2.1, 2.3, 
2.1, 2.3, 3.1, 3.1, and 3.1). Proliferation of peripheral blood lymphocytes to phy­
tohaemagglutinin and pokeweed mitogen was normal in both the LGS and the 
epilepsy control groups. 
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FIG. 1. In vivo IgG, IgA and IgM primary immune responses to haemocyamn (as percentage of positive reference samples) m 
the LGS group (n=12), epilepsy control group (n=7), and m normal centrali (n-i). 
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Antibody responses to haemocyanin immunization 
All pre-immunization anti-HPH titres were negative except for some very low IgG 
and IgM titres in all three groups (Fig. 1). The peak IgM response after 2 weeks did 
show significant differences between the groups (P<0.01): It was decreased in the 
LGS group compared to the epilepsy control group (P<0.05) and to the normal 
controls (P<0.005), whereas the epilepsy control group and the normal controls 
did not differ. The IgA response after 2 weeks was significandy different in the 
three groups (P<0.05) and was reduced in both the LGS (P<0.05) and the epilep­
sy control group (P<0.05) compared to normal controls, whereas the two epilep­
sy groups did not differ from each other. The IgG response did not differ signifi­
candy between the three groups (P>0.05), although there was a trend towards 
lower IgG responses in the LGS group compared to normal controls (P=0.04). 
Concerning the kinetics of the response, the increase in IgG, IgA and IgM anti-
HPH titres, respectively between 0 and 2 weeks, showed the same differences as 
the peak anti-HPH titres after 2 weeks. The decline in all three classes of anti-HPH 
titres between 2 and 6 weeks was the same for all three groups. 
In the LGS group there was a significantly positive correlation between IgM 
and anti-HPH IgM, anti-HPH IgA and anti-HPH IgG concentrations, respectively 
(all P<0.05). The Spearman correlation coefficients were 0.65, 0.75 and 0.66, re­
spectively. No such significant correlation existed between the serum IgG and IgA 
concentrations, and their anti-HPH titres (all P>0.05). 
Discussion 
The main finding of this study is the impaired humoral immune response in patients 
with cryptogenic LGS. Until now, this has not been reported in LGS nor in other 
types of epilepsy. A decreased cellular immune response after dinitrochloroben-
zene sensitization has only been described in one report on a group of patients 
with cryptogenic as well as symptomatic types of LGS and West syndrome8. Fac­
tors underlying the impaired humoral immune response in LGS patients are not 
yet known, and some can be ruled out from the present study. The immune re­
sponse does not have a delayed time course (anti-HPH titres declined between 2 
and 4 weeks); there is no decrease in the number of different types of immune 
cells; no decrease in IgM concentration (IgM enhances the humoral immune re­
sponse16); and no defect in lymphocyte proliferation in vitro. Since HPH is a T-cell 
dependent antigen the impaired humoral immune response does not necessarily 
point to a primary B-cell defect. A disturbance in the afferent arc of the immune 
system, a defective antigen processing or presentation by macrophages or a defi­
cient interaction between В and Τ cells, may well account for the decreased im­
mune responsiveness. 
In addition (unexpected in the light of the impaired immune responses), the in­
creased total IgG concentration in the LGS group points to a triggered immune 
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system. This increase in total IgG in epilepsy has also been reported by others7 and 
by our previous study14 on a more extended epilepsy group consisting of the pre-
sent LGS patients and patients with West syndrome. Such a triggered immune sys-
tem can be caused by infectious or autoimmune processes17. Infectious causes 
have been excluded during the investigation period in our study. 
In the current study, a drug effect cannot be entirely ruled out, but seems un-
likely because both the LGS group and the epilepsy control group received the 
same anticonvulsants. Moreover, valproate and nitrazepam were used, drugs that 
are not known to have an effect on immunoglobulins. 
A triggered as well as functionally impaired immune system, which may be 
called a dysbahnced immune system, is in accordance with and may partly explain 
the conflicting literature on immunological investigations in epilepsy. A study 
showing an elevated B-cell number has been interpreted as conflicting with the re-
port on an impaired cellular immune responsiveness'10. Because we have mea-
sured both, we have been able to reproduce in LGS patients just this combination 
of a triggered but nevertheless functionally impaired immune system, which has 
also been described in an auto-immune disease like systemic lupus erythematosus 
in humans12, and in genetically epilepsy-prone rats17. Therefore, we think that this 
combination of findings, instead of being the expression of conflicting results, 
may have a biological significance pointing to a misregulation of the immune sys-
tem. A possible explanation may be that high IgG concentrations cause a feedback 
inhibition of the immune response leading to a diminished capacity to respond to 
new antigenic challenges1617. Nevertheless, we could not confirm a significant 
negative correlation between IgG concentrations and immune responses in the 
LGS group. In addition, also the epilepsy control group showed increased IgG con-
centrations, however, without impaired humoral immune responses. We did find 
a significant positive correlation in the LGS group between IgM concentrations 
and immune responses, which is in accordance with the reported enhancing effect 
of IgM antibodies on the humoral immune response16. 
In conclusion, the present study did not find indications of an immune defi-
ciency, but rather of an immune dysbalance or misregulation in LGS. Interesting-
ly, LGS a severe form of epilepsy, can be defined neurologically also as a dysbalance, 
in this case of excitation and inhibition in neural networks leading to functional 
disturbances18. There are several possibilities that may account for the association 
between an immune and neural dysbalance19. One possibility is that the dysbal-
anced immune system alters neural function20'" and causes epilepsy. Certain anti-
bodies intracerebrally injected in experimental animals induce epileptiform activ-
ity (for review23). Secondly, the neural dysbalance i.e. epilepsy may modify im-
mune function2<l. As a consequence of epilepsy central nervous system antigens 
may become exposed to and trigger the immune system. In experimental animals, 
lesions of the anterior hypothalamus modify asthma and reduce humoral and cel-
lular responses to foreign antigens25. Thirdly, the disturbances both in the immune 
and nervous system could be due to a common underlying biological process. 
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This has been described in experimental mice that develop severe autoimmune 
disease and learning disabilities, each of which possibly originate from neu-
ropathological anomalies consisting of ectopic collections of neurons26 Whatev­
er the exact interaction might be, one could speculate that the association between 
the neural dysbalance and the immune dysbalance in LGS may offer the potential 
of new treatment approaches in this type of intractable epilepsy by addressing the 
nervous system via the immune system. 
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[H] 
Can human polyclonal immunoglobulin raise 
the threshold for convulsions in rats? 
Summary 
In the present preliminary study we explored the possibility of an anticonvulsant 
effect of normal human immunoglobulin in an animal epilepsy model based on 
direct cortical stimulation in freely moving rats. After human immunoglobulin ad-
ministration a significant and prolonged elevation of the threshold for convul-
sions was measured in 12% (6/49) of the total group of outbred Wistar rats. In 
the subgroup of more than 7 months old Wistar rats this was 67% (6/9). When a 
threshold increasing effect of immunoglobulin occurred, it was detectable within 
0.5 - 1 hour after administration, reached its maximum after approximately 2 
hours and continued for at least 40 hours. 
Introduction 
Normal human immunoglobulin (IVIg)* initially used for substitution of immun-
odeficiency syndromes has recently been reported to be effective in an increasing 
amount of diseases thought to be produced by immunopathology'2. Although 
epilepsy is one of the oldest applications of IVIg in neurological diseases3, and al-
though positive results have been published, IVIg treatment of intractable epilep-
sies, nevertheless, remains controversial": On the one side the various studies on 
IVIg in human epilepsy could not provide an indication for an immunological 
mechanism of action of IVIg4, on the other side it has been stated without pub-
lished data that IVIg lacks an anticonvulsant effect5. In the present study we ex-
plored the possibility of an anticonvulsant effect of IVIg in an animal epilepsy 
model based on direct cortical stimulation in freely moving rats6"7. In the subgroup 
in which IVIg was ineffective we investigated whether this was due to an inability 
of IVIg to cross the blood-brain barrier. 
* For reasons of convenience, the abbreviation "IVIg" will be used for normal human polyclonal immunoglob-
ulin preparations administered by the intramuscular, intravenous and intraperitoneal route 
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Materiah and methods 
Female (outbred) Wistar rats of 175-200 gram were purchased from Harlan/СРВ 
in Zeist, The Netherlands. They were housed individually in plastic cages, at con­
stant temperature (21°C), and in controlled lighting (light period 7.00 a.m. to 7.00 
p.m.). Food (standard laboratory rat, mouse, and hamster diets, R.M.H.-T.M., 
Hope Farms, Woerden, The Netherlands) and water were supplied ad libitum, ex­
cept during actual testing. 49 rats were used conforming to institutional policies 
and guidelines. 
Human IVIg was produced from the plasma of more than 3000 Dutch blood 
donors by ethanol fractionation, treated at pH 4 with a low concentration of 
pepsin (Central Laboratory of the Netherlands Red Cross Blood Transfusion Ser­
vice, Amsterdam, NL). IVIg dissolved in sterile water without solvents contains 
99% IgG, 1% IgA and traces of IgM. Its osmolality is equivalent to that of plasma, 
with a sodium concentration between 25 and 50 mmol/L, and a glucose concen­
tration between 160 and 300 mmol / L. No mannitol or glycine is added in this IVIg 
preparation. IVIg was administered in a comparable dosage as in humans (400-
1000-1500 mg/kg bodyweight), but by a different route i.e. by a single intraperi­
toneal (i.p.) dose. 
The anticonvulsant efficacy was tested and quantified using direct cortical 
stimulation with a ramp-shaped pulse train as described in detail elsewhere6 8. The 
threshold for localized seizure activity (TLS) has been used to quantify anticon­
vulsant effects. The TLS was defined as the current at which the first mild clonic 
forepaw movements appeared. TLS stimulation was stopped at this point and fur­
ther convulsive activity was then immediately aborted. In this way a postictal 
threshold increase was avoided. Before IVIg administration, the TLS was deter­
mined five times at 5 minutes intervals, to determine the average baseline value. 
Shortly after i.p. IVIg injection, TLS determination was performed, and during 3 
days the TLS was measured at regular intervals. TLS changes were expressed as 
elevation over the baseline value in μΑ. All test sessions were recorded on video. 
Before IVIg experiments were carried out, the animals were tested twice daily for 
2 weeks to stabilize the threshold7. The effect of IVIg on TLS was tested in more 
than 7 months old rats (n=9), and in younger rats (3-4.5 months, n=40). Some rats 
of the younger age group (n= 10) were treated previously with carbamazepine (40 
mg/kg), others (n=30) were drug-naive. 
In addition, we investigated (n=3) whether IVIg was ineffective due to an in­
ability to cross the blood-brain barrier: 2 days after IVIg administration rats were 
sacrificed, and brains were freshly fixed in formaldehyde-sublimate at 4°C for 24 
hours. After dehydration tissue was embedded in paraplast and 4 micron sections 
were cut using a Jung 2050 microtome. Dewaxed poly-L-lysine mounted sections 
were incubated with human IgG antiserum (lambda chain specific, Dakopatts) for 
48 hours at 4 degrees Celsius in a dilution of 1 /250. Immunohistochemical stain­
ing was performed using the avidin-biotin-peroxidase and the avidin-biotin-alka-
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line-phosphatase complex technique (ABC) according to the manufacturer in­
structions (Vector). All antibody dilutions were made in 0.05 M phosphate 
buffered saline (PBS) to which 0.1% Triton-X-100 was added. As negative controls 
we used rats (n=3) that also had experienced seizures due to cortical stimulation 
but without administration of human IVIg. 
Results 
After human immunoglobulin administration (500 mg/kg; Table 1) a significant 
and longlasting increase in TLS was measured in 12% (6/49) of the total group of 
outbred Wistar rats. In the subgroup of more than 7 months old Wistar rats this 
was 67% (6/9), in the other subgroup this was 0% (0/40)(Fisher exact test (P< 
0.0001), Table 1). Fig. 1 depicts the typical time-effect relationship in an animal 
showing an increase in TLS. When a TLS increasing effect of IVIg occurred, it was 
detectable within 0.5 -1 hour after administration, reached its maximum after ap­
proximately 2 hours and continued for at least 40 hours. 
In the subgroup (n=40) of 3 - 4.5 months old rats, neither three different dos­
es of IVIg (400, 1000, 1500 mg/kg), nor pretreatment with carbamazepine (40 
mg/kg) did show any effect on TLS. 
In control rats (with cortical stimulation, without IVIg treatment) immuno-
histochemical staining for human IgG was negative (Fig 2a), whereas in all (non-
responding) rats (n=3) sacrificed two days after IVIg administration, staining for 
human IgG was present in brain capillaries, chorioid plexus, and in brain tissue 
around blood vessels (Fig 2b). Some neuronal and glial cells showed immunohis-
tochemical staining. Thus, the lack of a threshold increasing effect by IVIg was not 
due to an inability of IgG to cross the blood-brain barrier. 
Table 1. The effect of human IVIg on the convulsive threshold in rats* 
Animals Immunoglobulin Results 
Number Age Dose (mg/kg) Increase of TLS* 
n=9 > 7 months 500 6 of 9 animals, 200μΑ 
(Avg. baseline 400μΑ) 
n=40 3-4.5 months 400, 1000 or 1500 Oof 40 animals 
* IVIg = human immunoglobulin, TLS = threshold for localized seizures 
** Ρ < 0 0001 by Fisher Exact test 
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Fig I. The effect of Í00 mg/kg human IVIg on the threshold for localized seizures (TLS) in S months old rats who had pre-
viously experienced generalized seizures and had been treated with carbamazepine 
Discussion 
These preliminary investigations indicate that human IVIg has the potential to 
raise the threshold for convulsions in rats. Already within the first hour after i.p. 
administration a significant and prolonged anticonvulsant effect occurred in 12% 
of all tested outbred Wistar rats. In the subgroup of more than 7 months old Wis-
tar rats this percentage was 67%, which suggests an age-related effect of the IVIg 
response. An age-related effect of epilepsy itself has been reported previously: 
seizure intensity increased with increasing age in genetically epilepsy-prone rats9. 
The present study confirmed the results of the only other study on administra-
tion of human IVIg in an animal epilepsy model (kindled cats)10. In the latter study 
and in our study a similar time-effect relationship and a similar immunohisto-
chemical staining pattern for human IgG were seen: IgG penetrated the blood-
brain barrier, could be found around the blood vessels, and was even taken up by 
some neuronal and glial cells in the cerebral cortex and deep structures of the 
CNS. These findings might be compatible with reports on blood-brain barrier per-
meability in various types of experimental epilepsies", the existence of IgG Fc re-
ceptors in adult rat brain and in normal human brains'20, and immunoglobulin 
affinity of neuronal and glial cells1415. 
The present experimental data are in accordance with the results of clinical 
studies on IVIg in patients with epilepsy. Of the several hundreds of IVIg treated 
patients with otherwise intractable epilepsies, overall some 23% showed total ces-
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Fig la. Immunohistochemical staining for human IgG was negative in control rats (with cortical stimulation, without IVIg 
treatment). 
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Fig 2b. Immunohistochemical staining for human IgG in rats treated with a single dose of I Vlg was present in and around 
enebral bloodvessels. 
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sation of seizures4. The variability of IVIg treatment effect in human epilepsy is 
still unexplained. It has been attributed to differences in IVIg preparations, types 
of epilepsy and seizures, duration of epilepsy, immunological abnormalities, or 
study design4. We can not exclude that on the clinical level these factors contnbute 
to the variable responses, but as can be concluded from the present study, in the 
more controllable animal-model a remarkable age-related variability in treatment 
response was found. Another contributing factors for the variability in IVIg re-
sponse might be genetical heterogeneity in both humans with epilepsy and out-
bred Wistar rats. 
In conclusion, we can not confirm that IVIg lacks an anticonvulsant effect5. On 
the contrary, this preliminary study suggests the potential of a significant and 
longlasting anticonvulsant effect of IVIg by increasing the threshold for convul-
sions. However, future studies are needed and should investigate: the effect of al-
bumin (as a control) on TLS in more than 7 months old animals, the repetitive IVIg 
administration in IVIg-responding animals, and the capability of IgG to cross the 
blood-brain barrier in IVIg-responding and non-responding animals. 
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[12] 
Human polyclonal immunoglobulin does not affect 
the GABAA receptor complex as measured by 
3H-TBOB binding 
Introduction 
An anticonvulsant effect may be mediated by alterations of membrane properties 
or membrane potentials, an antagonist action on excitatory neurotransmitter/re-
ceptors, or an agonist action on inhibitory neurotransmitter/ receptors such as the 
GABAA receptor. 
Because of the suggested efficacy of IVIg in intractable childhood epilepsies 
like West syndrome and Lennox-Gastaut syndrome, the goal of the present study 
was to determine whether IVIg can cause a GABAergic enhancing effect. 
Methods 
Using established methods1 (including positive and negative controls), we mea-
sured whether IVIg in the presence and absence of exogenous (2 mM) GABA 
could allosterically displace the radioligand 3H-TBOB from the convulsive site on 
the GABAA-benzodiazepine-receptorcomplex. 
Results 
Unlike benzodiazepines and GABA, IVIG tested in an IgG concentration of 1 
mg/L to 100.000 mg/L in the absence and presence of 2 mM GABA does not dis-
place 3H-TBOB from its receptor sites (Fig 1). 
Conclusions 
From this in vitro study it is not likely that a suggested anticonvulsant effect of IVIg 
in humans and in a subgroup of animals with epilepsy, is mediated by a direct 
GABAergic enhancing effect. 
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Fig 1 [Ή]ΤΒΟΒ binding as function of IgG concentration in the absence and presence of GABA 
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Intravenous immunoglobulin preparation 
increases myoplasmic calcium concentration 
by activating the dihydropyndine-
ryanodine receptor complex 
Summary 
A human intravenous immunoglobulin preparation (IVIg) released Ca2* from sar-
coplasmic reticulum of cultured human muscle cells in a dose-dependent manner. 
Blocking the dihydropyridine(DHP)-ryanodine receptor complex abrogated the 
IVIg-mediated Ca2+ response, whereas inhibition of the voltage-operated Na+-
channels or acetylcholine receptors did not. This effect of IVIg was not mediated 
by its main component, the IgG molecules, and differed between preparations 
from different manufacturers. The present data may be important in interpreting 
the (side) effects of IVIg in neuromuscular diseases. They show that an unidenti-
fied serum protein compound present in IVIg can influence a cell with an excita-
ble membrane. 
Introduction 
Rather than being just a supplement, human intravenous immunoglobulin (IVIg) 
is now increasingly used because of its therapeutic effects in (auto)immune disor-
ders, including neuromuscular diseases such as dermatomyositis1,2. We hypothe-
sized that an effect of CLB-IVIg on Ca2+ homeostasis of skeletal muscle might ex-
plain why IVIg, as opposed to plasma exchange, causes muscle cramps in a patient 
with neuromyotonia (Isaacs' syndrome)3'4. A (direct) effect of IVIg on muscle 
might also explain why myalgia which is difficult to distinguish from muscle 
cramps, is one of the most frequent side effects of IVIg treatment1. However, the 
exact mechanisms of action of IVIg are largely unknown in neurological diseases 
and it is undetermined whether IVIg in addition to its immunologic mechanisms 
of action may indeed exhibit a direct effect on a cell with an excitable membrane, 
such as the human muscle cell. 
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Materiab and Methods 
MateriaL·. 
Fura-2/acetoxymethylester (Fura-2/AM) was purchased from Molecular Probes, 
Uegene, OR, U.S.A.; ionomycin, ryanodine, tetrodotoxin, CC-bungarotoxin, hu­
man IgG, human albumin, transferrin, and α,-antitrypsin from Sigma, St. Louis, 
MO, U.S.A.; and nifedipine from Bayer, Leverkusen, F.R.G.. Recombinant human 
interferony (rhlFNy) was prepared by the Department of Tumor Immunology, 
University Nijmegen, The Netherlands. Two different IVIg preparations were tes­
ted: one from the Central Laboratory of the Netherlands Red Cross Blood Trans­
fusion Service, Amsterdam, The Netherlands (CLB-IVIg); the other from Serap­
harm, Münster, F.R.G. (Ser-IVIg). The former IVIg preparation was produced fr-
om plasma of more than 3000 Dutch blood donors by Cohn's ethanol fractiona-
tion and subsequent treatment at pH 4 with low concentrations of pepsin to pre-
vent or inhibit aggregate formation. The latter preparation was also produced by 
ethanol fractionation, but was additionally centrifuged and treated with anorga-
nic adsorbents. A human albumin preparation for intravenous use manufactured 
by the CLB (CLB-Alb) was also tested. 
Human skeletal muscle cell cultures. 
Biopsies from quadriceps muscle were obtained from individuals without any 
known muscular disorder, as approved by the Committee on Medical Ethics. Cell 
physiological studies were performed with muscle cells grown on glass coverslips 
(30 χ 10 mm) which proliferated until confluency and subsequently differentiated 
for 7-12 days on sera-containing medias. 
Ca2+ homeostasis: fluorescence ratio measurement. 
The free cytosolic Ca2+ concentration ([Ca2+],) was determined by Fura-2 ratio 
measurement6. Myotubes were washed with physiological salt solution (PSS, con­
taining in mM: 125 NaCl, 10 NaHC0 3 ,1 NaH 2 P0 4 , 5 KCl, 2 MgS04, 1.8 CaCl2,10 
Hepes and 10 glucose, pH 7.4) and loaded with 5 μΜ Fura-2 / AM in PSS for 60 min 
at 37°C in the presence of 5% C 0 2 and 95% air. Excess of dye was removed by 
washing thrice with PSS. Ratio measurement was performed using a Shimadzu 
RF-5000 spectrofluorophotometer at an emission wavelength of 492 nm and al­
ternating excitation wavelengths of 340 and 380 nm as described earlier7,8. During 
the measurements the cells were superfused with PSS (4 ml /min; 37°C) with ad­
ditions as indicated in the Results. For blocking experiments, during the last 3 min 
of Fura loading muscle cells were incubated with inhibitor for 30 min at 37°C pri­
or to [Caz+], measurements. [Ca2 f ], was calibrated with 4 μΜ ionomycin in the pre­
sence of 10 mM Ca2+ (pH 7.7) or 20 mM EGTA (pH 8.5). 
Other procédures. 
Both human IVIg preparations were dissolved in PSS. Their IgG concentrations 
were determined as described previously9. An IgG-free supernatant ([IgG] < 0.1 
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mg/ml) was prepared by treatment of CLB-IVIg (2.5 mg in 1 ml PSS) with pro­
tein G-loaded Sepharose balls. The CLB-Alb preparation was concentrated by al­
cohol precipitation and lyophilisation, and dissolved in PSS. Sera from normal 
controls and patients with amyotrophic lateral selerosis (ALS) were diluted with 
PSS to an IgG concentration of 2.5 mg/ml. 
Results 
Effects of CLB-IVIg and Ser-TVlg on [Ca2*]
r 
At rest [Ca2 i], in cultured human muscle cells is about 130 nM (Table I) which is 
in line with published data810. Addition of 2.5 mg/ml CLB-IVIg causes a transient 
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Fig. 1. Effects of CLB-IVIg and Ser-lVIg on [Ca"l CLB-IVIg (2.5 mg/ml) increases [Ca'+], m the presence (A) as well as ab­
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response of [Ca2+], to 1.5 μΜ, both in the presence and in the absence of extra­
cellular Ca21- (Fig. I A, B). The latter implies that the increase of [Ca2+], results from 
a Ca2+ release from the sarcoplasmic reticulum (SR), which indicates a skeletal 
muscle type of signal transduction8". The CLB-IVIg induced increase of [Ca2+], is 
dose-dependent and half-maximal at an IgG concentration of 0.9 mg/ml (Fig. 1С). 
With a different batch of CLB-IVIg comparable results are obtained. The Ser-IVIg 
preparation (2.5 mg/ml), however, does not elicit a Ca2+ response (Fig. ID). 
Inhibition of ryanodine or DHP receptors by 10 μΜ ryanodine and 5 μΜ 
nifedipine, respectively, abrogates the CLB-IVIg-evoked Ca2 t response (Fig. 2A, B). 
Inhibition of voltage-operated Na+-channels (5 μΜ tetrodotoxin) or acetylcholine 
receptors (5 μΜ α-bungarotoxin) does not prevent the CLB-IVIg induced Ca2" re­
sponse (Fig. 2C, D). 
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Table I. Effects of CLB-IVIg, Ser-IVIg various serum proteins and sera from healthy controL· and 
from patients with ALS on the cytosohc Ca2 h concentration m cultured human skeletal muscle cel­
ls. 
Addition [Ca2*], (nM) (η) 
None 134 ±18 32 
CLB-IVIg 
CLB-IVIg in the absence of extracellular Ca2* 
Ser IVIg 
Human IgG 
Supernatant of Protein-G treated 
CLB-IVIg ([IgG] < 0 1 mg/ml) 
IgG recovered from protem-G-balls 
Heat inactivated supernatant of 
Protein G treated CLB IVIg ([IgG] < 0 1 
CLB-Alb 
Albumin 
Transferrin 
a, antitrypsin 
rhIFNy(^/ml) 
Control sera 
ALS sera 
mg/ml) 
1408 ± 265 
1339 ±293 
143 ±25 
135 ± 2 1 
1443 + 261 
139 ± 3 0 
145 ± 26 
121 ±31 
154 ± 3 3 
142 ± 29 
1391 ±201 
132 ± 2 7 
1056 ± 473 
1304 ± 236 
12 
11 
7 
3 
4 
4 
3 
3 
3 
3 
5 
3 
3 
3 
Concentration of protein added was 2 5 mg/ml except otherwise indicated Protein G treatment was repe­
ated four times Sera were diluted 3 4 fold with PSS until an IgG concentration of 2,5 mg/ml was reached, 3 con­
trol and 3 ALS sera were tested 
Values are means ± SD of independent assays in the number of individual cultures originating from diffe­
rent muscle biopsies (n) 
The CLB-IVIg induced Ca1+ response is not caused by IgG but by another protein. 
Since Ser-IVIg did not rise [Ca2+], it became doubtful if IgG, which is the main 
component of both IVIg preparations, is responsible for the Ca2+ response. Pure 
human IgG (Sigma, 2.5 mg/ml) does not affect [Ca2+], (Table I). The supernatant 
of protein G-treated CLB-IVIg (IgG concentration less than 0.1 mg/ml) induces a 
Ca2H response comparable to untreated CLB-IVIg, whereas IgG recovered from 
the protein-G-loaded Sepharose balls does not affect [Ca2+],. 
After heating the supernatant of protein G-treated CLB-IVIg (10 min. at 100°C) 
the Ca2+ release from the SR was absent. This identified the causative factor pre­
sumably as a protein. Gel electrophoresis (SDS-PAGE), however, did not show any 
differences between CLB-IVIg and SER-IVIg, nor did isoelectric focussing. The su­
pernatant from protein G-treated CLB-IVIg did not show any material on elec­
trophoresis due to low concentrations. 
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CLB-Alb did not affect [Ca2+]¡. Predominant serum proteins such as albumin and 
transferrin (both 2.5 mg/ml) are unable to rise [Ca2+]¡. A third quantitatively im-
portant serum protein, a,-antitrypsin (2.5 mg/ml) causes a CLB-IVIg-like Ca2+ re-
sponse. However, this serum component is not detectable (< 10 Ц§/т1) in CLB-
IVIg. A concentration of 1 U/ml of rhlFNy (human plasma concentration varies 
between 0.2 - 0.3 U/ml) is unable to elicit changes in [Ca2*]¡. Sera from healthy 
controls and from patients with sporadic ALS both cause a significant Ca2+ 
response. 
Dticussion 
CLB-IVIg showed a dose-dependent [Ca2+], increase in cultured human skeletal 
muscle cells. In the presence as well as absence of extracellular Ca24 the same ef-
fect was obtained, which means that the [Ca2+]¡ transient resulted from Ca2f rele-
ase from SR. This was confirmed by blocking experiments. During excitation of 
skeletal muscle, acetylcholine receptors, voltage-operated Na+-channels, DHP re-
ceptors (i.e. voltage sensors), and ryanodine receptors (i.e. Ca2+ release channels) 
are sequentially activated. Blocking of either the DHP receptor of the T-tubules, 
or the ryanodine receptor of the SR abrogated the CLB-IVIg-mediated Caz+ re-
sponse, whereas inhibition of the voltage-operated Na+-channels or acetylcholine 
receptors did not. Hence, CLB-IVIg contains an agonist of the DHP-ryanodine re-
ceptor complex. Effects of immunological substances (interleukin-2, IgG's of pa-
tients with ALS) on muscle cells have been reported12", but the present study 
shows for the first time a direct effect of an IVIg preparation on skeletal muscle 
cells, i.e. non-immune cells. 
Secondly, we found that this CLB-IVIg effect was not caused by its main com-
ponent the IgG molecules, because: (i) Ser-IVIg did not rise [Ca2+]¡ at all, (ii) pure 
human IgG did not affect [Ca21"];, (iii) the supernatant of protein G-treated CLB-
IVIg ([IgG] <0.1 mg/ml) induced a Ca2* response comparable to untreated CLB-
IVIg, (iv) IgG recovered from the protein-G-loaded Sepharose balls does not affect 
[Ca2+],. Thus, a general effect of IgG molecules can be excluded. 
A specific effect by distinct IgG molecules has been reported by others12: IgG's 
from patients with ALS and Guülain-Barré syndrome acted on the DHP receptor 
complex of cut rat skeletal muscle fibers, whereas IgG's from patients with other 
neurological diseases and healthy controls did not12. Using cultured human skele-
tal muscle cells, we found that IgG derived from serum of ALS patients and from 
normal controls both induced a significant Ca2+ response, comparable with that 
of CLB-IVIg, which means that the effect of CLB-IVIg is probably caused by an 
endogenous serum molecule. 
Heating the supernatant of the protein G-treated CLB-IVIg inhibited the Ca2+ 
response. Thus the response is mediated by a protein, which, however could not 
be identified using SDS page gel electrophoresis and isoelectric focussing, proba-
bly due to very low concentrations, (< 1 ng, i.e. the detection limit of silver stai-
ning). Because CLB-Alb and CLB-IVIg are both produced by ethanol precipitation 
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as serial "Cohn fractions" of human plasma, and because their effects on [Ca2+], 
differ, we infer that the protein is obviously still in solution after albumin precipi­
tation. Proteins such as IgA and IgM molecules, which are present in the super­
natant of protein-G treated CLB-IVIg, are unlikely to cause the Ca2+ response be­
cause they are present in low concentrations (< 0.02% of IgG) in both CLB-IVIg 
and Ser-IVIg. Although a,-antitrypsin is not responsible for the CLB-IVIg effect (it 
was not detectable in this preparation (< 10 μg/ml))) it is remarkable that this se­
rum protein elevates [Ca2+], of skeletal muscle cells. The biological significance of 
this phenomenon awaits further elucidation. 
Thirdly, we showed that different IVIg preparations can have different effects: 
in contrast to CLB-IVIg Ser-IVIg did not increase [Ca2*],. This may relate to the re­
cently reported differences in content, such as soluble CD4 or HLA molecules in 
various IVIg preparations14. 
To summarize, although the 'active component' of CLB-IVIg remains an uni­
dentified serum protein, three conclusions can be drawn from this study which 
may be important in interpreting the results of clinical studies on IVIg. (i) In ad­
dition to an immunomodulatory effect, IVIg can have a Ca2+-modulating effect on 
muscle cells, (ii) The (side) effects of IVIg are not necessarily mediated by its main 
component, the IgG molecules, (iii) Various IVIg preparations may show different 
effects. Thus, this study confirms that IVIg is indeed complex material, which can 
have undesirable consequences in clinical practice. Experimentally, nevertheless, the 
complexity of IVIg can be fruitful and enables to study interactions between pro­
teins and muscle cells. 
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Overview, summary and concluding remarks 
The results of the research presented in this thesis are summarized in six questions 
and answers which are presented below. 
Part I, Clinical Aspects 
1 Does IVIg have a favourable effect on intractable (childhood) epilepsies? 
The studies so far, including our own, suggest some efficacy: 
Literature review (Chapter 4): Uncontrolled clinical observations (24 studies, 368 
patients) showed on the average a mean clinical seizure reduction and mean 
EEG improvement of 52% and 45%, respectively. On the average, the percent-
age of patients with complete seizure remission, and the percentage of patients 
with behavioral improvement were 23% and 63%, respectively. These studies 
suggest that IVIg might be effective in some patients with intractable epilepsy, 
and may be considered a safe add-on medication in various types of idiopath-
ic, cryptogenic and symptomatic intractable epilepsy. 
Own study (Chapter 5) : In an add-on pilot study, a group of 15 children with cryp-
togenic and intractable West syndrome (WS) and Lennox-Gastaut syndrome 
(LGS) received intravenous immunoglobulin during 3 months. No clinical ad-
verse effects were seen. The reduction in clinical seizure frequency averaged 
70%, mean reduction in epileptic discharges on EEG, blindly measured, was 
40%. This study gives additional arguments that the IVIg preparation can be ef-
fective in treating these types of intractable epilepsy, and should be considered 
when other treatments have failed. 
Part II, CSF Aspects 
2 Can the IgG molecules of the IVIg preparation reach the central nervous system (CNS)? 
The CSF studies suggest that it is not impossible for the IgG molecules to reach the CNS: 
Cerebrospinal fluid-study (Chapter 7): Following IVIg administration in the pa-
tients with WS and LGS, serum IgG concentrations increased in all patients, in 
mean 76%. All patients had an undisturbed blood-CSF barrier permeability be-
fore and after IVIg administration, as measured by Q albumin. CSF IgG in-
creased in all patients except one, in mean 44%. CSF IgG concentrations after 
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IVIg administration increased significantly and proportionally to the Q albu-
min levels Because no restrictive barrier appears to exist between CSF and the 
extracellular fluid of the brain at least withm short diffusion distances, IgG 
should be able to reach certain parts of the CNS adjacent to the CSF 
3 Do extensive CSF studies give information about possible etiological factors or conse-
quences of chronic malignant epilepsies (WS and LGS)? 
Extensive CSF studies did not contribute to the elucidation of possible etiological factors 
or consequences of chronic malignant epilepsies (WS and LGS). 
Cerebrospinal fluid-studies (Chapters 6,7) Hypotheses concerning etiological fac-
tors like CNS infections, neuroimmunological disorders, or disturbances in 
neurotransmitter metabolites could not be confirmed, which is in accordance 
with the cryptogenic etiology of the epilepsies in the reported patients Nor 
could hypotheses concerning seizure consequences, such as increased blood-
CSF permeability, increased markers of brain cell destruction, or increased 
metabolic components be confirmed 
4 Do extensive CSF studies show signs of adverse effects of IVIg? 
No signs of adverse effects of IVIg have been found in CSF. 
Cerebrospinal fluid-studies (Chapters 6,7) Compared to the age-related reference 
values, the investigation of cell counts, total protein concentrations, brain spe-
cific protein concentrations, and Q albumin levels after IVIg did not show any 
signs of adverse effects such as aseptic meningoencephalitis 
What kind of interaction could exist between IVIg and (intractable childhood) epilepsy^ 
Part III, Immunological Aspects 
5 Is (intractable childhood) epilepsy associated with immunologic abnormalities and could 
IVIg suppress epilepsy through an immunological mechanism? (clinical research) 
This exphnatwn can not be rejected, the immune system seems to be involved, and sever-
al of our findings support this expUnation, however uncertainties remain 
Immunogenetic study (Chapter 8) in LGS a significant increase in the frequency 
of DR5 antigen and an indication of a decrease in the frequency of DR4 anti-
gen were found These HLA associations could make individuals susceptible to 
development of epilepsy when exposed to various factors such as viral infec-
tions, and could be compatible with an autoimmune genesis of this epilepsy 
Immunological study (Chapter 9) In 26 children with epilepsy, including 15 with 
WS or LGS, mean serum IgG and IgM concentrations were increased com-
pared to normal controls, whereas the kappa/lambda ratios of total serum im-
munoglobulin, IgG and IgM were lower in the children with epilepsy These 
findings may suggest reciprocal interactions between the CNS and immune 
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system in childhood epilepsies, and are compatible with the hypothesis of a 
concomitant developmental delay in immuno-pathophysiological and in neu-
ropathophysiological mechanisms in childhood epilepsies. 
Immunological study (Chapter 10): in patients with LGS a misregulation of the im-
mune system was found: a functionally impaired humoral immune response to 
a primary antigen despite signs of a triggered immune system consisting of el-
evated IgG concentrations. This combination of immunological findings, con-
sidered to be the expression of a dysbalanced-triggered as well as functionally 
impaired-immune system, has also been described in genetically epilepsy-
prone rats, and in an autoimmune disease like SLE in humans. 
Part IY Experimental Aspects 
6 Has the commercially avaihble IVIg preparation a direct neuromodulating effect? 
(experimental research) 
In vivo, IVIg shows a significant and prolonged elevation of the threshold for convulsions 
in a subgroup of rats 
Threshold study in rats (Chapter 11): 0.5 - 1 hour after IVIg administration a sig-
nificant and prolonged elevation of the threshold for convulsions by direct cor-
tical stimulation was measured in a subgroup ( 12%) of outbred Wistar rats. Im-
munohistochemical analysis confirmed penetration of the IgG molecules into 
brain tissue. Caution to ascribe the effect to the IgG molecules is necessary as 
IVIg is not a pure preparation. 
In vitro a direct neuromoduhting effect of IVIg is found. This effect on celh with excitable 
membranes L· not caused by IgG molecules, but by another protein 
Effect of IVIg on cytoplasmic calcium concentration in cultured human muscle celb 
(Chapter 13): A human intravenous immunoglobulin preparation (IVIg) re-
leased Ca2+ from sarcoplasmic reticulum of cultured human muscle cells in a 
dose dependent manner. Blocking the dihydropyridine(DHP)-ryanodine re-
ceptor complex abrogated the IVIg-mediated Ca2t response, whereas inhibi-
tion of the voltage-operated Na+-channels or acetylcholine receptors did not. 
This effect of IVIg was not mediated by its main component, the IgG mole-
cules, and differed between preparations from different manufacturers. The 
present data may be important in interpreting the (side) effects of IVIg in neu-
rological diseases. They show that an unidentified serum protein compound 
present in IVIg can influence a cell with an excitable membrane. 
Concluding remarks 
This study 
WS and LGS are, until now, unexplained intractable age-related epilepsies. Be-
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cause neuroimmunological mechanisms could play a role in the genesis or main-
tenance of the epileptic encephalopathy treatment with IVIg was initiated. Based 
on the results of this study further research on a neuroimmunological approach 
of these epilepsies was elaborated. The results of these studies indicate that there 
may be a bidirectional interaction between the immune system and the CNS in in-
tractable epilepsies. Firstly, the human immunological data can be interpreted as 
a contribution to the hypothesis that immunogenetic mechanisms may play a role 
in triggering or maintaining the cryptogenic childhood epilepsies of WS and LGS. 
IVIg could thus act on these immunogenetic mechanisms associated with epilep-
sies by its broad immunomodulatory mechanism of action, for example, by 
restoration of a normal immune repertoire or by antiidiotype interaction. Sec-
ondly, our data of in vivo as well as in vitro studies contribute to the hypothesis that 
IVIg may have a direct neuromodulating effect. Nevertheless, the active compo-
nents responsible for such an effect and their mechanisms of action are unknown 
and not necessarily the same in the in vivo and in vitro situations. An in vivo anti-
convulsant effect (in humans or in animal models) can not readily be compared 
with in vitro studies on an isolated single cell level, because epilepsy is a prototype 
of a pathological synchronization in a multi- and intercellular network. 
The data suggest that it is reasonable to search for therapeutic agents of im-
munological origin in order to influence the CNS in epilepsies (immunopharmo-
cotherapy). 
What did we confirm? 
- Concerning IVIg treatment in intractable epilepsies: suggestive evidence that 
IVIg is effective in treating intractable childhood epilepsies like cryptogenic WS 
and LGS. 
- Concerning animal studies: a similar time-effect relationship and a similar im-
munohistochemical staining pattern for human IgG as has been reported in the 
only other study on IVIg in an animal epilepsy model. 
What is new? 
- Concerning IVIg treatment in intractable epilepsies: the use of a relatively ho-
mogeneous group of patients; blinded evaluation of EEG data; the demon-
stration that (3 months of) IVIg treatment significantly increases serum IgG 
and CSF IgG concentrations. 
- Concerning intractable childhood epilepsies: extensive CSF investigations in 
cryptogenic types revealing no abnormalities; demonstration of functional im-
mune abnormalities in LGS, demonstration of an HLA class II association in 
LGS. 
- Concerning animal studies: suggestive evidence that IVIg increases the thresh-
old for convulsions in a subgroup of rats. 
- Concerning in vitro effect of IVIg on the GABAA receptor: the conclusion that 
IVIg has no direct GABAergic enhancing effect. 
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- Concerning IVlg préparations: proof that IgG molecules of the IVIg prepara-
tion cross the blood-CSF barrier and significantly increase CSF IgG; establish-
ing an effect of an IVIg preparation on cells with excitable membranes, al-
though this effect was not caused by the main component of the IVIg prepa-
ration, the IgG molecules; proof that two IVIg preparations can cause different 
in vitro effects. 
What to dof 
- Concerning IVIg treatment in intractable epilepsies: double blind controlled 
study of IVIg in WS and LGS*; investigation of the effect of IVIg on REM sleep; 
long term follow up of IVIg treatment in epilepsies. 
- Concerning animal studies: investigating the variability in IVIg effect on the 
threshold for convulsions; exploring the potential existence of specific anti-
convulsant monoclonal immunoglobulins. 
- Concerning IVIg preparations: investigation of the effect of various compo-
nents of the IVIg preparation (such as endogenous proteins, e.i. cytokines and 
soluble cytokine receptors) on experimental epilepsy, and on cells with ex-
citable membranes, especially neurons. 
* During the preparation of this thesis one double blind placebo controlled trial on IVIg in intractable epilepsies 
was published (van Rijckevorsel et al Treatment of refractory epilepsy with intravenous immunoglobulins Int 
J Clin Lab Res 1994,24 162-166) In this study one patient with LGS received IVIg and no patients with WS re 
ceiving IVIg could be found in the patient data 
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Open questions, considerations 
and speculations 
The present thesis may be conceived as a first approach of "immunopharmacother-
apy" in WS and LGS, i.e. the search for therapeutic agents of immunological ori-
gin that influence CNS in order to control epileptic activity. Because of the rela-
tive novelty of the approach, the present study shows the characteristics of an ex-
ploration, obviously presents more questions than answers, and has to be consid-
ered as a "corridor" investigation instead of a "closet" investigation: answering 
one question enables a view on several others. 
Why are both WS and LGS such homogeneous phenotypes? 
It is remarkable that despite the diversity of etiologies (Chapter 2) or even in the 
absence of a detectable cause (cryptogenic types, see Chapter 2) the epilepsy in 
WS respectively LGS shows such homogeneous/monomorphic clinical and EEG ex-
pressions. The epileptic phenotypes of WS and of LGS are not "cause"- but "age"-
relateà. Several hypotheses exist why the immature brain has a lower susceptibili-
ty to seizures (Chapter 2), and it is conceivable that all the different factors lower-
ing the brain threshold for excessive discharges, act by a 'final common pathway' 
as determined by age-related brain maturation. 
When WS and LGS are caused by so many etiologies why are their 
incidences not higher? 
When so many etiologies can cause WS and also LGS at certain ages, why do on-
ly a minority of all children develop WS and LGS (WS and LGS comprise only 10-
15% of all childhood epilepsies)13. In addition to a certain etiology, other factors 
must be responsible for the development of WS or LGS. One of the possibilities 
might be an immuno-genetic predisposition, i.e. a certain reactivity of the child's 
developing neuro-immunological network to exogenous triggers like infections, im-
munizations or stress. The combination of endogenous and exogenous factors 
might initiate an encephalopathic process, characterized by mental regression, fre-
quent seizures, and an interictally severely disturbed EEG. In this concept, WS and 
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LGS can be considered as the developing brain s relatively uniform answers to the 
dynamic interaction between genetics, maturation, and environmental factors'". 
How is it possible that even in the cryptogenic types of these severe 
epileptic encephalopathies, CSF studies and brain MRI are normal? 
Despite the severity of the epileptic encephalopathies in WS and LGS, the CSF 
(Chapters 6 and 7) and neuroimaging studies of the brain were normal. Therefore 
it can be speculated that epilepsy is a CNS dysfunction, a disturbance of the neu­
rochemical network of the brain, with a lowered threshold for seizures caused by 
micro-architectonic abnormalities or dysregulation of metabolic homeostasis. 
Which parallel can be drawn between the CNS and immune system in 
epilepsy? - The immunoglobulin superfamily, - Shared ligands and 
receptors 
Quantitative neuroanatomical analyses of the CNS in patients with LGS showed 
defective arborization of the cortical dendrites11,31. This finding might be inter­
preted as the expression of delayed maturation, and fits with the hypothesis of an 
'immature' CNS in a childhood epilepsy such as West syndrome32. The abnormali­
ties found in the immune system, decreased κ/λ light chain ratios (Chapter 9) can 
also be interpreted as the expression of an 'immature' immune system. How can 
IVIg act on both? IVIg may manipulate the child's immune system by causing a 
kind of normalization of the immune system. The IgG repertoire of infants and 
children with epilepsy normalizes and matures by administration of 'adult' IVIg. 
The artificially increased maturation of the IgG repertoire may, in turn, change 
the interaction with and the function and maturation of the CNS. It can be spec­
ulated that such an "immune restoration" of the normal function of the network, 
or "immune defibrillation" may in turn change the "epileptic brainstorm" by inter­
acting with the function and maturation of the CNS. 
At a conceptual level, the two systems share many features, and the immune 
system has long had heuristic attraction as a model for the CNS. Ultimately how­
ever, any understanding of how these systems talk to each other will depend on 
knowledge of the molecules involved. One common molecular theme between 
the CNS and the immune system is provided by the immunoglobulin superfamily^. 
The immunoglobulin superfamily includes a wide variety of molecules that con­
tain one or more structural domains that are related in primary sequence to the 
classically defined variable or constant region domains of immunoglobulins. 
While this protein family contains many members, such as the prototype im­
munoglobulins, which are expressed on cells of the immune system, it also in­
cludes proteins of nonimmune origin, particularly several that are expressed 
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abundantly or exclusively in the CNS, such as the neural cell adhesion molecule 
(N-CAM), myelin-associated glycoprotein (MAG), and the peripheral myelin pro-
tein P„. All of these molecules are cell surface glycoproteins, and several are be-
lieved to mediated cell-cell interactions during neural development. Such process-
es may be mediated by binding between immunoglobulin-like domains presented 
on cell surfaces. However, it is not clear whether this shared molecular motif of-
fers opportunities for functional interactions between the nervous system and im-
mune system or merely represents a general strategy by which such independent 
complex systems achieve their required pattern of cell-cell communications. In 
favour of the former are the recent publications of van Schaik and others show-
ing that certain IgG molecules contained in the IVIg preparation cause upregula-
tion of a gene encoding for the myelin protein PMP-22"5. 
Another common molecular theme between the CNS and the immune system 
is the recently discovered structure similarity between receptors and ligands in the 
CNS and immune system6·17. For example, cytokines can act as neuronal differen-
tiation factors and may be involved in synaptic plasticity28. 
Which might be the possible mechanisms of action of IVIg in epilepsies? 
The mechanism of action of IVIg (Chapter 3) in epilepsies may be different in 
studying humans, animals or in vitro systems. In addition, even in the same system 
one mechanism of action does not exclude another one. Regardless of these dif-
ficulties, several potential mechanisms of action of IVIg in epilepsies can be con-
sidered. 
Table 1. Possible mechanisms of action of IVIg in epilepsies 
1 Antiidiotype activity 
2 Fc receptor blockade 
3 (Neuro)immunomodulation (cytokines) 
4 Effect of "contaminating'' proteins 
Mechanisms: 1. Anti-idiotype activity 
Intracortical application of anti-CNS autoantibodies can induce abnormal burst-
ing, which results in epileptiform activity in the mammalian brain21. Recently it 
has been shown that antibodies directed against small regions of the Na+ channel 
can slow inactivation47. Conversely, experimental epilepsies are associated with 
production of anti-CNS autoantibodies50. In humans with epilepsies one study in-
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deed reported an increased prevalence of anti-CNS autoantibodies2'. The role of 
these autoantibodies in human epilepsies, however, remains unclear1. It is unsettled 
if they are causative for, or secondary to the epilepsies, or if both the epilepsies 
and the autoantibodies are caused by a third variable, for example a genetically de-
termined susceptibility29,39. 
When anti-CNS autoantibodies indeed might play a role in the pathophysiolo-
gy of (intractable) epilepsy, IVIg may inhibit epilepsy by suppressing these anti-
CNS autoantibodies by an anti-idiotype interaction. Such a mechanism has been 
shown for the efficacy of IVIg in suppressing anti-factor VIII autoantibodies in pa-
tients with severe bleeding complications34. Thus, IVIg may manipulate the im-
mune system by suppression of possible anti-CNS autoantibodies, and by in-
creasing IgG variable (V)-region connectivity35. 
In autoimmune diseases, Kaveri divides the activity of IVIg in early and long term 
effects. In the latter, changes in serum antibody concentrations observed after in-
fusion with IVIg do not merely reflect passive transfer of IgG into the patient22. 
They are also the expression of alterations in structure and dynamics of the idio-
type network in the autoimmune patient. In other words, the effect of IVIg out-
lusts the effect predicted by the pharmacological half-life, this may be due to a kind 
of "immune defibrillation". 
The idea that IVIg could be envisaged for pathological states other than im-
munodeficiency and autoimmunity, such as epilepsies, is in accordance with re-
cent immunological theories on the role of immunoglobulins, not only in the reg-
ulation of the immune system but also in the general homeostasis of the organ-
ism81016. Recently we showed that polyclonal mouse IgG (comparable to the hu-
man IVIg preparation) promotes CNS remyelination in a viral (Theiler's virus) 
model of demyelination42. Even in a non-primary immune model of demyelina-
tion, manipulating the immune system can play a beneficial role in myelin repair: 
1
 The role of autoantibodies, especially natural occurring autoantibodies remain problematic. Classically, im-
munoglobulins have been considered deletenous molecules in autoimmune diseases, whereas they have been 
shown to have a protective function during productive immune responses (e g clearing infectious agents). Wit 
hin this paradigm, the existence and function of naturally occurring autoantibodies in the 'resting' immune sys 
tem is not yet fully understood2 s ls Recent immunological theories and hypotheses * * '° '6 * suggest that these 
ubiquitous natural autoantibodies have various potential biological roles While classical antibodies serve to cle-
an the body of foreign invading agents, natural autoantibodies nd the organism of its own catabohc products 
and may establish an extensive dynamic network that contributes to the normal homeostasis of the organism 
In accordance with these ideas, autoimmune diseases may be successfully treated not by suppressing the rmmu 
ne network, but by strengthening it - such as by the administration of IVIg (which also contains natural autoan-
tibodies") This suggestion is in agreement with the frequent association of autoimmunity with immunodefi-
ciency '° IVIg may neutralize existing autoantibodies ", which may account for the immediate effect of such tre-
atment Some have speculated that, in the long term, a large dose of normal immune components may restore 
normal organization to the abnormal immune network " These views may provide a framework for under-
standing the therapeunc effects of IVIg in a variety of autoimmune diseases 
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a natural occurring autoantibody promotes remyelination in a toxic traumatic 
(Lysolecithin) model44 of demyelination. 
Mechanisms: 2. Fc receptor blockade 
Inflammation does not seem to be a major pathological finding in WS or LGS, and 
the role of macrophages or microglia in these syndromes is unclear. Thus, in 
epilepsies efficacy of IVIg on macrophage or microglial Fc receptors is uncertain, 
whereas neurons and oligodendrocytes do not seem to posses Fc receptors48. Nev­
ertheless, Fc receptors have been described in rat and human brains (microglial 
cells), and it can not be excluded that IVIg may influence epilepsies by blockade of 
Fc receptors. Immunosuppression by cyclophosphamide indeed does reduce 
epilepsy in an animal epilepsy model37. 
Mechanisms: 3. Immunomodulation 
Several theories for the development of WS exist (Chapter 2). Recently Baram 
proposed a new hypothesis for the pathophysiology of WS taking into account 
the age-related occurrence of WS, and the effect of ACTH5. The hypothesis im­
plicates an endogenous neuropeptide, corticotropin-releasing hormone (CRH), 
which indeed is known to cause seizures in infant rats, and is suppressed by ACTH 
and corticosteroids. Baram hypothesized that an abnormally increased CRH syn­
thesis and activity, secondary to antecedent injury or psychological and physical 
stress, results in selective neuronal hyperexcitability and WS5. We would like to ex­
pand this hypothesis to the other main epileptic encephalopathy, LGS, and use re-
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cent insights in immune-neuro-endocrine interactions to try to explain the phe-
notypes (Fig 1.) (for review6). 
In the CNS, both exogenous interleukin-1 (IL-1, from immune cells, like mononu-
clear phagocytes) and also "electric shocks" (seizures) stimulate endogenous IL-1 
production in astrocytes, microglia, and neurons in the hypothalamus (Fig 1). Ex-
ogenous as well as endogenous IL-1 cause release of CRH from the hypothalamus. 
CRH has been shown to be an intrinsic convulsant especially in infant rats. It ele-
vates IL-1 receptor (IL-1R) levels in the pituitary gland and induces the release of 
ACTH. The ACTH and glucocorticoid release inhibits virtually all components of 
the immune response including IL-1 production by immune cells30. 
Any putative mechanism for WS and LGS must explain, or at least be compat-
ible with, most of the unique features of these seizure disorders. Some of these 
are: How can a single entity like WS or LGS have diverse causes? Why does WS 
and LGS arise only in infants and children? Why are they associated with profound 
and lasting cortical dysfunction? Why does (especially) WS respond to ACTH and 
corticosteroids? Why is the percentage of REM sleep decreased1819? 
We hypothesize that thefìnal common pathway in WS and LGS could be an ab-
normally increased CRH production, release or response. This can be the result of: 
(1) Abnormal stress (such as infections or vaccinations) in early life that lead to 
pathological sprouting and hyperfunction of CRH-neuronal pathways. 
(2) Certain, e.i. genetic traits (certain HLA associations (Chapter 8) of patients 
with WS or LGS leading to an excessive CRH activation in response to usual, 
"normal" stress. 
(3) A diminished feedback inhibition by ACTH and glucocorticoids on the convulsant 
CRH. This may be due to superimposed neural elements (like stress, different 
cytokines) that can override the normal negative-feedback relation30. 
These three mechanisms can result in an abnormally increased CRH production, re-
lease or response, which in turn may cause: 
(l)an epileptic encephalopathy with EEG and behavioral changes due to an exag-
gerated loop: IL-1 —> CRH —» seizures/EEG changes —> IL-1. In a recent study, 
the peripheral blood mononuclear cells from epileptic patients as compared to 
normal controls, showed indeed a greater production of IL-1 (a and β), and IL-
6 in response to in vitro stimulation with phytohaemoagglutinin27. Levels of IL­
ICI were elevated in surgically resected human temporal lobe tissues from pa­
tients with intractable epilepsy compared with neurologically unaffected pa­
tients38. In addition, IL-1 itself influences neuronal function (increase slow-
wave sleep), behaviour, neuroendocrine systems and metabolism, all of which 
appear to be mediated by direct actions on the CNS11,36. 
(2) a dysimmune encephalopathy due to the following pathway: stress/IL-1 —» CRH 
—» IL-IR increase in pituitary —» glucocorticosteroid release —» inhibition of 
immune responses (Part 3). The stress or IL-1 induced CRH release profound­
ly sensitizes the pituitary gland to inflammatory cytokines such as IL-1 by ele­
vating IL-lR levels in the pituitary gland''6. This in turn enhances the CRH ef-
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feet on ACTH and glucocorticoid production which causes immunosuppres­
sion. Even though the original stress may be mild, this mechanism may cause 
an exaggerated glucocorticoid response. 
Summarizing from the above considerations and hypotheses the third potential 
mechanism of action of IVIg on epilepsies may be a modulation of cytokines. Just 
like corticosteroids, IVIg has been reported to change several cytokines (e.i. IL-122, 
IL-21, IL-624, IFN-gamma23,2"). Such a mechanism of action may change epilepsy 
and CNS functioning directly. Because of the structure similarities between the cy­
tokines and the neuroendocrine hormones/neurotransmitters, and also between 
their receptors6, the potential for functional crossover between these molecules is 
high. Thus it is possible that, during development, a single ligand may have effects 
on the differentiation of both maturing neurons and blood cells17. Cytokines can 
act as neuronal differentiation factors and may be involved in synaptic plasticity28. 
IL-1 and IL-2 have been shown to change electrophysiological properties of neu­
rons
52
. 
A cytokine modulating action of IVIg can affect epilepsy also indirectly by mod­
ulating the hypothalamic-pituitary-adrenal (ΗΡΑ) axis; changes in cytokine activ­
ity may block, just like ACTH or corticosteroids do, the endogenous convulsant 
CRH. 
Mechanisms: 4. Effect of contaminating molecules 
IVIg is a complex soup of numerous different IgG molecules and other "contam­
inating" molecules such as cytokines, and soluble cytokine-, CD4-, CD8- and 
HLA-receptors (Chapter 3). It is possible that the immunomodulating effects of 
IVIg are due, at least partly, to these 'contaminating' molecules7. 
In human striated muscle cells we showed (Chapter 13) that the IVIg prepara­
tion caused a dose-dependent intracellular calcium release from sarcoplasmic 
reticulum, and that the IVIg effect on the excitable membrane of this cell was not 
mediated by the IgG molecules but by another 'contaminating' protein. In addi­
tion, various IVIg preparations showed different effects. 
Based on the above, it may be concluded that: 
(i) the IVIg preparation known to manipulate the immune system, can in vitro al­
so have a direct effect on cells with excitable membranes. 
(ii) in this neuroimmunological respect IVIg seems to share some characteristics 
with ACTH/corticosteroids, drugs especially used in WS and affecting also both 
the CNS and immune system12,20. 
(iii) Influencing the immune-neuro-endocrine system may be of potential thera­
peutic benefit in epilepsies. 
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IVIg, an immunopharmacon? 
Redundancy is a characteristic of the immune system, and specificity of treatment 
is probably not always the highest goal in immune mediated diseases. Some ac­
tivities of polyclonal IVIg cannot be easily reproduced by a single (monoclonal) 
antibody, because the best antibody activity is sometimes mediated by combina­
tions of antibodies recognizing different antigenic motifs on the target molecule3. 
In addition, several mechanisms of action of IVIg are probably occurring, so the 
use of polyspecific IVIg may continue to be necessary. 
The complexity of the IVIg preparation can be its strength, when at least a 'clin­
ical bedside with α laboratory bench' approach is combined. In this respect, IVIg treat­
ment offers a unique experimental tool to study interactions within the human 
immune system and between the immune and nervous system. Along these lines, 
the availability, therapeutic efficacy and safety of IVIg treatment have already 
taught us something, it urged us, clinicians and immunologists, to reassess the role 
of IgG's in an autoimmune disease, such as multiple sclerosis26'"0""1. 
Concerning the role of IVIg in epilepsies: the complexity of the IVIg "soup" and 
especially its unspecificity can also have undesirable consequences in clinical prac­
tice. Even if IVIg tested by a double blind placebo controlled design, would show 
efficacy in WS and LGS, IVIg treatment would because of its unspecificity proba­
bly not be the final immunopharmacotherapeutical approach. 
Experimentally, the complexity of the IVIg preparation can be fruitful, because 
IVIg treatment of epilepsies allows the study of interactions between the CNS and 
the "soup" of substances contained in the IVIg preparation. These substances are 
in principle mostly of endogenous origin, which enables while studying treatment 
effects, to investigate (patho)physiology as well. IVIg may serve as a tool to study 
the role of some endogenous proteins in epilepsies. Research into the pathophys­
iology of epilepsy has largely focused upon discovering those factors responsible 
for seizure initiation, whereas another approach might be to investigate endoge­
nous factors that ameliorate and suppress seizures14. The race to develop such nov­
el compounds, be they cytokines, soluble cytokine receptors, or neuropeptide 
modulators that are capable of regulating the immune-neuro-endocrine feedback 
loops, has already begun15 and offers one of the most exciting areas for future neu-
robiological research. 
In conclusion, we think that until more-specific treatments are available, poly­
clonal IVIg temporarily deserves a place in the new and promising discipline of 
immunopharmacotherapy. 
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Samenvatting 
De resultaten van het onderzoek gepresenteerd in dit proefschrift kunnen samen-
gevat worden in de volgende 6 vragen en antwoorden. 
Part I: Clinical Aspects 
1 Heeft de intraveneuze toediening van humaan Immunoglobuline (Wig) een gunstig effect 
op anderszins onbehandelbare (kinder)epilepsieën? 
De studies tot nu toe, inclusief onze eigen studie, suggereren een gunstig effect. 
Literatuuroverzicht (Chapter 4): Ongecontroleerde klinische observaties (24 stu-
dies, 368 patiënten) toonden in het algemeen een gemiddelde klinische aan-
valsreductie en een gemiddelde EEG-verbetering van respectievelijk 52% en 
45%. Gemiddeld was het percentage patiënten met een totale aanvalsstop en 
het percentage patiënten met gedragsverbetering respectievelijk 23% en 63%. 
Deze studies suggereren dat IVIg effectief kan zijn bij sommige patiënten met 
onbehandelbare epilepsie, en dat het beschouwd kan worden als een veilig mid-
del in de verschillende typen van idiopathische, cryptogene en symptomatische 
onbehandelbare epilepsie. 
Eigen studie (Chapter S): Een groep van 15 kinderen met cryptogeen en onbe-
handelbaar West-syndroom (WS) of Lennox-Gastaut-syndroom (LGS) kreeg 
gedurende 3 maanden IVIg toegediend. Er werden geen bijwerkingen gesig-
naleerd. De afname in klinische aanvalsfrequentie was gemiddeld 70%, de ge-
middelde afname van de epileptische ontladingen op het EEG (blind gemeten) 
was 40%. Dit onderzoek geeft additionele ondersteuning aan de opvatting dat 
IVIg effectief kan zijn in de behandeling van de bovengenoemde types epilep-
sieën en dat toediening van IVIg overwogen kan worden wanneer andere be-
handelingen niet het gewenste resultaat opleveren. 
Part II: CSF Aspects 
2 Kunnen de IgG-moleculen van het IVlg-preparaat het centrale zenuwstelsel (CZS) berei-
ken? 
De liquorstudies suggereren dat het niet onmogelijk is dat de IgG-moleculen het CZS be-
reiken: 
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Liquoronderzoekingen (Chapter 7) Na IVIg-toediening steeg de concentratie van 
serum-IgG bij alle patiënten en wel met een gemiddelde van 76% Alle patiën-
ten hadden een ongestoorde perméabilité« van de bloed-liquor barrière (ge-
meten middels de Q-albumine) voor en na IVIg-toediening Liquor-IgG con-
centraties stegen bij alle patiënten op één na, met een gemiddelde van 44% De 
stijging na IVIg-toediening was significant en proportioneel met de Q albumi-
ne-waarden Omdat er geen restrictieve barrière lijkt te bestaan tussen de li-
quor en de extracellulaire vloeistof van het CZS, althans binnen korte diffu-
sieafstanden, zou het IgG bepaalde gedeelten van het CZS in directe nabijheid 
van de liquor moeten kunnen bereiken. 
3 Gaven uitvoerige liquorstudies informatie over de mogelijke etiologische factoren of con-
sequenties van chronische maligne epilepsieen van het type WS en LGS? 
Uitvoerige liquorstudies droegen met bij aan de opheldering van mogelijke etiologische fac-
toren of consequenties van de genoemde chronische maligne epilepsieen. 
Liquorstudies (Chapters 6,7) Hypotheses met betrekking tot etiologische factoren 
zoals CZS-infecties, neuro-immunologische ziekten of afwijkingen in neuro-
transmitter metaboheten konden in de bestudeerde patiëntengroep niet wor-
den bevestigd Dit is in overeenstemming met de cryptogene enologie van de 
epilepsieen Ook konden hypotheses over gevolgen van epileptische aanvallen 
zoals een toegenomen permeabihteit van de bloed liquor-barrière, toename 
van CZS-afbraakprodukten ten gevolgen van beschadiging of toename van 
metabole componenten niet bevestigd worden 
4 Toonden uitvoerige liquoronderzoekingen tekenen van bijwerkingen van IVIg? 
Bij uitvoerige liquoronderzoekingen konden geen tekenen van bijwerkingen van IVIg ge-
vonden worden. 
Liquorstudies (Chapters 6,7) Vergeleken met leeftijdsafhankelijke referentie-
waarden vertoonden celgetal, totaal eiwitconcentratie, concentratie van her-
senspecifieke eiwitten en Q albumine-waarden na IVIg geen enkel teken van 
bijwerkingen zoals aseptische meningo-encefalitis 
Wat voor interactie kan er bestaan tussen IVIg en (onbehandelbare kinder)epilepsie? 
Part III Immunological Aspects 
5 Is (onbehandelbare kinder)epilepsie geassocieerd met immunologische afwijkingen en 
kan Wig de epilepsie onderdrukken via een immunologisch werkingsmechanisme? (klini-
sche research) 
De hypothese dat het immuunsysteem betrokken lijkt kan niet worden verworpen. Ver 
schillende van onze resultaten ondersteunen deze hypothese, hoewel nog vele onopgeloste 
vragen blijven bestaan. 
Immunogenetische studie (Chapter 8) Bij patiënten met LGS vonden we een sig-
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niñeante toename van de frequentie van het HLA-DR5-antigeen en een indi-
catie voor een afname van de frequentie van het DR4-antigeen. Mensen met 
dergelijke HLA-associaties zouden epilepsie kunnen ontwikkelen wanneer ze 
blootgesteld worden aan bepaalde factoren zoals virale infecties. De gevonden 
HLA-associaties in deze vorm van epilepsie (LGS) kunnen compatibel zijn met 
een auto-immuun genese. 
Immunologische studie (Chapter 7): In een groep van 26 kinderen met epilepsie, 
inclusief 15 met WS of LGS waren de gemiddelde serum-IgG en- IgM-waar-
den verhoogd vergeleken met normale controles. De kappa/lambda-ratio's 
van de totale serum-immunoglobulines en van IgG en IgM waren lager in kin-
deren met epilepsie. Deze immunologische resultaten zouden kunnen passen 
bij reciproke interacties tussen het CZS en het immuunsysteem in kinderepi-
lepsieën. Ze zijn compatibel met de hypothese van een gelijktijdige ontwikke-
lingsvertraging in immunopathofysiologische en neuropathofysiologische me-
chanismen bij kinderepilepsieën. 
Immunologische studie (Chapter 10): Bij patiënten met LGS vonden we een disre-
gulatie van het immuunsysteem: een functioneel verminderde humorale im-
muunrespons tegen een primair antigeen ondanks tekenen van een geactiveerd 
immuunsysteem bestaande uit verhoogde IgG-concentraties. Deze combina-
tie van immunologische bevindingen, geïnterpreteerd als de uitdrukking van 
een immuunsysteem in disbalans (geactiveerd en tevens functioneel vermin-
derd), is ook beschreven bij ratten met genetische epilepsie en bij auto-im-
muunziekten als SLE in mensen. 
Part IV: Experimental Aspects 
6 Heeft het commercieel verkrijgbare IVIg-preparaat een direct neuromodulatief effect? (ex-
perimentele research) 
In vivo veroorzaakt IVIg een significante en hngaanhoudende verhoging van de drempel 
voor convubies in een subgroep ratten. 
Drempehtudie in ratten (Part 4a): Een significante en langaanhoudende verho-
ging van de drempel voor convulsies (opgewekt door directe corticale stimu-
latie) werd gevonden 0.5 -1 uur na IVIg-toediening in een subgroep (12%) Wi-
starratten. Immunohistochemische analyse bevestigde penetratie van IgG-mo-
leculen in het hersenweefsel. Voorzichtigheid is geboden om het anticonvul-
sieve effect à priori toe te schrijven aan de IgG-moleculen omdat IVIg geen zui-
ver IgG-preparaat is. 
In vitro wordt een direct neuromoduhtief effect van IVIggevonden. Dit effect op cellen met 
een excitabele membraan wordt niet veroorzaakt door de IgG-moleculen, maar door een 
ander eiwit. 
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Het effect van IVIg op de cytophsmatische calaumconcentratie van gekweekte huma 
ne spiercellen (Chapter 13) IVIg veroorzaakte een dosisafhankehjke calciumaf-
gifte uit het sarcoplasmatisch reticulum van humane spiercellen in kweek 
Blokkering van het dihydropyndine(DHP)-ryanodine receptor complex on 
derdrukte de IVIg gemedieerde calcium respons, terwijl blokkering van de vol-
tage afhankelijke natnumkanalen of van de acetylcholine-receptoren dat niet 
deed Dit IVIg-effect werd met veroorzaakt door de belangrijkste component, 
de IgG-moleculen en verschilde tussen de beide geteste preparaten afkomstig 
van verschillende fabrikanten 
Concluderende opmerkingen 
Onderhavige studie 
WS en LGS zijn tot nu toe onbegrepen, onbehandelbare, leeftijdsafhankehjke epi-
lepsieen Omdat neuro-immunologische mechanismen een rol zouden kunnen 
spelen bij het ontstaan of voortduren van de epileptische encefalopathie, werd 
behandeling middels IVIg onderzocht Naar aanleidingvan de gunstige resultaten 
van deze studie verrichtten wij verder neuro-immunologisch onderzoek van de-
ze epilepsieen De resultaten van deze studies wijzen erop dat er een wederken-
ge relatie zou kunnen bestaan tussen het immuun systeem en het zenuwstelsel bij 
onbehandelbare epilepsieen Ten eerste kunnen de data geïnterpreteerd worden als 
een bijdrage aan de hypothese dat immunogenetische mechanismen een rol zou-
den kunnen spelen in het uitlokken of onderhouden van cryptogene kinderepi-
lepsieen van het type WS of LGS IVIg zou dus kunnen werken op deze aan epi-
lepsie geassocieerde immunogenetische mechanismen door een ïmmunomodu-
latief werkingsmechanisme, bij voorbeeld door herstel van een normaal im-
muunrepertoir of door anti-idiotype interactie Ten tweede dragen onze data van 
de m vivo en m vitro studies bij aan de hypothese dat IVIg een direct neuromodu-
latief effect kan hebben De actieve component verantwoordelijk voor dergelijke 
effecten en de werkingsmechanismen zijn onbekend en niet noodzakelijkerwijs 
hetzelfde in de m vivo en m vitro situaties Een m vivo anticonvulsief effect (in men-
sen en in diermodellen) kan niet gemakkelijk vergeleken worden met m vitro stu-
dies van geïsoleerde cellen, omdat epilepsie een prototype is van een pathologi-
sche synchronisatie in een multi-en intercellulair netwerk 
De data suggereren dat het redelijk is te zoeken naar therapeutische middelen 
van immunologische origine om het zenuwstelsel wat betreft epilepsieen te beïn-
vloeden (immunofarmacotherapie) 
Wat konden we bevestigen? 
- Met betrekking tot IVIg-behandeling van onbehandelbare epilepsieen aan-
wijzingen dat IVIg effectief kan zijn bij de behandeling van onbehandelbare 
kinderepilepsieen zoals cryptogeen WS en LGS 
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- Met betrekking tot dierstudies: vergeleken met de enige andere studie over 
IVIg in een diermodel voor epilepsie, een identieke relatie tussen tijd en effect 
en een identiek immunohistochemisch kleuringspatroon voor humaan IgG. 
Wat is nieuw? 
- Met betrekking tot IVIg-behandeling van onbehandelbare epilepsieën: het ge-
bruik van een relatief homogene groep patiënten; blinde evaluatie van EEG-
data; het bewijs dat (3 maanden) IVIg behandeling de serum en liquor-IgG con-
centraties significant doet stijgen. 
- Met betrekking tot onbehandelbare kinderepilepsieën: de uitvoerige liquor on-
derzoekingen welke in cryptogene types epilepsie geen afwijkingen aan het 
licht brachten; het aantonen van functionele immunologische afwijkingen en 
HLA-klasse-II associaties in LGS. 
- Met betrekking tot dierstudies: de aanwijzingen dat IVIg de drempel voor con-
vulsies doet toenemen in een subgroep van ratten. 
- Met betrekking tot het in vitro effect op de GABAA receptor: de conclusie dat 
IVIg geen direct GABAerg effect heeft. 
- Met betrekking tot IVIg-preparaten: het bewijs dat de IgG-moleculen van het 
IVIg-preparaat de bloed-CSF-barrière doordringen, wat het CSF-IgG signifi-
cant doet stijgen; het aantonen dat IVIg een effect heeft op cellen met excita-
bele membranen, hoewel dit effect niet wordt veroorzaakt door de belangrijk-
ste component van het IVIg-preparaat de IgG-moleculen; het bewijs dat ver-
schillende IVIg-preparaten verschillende in vitro effecten kunnen bewerkstelli-
gen. 
Wat verder te doen? 
- Met betrekking tot IVIg-behandeling van onbehandelbare epilepsieën: een 
dubbel-blinde, gecontroleerde studie van IVIg in WS en LGS*; onderzoek naar 
het effect van IVIg op de REM slaap; bestudering van de lange-termijn-effecten 
van IVIg op epilepsieën. 
- Met betrekking tot dierstudies: onderzoek naar de variabiliteit van het IVIg-ef-
fect op de drempel voor convulsies; exploratief onderzoek naar het eventuele 
bestaan van specifieke anticonvulsieve monoclonale immunoglobulines. 
- Met betrekking tot IVIg-preparaten: onderzoek naar het effect van de verschil-
lende componenten van het IVIg-preparaat (zoals endogene proteïnes, bijv. cy-
tokines en oplosbare cytokine receptoren) op experimentele epilepsie en op 
cellen met excitabele membranen, vooral neuronen. 
* Tijdens het schrijven van dit proefschrift verscheen een dubbel-blinde, placebo gecontroleerde studie be 
treffende IVIg toediening bij patiënten met onbehandelbare epilepsieën (van Rijckevorsel et al Treatment of re-
fractory epilepsy with intravenous immunoglobulins. Int J Clin Lab Res 1994,24 162-166) In deze studie werd 
één patient met LGS behandeld met IVIg en patiënten met WS konden m de data niet gevonden worden 
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Stellingen 
behorend bij het proefschrift 
A neuroimmunological approach 
to intractable childhood epilepsies 
Baziel van Engelen 
6 december 1995 
1. rVIg is een humaan bloedprodukt en niet een klassiek, 
chemisch gesynthetiseerd farmacon. Dit betekent dat van 
100% zuiverheid geen sprake is. Voor de klinische toepas-
sing is dit mogelijk een nadeel. Voor experimenteel onder-
zoek naar de effecten van endogene eiwitten kan het een 
voordeel zijn. 
2. rVIg heeft enkele karakeristieken van een Zwitsers leger-
mes: het is relatief duur maar het kan voor verschillende 
doeleinden gebruikt worden. 
3. Een mogelijke verklaring voor de identieke leeftijdsgeasso-
cieerde toename van de hersenspecifieke eiwitten in de 
liquor (NSE, S-100 en MBP) en van het totale liquoreiwit 
is een toename van de halfwaarde-tijd ten gevolge van een 
verminderde bulk-flow op hogere leeftijd. 
4. De bloed-liquor barrière is geen absolute hindernis voor 
het IgG van het IVIg preparaat: na toediening van de 
gebruikelijke doseringen IVIg stijgen de liquor-IgG con-
centraties significant. 
5. Het feit dat de werkzaamheid van IVIg soms langer aan-
houdt dan op basis van de farmacologische halfwaardetijd 
te verwachten is, zou men analoog aan hetgeen gebeurt 
bij cardioversie aan een "immuun-defibrillatie" kunnen 
toeschrijven. 
6. Een humaan immunoglobuline-preparaat veroorzaakt een 
dosis-afhankelijke calciumafgifte uit het sarcoplasmatisch 
reticulum van humane spiercellen in kweek. Dit effect is 
niet gemedieerd door de IgG-moleculen. 
7. Bij het syndroom van continue spieractiviteit (Isaacs' syn-
droom) is beschreven dat plasmaferese de continue spier-
activiteit doet afnemen terwijl IVIg de spierkrampen gelei-
delijk doet toenemen. Dit gerapporteerde verschil in effect 
van IVIg en plasmaferese berust waarschijnlijk op hetzelf-
de mechanisme als genoemd in de vorige stelling. 
8. Gebaseerd op experimentele en klinische gegevens moet 
het traditionele concept van IgG als een uitsluitend scha-
delijk molecuul betrokken bij de pathogenese van demye-
liniserende ziekten als multipele sclerosis worden herzien. 
9. Manipulatie van het immuunsysteem kan remyelinisatie 
bevorderen in virale, maar ook in toxische modellen van 
demyelinisatie. 
10. De verhouding tussen ziekte en etiologie wordt meestal 
eenvoudig rekenkundig omschreven als een robuuste 
lineaire oorzaak-gevolg relatie. De winst van wiskundige 
concepten afkomstig van de niet-lineaire dynamica of 
chaos-theorie kan gelegen zijn in (1) het feit dat gedragin-
gen van complexe systemen (bijv. het neuronale netwerk 
bij epilepsie, het immunologische netwerk van natuurlijk 
voorkomende autoantilichamen) beschreven kunnen 
worden en (2) het inzicht dat subtiele externe verande-
ringen in complexe systemen grote gevolgen kunnen 
hebben. 
11. Het belang van de sensoriek voor de motoriek wordt 
onderschat wat blijkt uit het ontbreken van een sensore 
prothese voor patiënten met sensore ataxie. 
12. Das Erfinden ist kein Werk des logischen Denkens, wenn 
auch das Endprodukt an seiner Gestalt gebunden ist. A. 
Einstein 
13. He who only knows medicine does not know medicine 
at all. 
14. Wanneer een arts in buis is, is hij zelden thuis. 
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